I notes
(Ophthalmology PG Exam Notes)

Dhaval Patel MD (AIIMS)
drdpatel87@gmail.com

by inotesforPG.blogspot.com
1st edition, February 2014

This is a compilation effort from my preparation notes and other sources, thus any contributions or comments are welcomed in the effort to improve this book. Therefore, feel free to e-mail me at drdpatel87@gmail.com
Thank you GOD

This manual is collection of the notes I made, found in books or internet while studying for the Final MD exams for ophthalmology.

I have segregated topics just like book chapters to find them back easily. Though these all might be far less then other preparation notes available, I am proud of what I have made and I feel nice to present them to my upcoming ophthalmology friends.

Good luck!

-Dhaval Patel MD
drdpatel87@gmail.com
February 2014
Retina

Anatomy and Physiology ................................................................. 5
Vitreous ......................................................................................... 13
Retinitis Pigmentosa ................................................................. 16
Hereditary Vitreoretinal Degenerations ........................................ 25
Macular Dystrophies ................................................................. 30
Hereditary Choroidal Diseases .................................................. 37
Abnormalities of Cone and Rod Function ................................... 39
Myopia ......................................................................................... 41
Diabetic Retinopathy ................................................................. 44
Hypertension .............................................................................. 69
Retinal Artery Obstructions ....................................................... 70
Acquired Retinal Macroaneurysms ............................................ 75
Retinal Vein Occlusions ............................................................ 76
Macular Telangiectasia ............................................................... 86
Coats Disease ............................................................................ 88
Hemoglobinopathies ................................................................. 91
Radiation Retinopathy .............................................................. 94
Ocular Ischemic Syndrome ...................................................... 96
ROP ........................................................................................... 98
ARMD ....................................................................................... 105
Epiretinal Membranes ............................................................. 130
Macular Hole ............................................................................ 134
CME - VMT ............................................................................. 141
Anatomy and Physiology
RPE
Muller Cell
Mechanisms of Normal Retinal Adhesion
Bruch's Membrane

Vitreous
Retinitis Pigmentosa
Genetics
Typical retinitis pigmentosa
Complicated retinitis pigmentosa
DD
Pseudo-Retinitis Pigmentosa
Treatment

Hereditary Vitreoretinal Degenerations
Snowflake vitreoretinal degeneration
The chromosome 5Q retinopathies
Chondrodysplasias associated with vitreoretinal degeneration
X-linked retinoschisis NR2E3 related diseases

Macular Dystrophies
Best macular dystrophy
Stargardt disease
Stargardt-like dominant macular dystrophy (SLDMD)
Pattern dystrophy
Sorsby fundus dystrophy
Autosomal dominant radial drusen ADRD
North carolina macular dystrophy
Spotted cystic dystrophy
Dominant cystoid macular dystrophy
DCMD
Fenestrated sheen macular dystrophy (FSMD)

Glomerulonephritis type II and drusen
Hereditary Choroidal Diseases
Abnormalities of Cone and Rod Function
Cone Disorders
Congenital stationary night blindness
Myopia
High Myopia
Diabetic Retinopathy
Epidemiology
Etiology
NPDR
PDR
DME
Telescreening
Hypertension
Retinal Artery Obstructions
CRAO
BRAO
CLARA- Cilioretinal artery occlusion
Combined retinal artery and vein occlusion
Cotton-wool spots
Acquired Retinal Macroaneurysms
Retinal Vein Occlusions
BRVO
CRVO
Macular Telangiectasia
Coats Disease
Hemoglobinopathies
Radiation Retinopathy
Ocular Ischemic Syndrome
ROP
ARMD
Epidemiology
Pathogenesis
Non-neovascular AMD
Neovascular AMD
Pharmacotherapy
Surgical Therapy
Epiretinal Membranes

Classification and Grading
Macular Hole
MH Indices
CME - VMT
CNVM
Submacular Hemorrhage
Cystoid Macular Edema
Giant Retinal Tear
Angioid Streaks
Infectious Endophthalmitis
Retinal Tumors
Cavernous Hemangioma
Metastases
Paraneoplastic Retinopathy
Melanocytoma of the Optic Disc
CHRPE
CHRRPE
Primary Vitreoretinal Lymphoma

Phakomatoses
Capillary Hemangioblastoma - VHL
Tuberous Sclerosis
Neurofibromatosis
sturge-weber syndrome wyburn-mason syndrome

Choroidal Melanoma
Epidemiology
Prognosis
Molecular Genetics
Pathology
Management

Choroidal Tumors
Choroidal Nevi
Choroidal Metastases
Choroidal Osteoma
Circumscribed Choroidal Hemangioma

Retinal Detachment
Types
Nonrhegmatogenous Retinal Detachment
<table>
<thead>
<tr>
<th>Proliferative Vitreoretinopathy</th>
<th>Mechanics Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenesis</td>
<td>Primary Vitrectomy</td>
</tr>
<tr>
<td>Classification</td>
<td>Pneumatic Retinopexy</td>
</tr>
<tr>
<td>Ocular Trauma</td>
<td>Adjuncts to Treatment</td>
</tr>
<tr>
<td>Closed Globe Injuries</td>
<td>Intraocular gases</td>
</tr>
<tr>
<td>Open-globe injuries</td>
<td>Perfluorocarbon liquid</td>
</tr>
<tr>
<td>Scleral Buckles</td>
<td>Silicon Oil</td>
</tr>
<tr>
<td>Effects</td>
<td>Heavy Temponade</td>
</tr>
<tr>
<td>Techniques</td>
<td>Prevention of RD</td>
</tr>
<tr>
<td>Complications</td>
<td>Retinotomies and</td>
</tr>
<tr>
<td>Vitreoretinal Surgery</td>
<td>Retinectomies</td>
</tr>
<tr>
<td>History</td>
<td>Macular Translocation</td>
</tr>
<tr>
<td>23G</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnostic and</td>
</tr>
<tr>
<td></td>
<td>Therapeutic Vitrectomy</td>
</tr>
<tr>
<td></td>
<td>Transplantation and</td>
</tr>
<tr>
<td></td>
<td>Artificial Vision</td>
</tr>
<tr>
<td></td>
<td>Pharmacology at Surgery</td>
</tr>
<tr>
<td></td>
<td>Artificial Vision</td>
</tr>
<tr>
<td></td>
<td>PFVS</td>
</tr>
<tr>
<td></td>
<td>MISC</td>
</tr>
<tr>
<td></td>
<td>Q: Anti VEGF</td>
</tr>
<tr>
<td></td>
<td>Macular Infarction</td>
</tr>
<tr>
<td></td>
<td>Leber Congenital</td>
</tr>
<tr>
<td></td>
<td>Amaurosis</td>
</tr>
</tbody>
</table>
Anatomy and Physiology

RPE

- highly specialized neuroectodermally derived pigmented cells

- \(3.5 \times 10^6\) RPE cells - cuboidal monolayer

- The apical microvilli of the RPE cells interdigitate with the OS of the photoreceptors, while the RPE basal side is attached firmly to the underlying Bruch's membrane

- brown color of the RPE is imparted by its melanin granules

- highest concentration of pigment is found in the peripheral retina, the lowest in the macular

- specialized functions of the RPE
  
  o **Absorption of light:** RPE cells possess the enzymatic mechanism to convert vitamin A to 11-cis-RAL as well as the mechanism to deliver it to the photoreceptors
  
  o **Phagocytosis of rod outer segments:** continuously shed OS \(\rightarrow\) Binding of the rod OS is followed by invagination of the plasma membrane around the OS fragment, leading to its ingestion into a phagosome.
  
  o **Role in visual cycle:** reaction of photons with light-sensitive pigments
  
  o **Role in maintaining avascular outer retina:** antiangiogenic activity of PEDF
  
  o **Immune privilege:** tight junctions between RPE; lack of lymphatic drainage from subretinal space; low levels of major histocompatibility antigen expression
  
  o **Transport of nutrients, ions, and water:**
  
  o **Secretion of cytokines and growth factors**

Muller Cell

- retina contains two types of macroglial cell: astrocytes and Müller cells

- **astrocytes:** crucial role in retinal vascularization; the localization of these cells in the mature retina is restricted to the nerve fiber and ganglion cell layers

- **Heinrich Müller** (1820–1864)
- radial glial cells which span the entire thickness of the neural retina, from the subretinal space to the vitreous surface
  - outer stem process: surround the photoreceptor inner segments
  - inner stem process: funnel-shaped endfoot and forms ILM
  - Lateral processes: sheaths around the neuronal synapses
- 8-10 million regularly arranged Müller cells
- **functional retinal columns**: Each Müller cell constitutes the core surrounded by one cone per Müller cell and up to 10 rods, as well as 6/4 inner nuclear layer neurons, and 2.5/0.3 ganglion cell layer neurons
- **Functions of Müller Cell**
  - Light guidance
  - Recycling of cone photopigments
  - Regulation of the synaptic activity by neurotransmitter uptake
  - Production of neurotransmitter precursors
  - Trophic support of photoreceptors and neurons
  - Antioxidative support of photoreceptors and neurons
  - Removal of carbon dioxide
  - Regulation of the extracellular pH
  - Spatial potassium buffering
  - Water clearance
  - Contribution to edema development and resolution
  - Regulation of the blood-retinal barrier
  - Mediation of neurovascular coupling
  - Regulation of the extracellular space volume
  - Responses to mechanical stress
  - Regulation of neuronal activity by release of gliotransmitters
Mechanisms of Normal Retinal Adhesion

- No anatomic junctions bridge the mammalian subretinal space
- mixture of anatomic, physical, and metabolic factors
- *adhesive force*: 100-180 dyn/cm in rabbit
- *temperature*: adhesiveness drops rapidly postmortem at 37 °C, but remains near control levels for hours at 4 °C
- *ionic environment*: calcium appears to be a necessary element for the maintenance of normal adhesiveness in the living eye
- *Mechanical forces outside the subretinal space*: fluid and vitreous pressure
  - *Fluid pressure*:
    - Fluid is driven passively from vitreous to choroid by both intraocular pressure and the osmotic pressure of the extracellular fluid in the choroid.
    - *hydrostatic*
    - RPE can pump fluid from the subretinal space to choroid at a very high rate (about 0.3 μL/h/mm² of RPE) comparable with that of aqueous secretion.
    - resorption of detachments showed a rate of 0.11 μL/h/mm² of RPE = 3.5 mL of fluid per day which explains why a rhegmatogenous detachment can settle within 24 hours
    - *osmotic*
    - intravenous injection of mannitol will increase retinal adhesiveness by roughly 50% within 1-2 hours of injection
  - *Vitreous support*
• status of the gel → retinal hole in a young eye is blocked by gel pressure and can seal uneventfully; a hole in an old eye is more likely to allow fluid to enter the subretinal space and cause detachment

  o weight of Retina

• Mechanical forces inside the subretinal space
  o Mechanical interdigitation
    ▪ RPE microvilli wrap closely around the tips of the outer segments, and this connection is strong enough to allow for daily phagocytosis of outer-segment fragments as the photoreceptors renew their disc material
    ▪ Interdigitation begins to develop within 3 days of reattachment, but retinal adhesiveness does not return to normal until 5-6 weeks after reapposition

  o Interphotoreceptor matrix properties
    ▪ composed largely of proteins, glycoproteins, and proteoglycans
    ▪ Berman
    ▪ Cones: matrix stained by peanut agglutinin (PNA)
    ▪ Rods: matrix stained by wheatgerm agglutinin (WGA)
    ▪ cone or rod matrix sheaths to serve as a structural bond between retina and RPE

  o Metabolic factors
    ▪ just 1 minute of ocular ischemia in living rabbits weakens adhesion dramatically
    ▪ metabolic inhibitors: cyanide, dinitrophenol → decreases adhesion
    ▪ transport inhibitors: ouabain, Acetazolamide → enhances adhesion

• Pharmacologic modification of adhesion
  o Mannitol: 50% increase in retinal adhesiveness
    ▪ 2-3 hours
    ▪ fluid movement “pulling” the retina against the RPE
    ▪ dehydration of the IPM, which strengthens bonding characteristics
  o acetazolamide: 30-45% increase in retinal adhesiveness
    ▪ 3-4 hours
- only occur when the RPE is basically healthy and receptive to metabolic stimulation
- not useful in: RD, CSR, DME, CME
- useful in: intraretinal cysts, retinitis pigmentosa, X-linked juvenile retinoschisis, enhanced S-cone syndrome and sometimes macular epiretinal membrane formation
  - cold temperature and ouabain: increase retinal adhesiveness
  - Ionic changes: removal of local calcium and magnesium ions, or lowering the pH, causes a dramatic fall in retinal adhesive force
- **Recovery of adhesiveness without retinopexy**
  - restoration of normal adhesive strength requires 4-6 weeks
- **Effects of retinopexy**
  - laser photocoagulation produces a bond that approaches normal adhesive strength within 24 hours, possibly from local effects such as fibrin formation → reaches levels roughly twice normal by 2-3 weeks
  - Cryotherapy, however, weakens adhesion for the first week, after which the adhesive force rises
- **Pathophysiology of serous detachment**
  1. a defect in the RPE barrier that allows access to the subretinal space
  2. a source of fluid pressure, to move fluid in
  3. an impairment of outward fluid transport (or a broad area of leakage), so fluid spreads and persists in the subretinal space

**Bruch’s Membrane**
- thin (2-4 µm), acellular, five-layered extracellular matrix located between the retina and choroid
- anteriorly to the ora serrata, interrupted only by the optic nerve
- 1844, **Carl Ludwig Wilhelm Bruch**: lamina vitrea
- 6-7 weeks → inner layer is composed of ectodermal tissue and its outer layer is composed of mesodermal

- **Hogan**'s five-layer nomenclature for Bruch's membrane
  1. RPE basal lamina (RPE-BL)
  2. Inner collagenous layer (ICL)
  3. Elastic layer (EL)
  4. Outer collagenous layer
  5. Choriocapillaris basal lamina (ChC-BL)

- **Gass** proposed a three-layer system (no basal laminas)

- **Changes with Aging**
  - profound accumulation of lipids
  - **Bird and Marshall's hypothesis**: lipophilic barrier in Bruch's blocked a normal, outwardly directed fluid efflux from the RPE (as opposed to leakage from CNV).
  - fluorescent marker, **filipin**, which binds the 3β-hydroxy group of sterols to reveal unesterified (free) cholesterol (UC) or EC depending on tissue pretreatment
  - Bruch's membrane lipoproteins are found to be EC-enriched
  - Bruch's membrane thickens throughout adulthood (20-100 years) two- to threefold under the macula

- **Function of Bruch's membrane**

  - **Structural role**
    - contributes to load bearing → withstands IOP and returns to its original shape when IOP decreases.
    - stretches to accommodate changes in choroidal blood volume
    - spring that pulls the lens during accommodation
    - elasticity in Bruch's membrane choroid preparations to be 7-19 MPa
    - modulus of elasticity of human Bruch's membrane-choroid complex increases ($P < 0.001$) at a rate of $\sim$1% per year

  - **Transport role**
Hydraulic conductivity: \((L_p)\)

- RPE pumping rates: \(11 \, \mu\text{L/h/cm}^2\)
- ICL is responsible for most of the flow resistance in Bruch’s membrane
- \(L_p\) decreased significantly with age.
- \(L_p\) of macular Bruch’s membrane dropped more rapidly with age than did that of the periphery, consistent with an accelerated process occurring in the macula. (due to lipid deposition in AMD)
- Decreased \(L_p\) and increased resistivity of Bruch’s membrane with aging are closely related to the age-related accumulation of lipids, primarily EC

Permeability to solute transport:

- **Peclet number**: relative magnitude of convection of a species due to bulk flow to that of diffusion

Pathology

- **AMD lesions**
  - extracellular accumulation in tissue compartments anterior to the ICL \(\rightarrow\) drusen and basal deposits

- **Drusen**
  - Donders and Wedl \(\rightarrow\) “colloid bodies” \((\text{Colloidkugeln})\) or “hyaline deposits”
  - Müller in 1856 \(\rightarrow\) Drusen
  - yellow-white deposits 30-300 \(\mu\text{m}\)
  - more numerous in peripheral retina than in macula
  - theories for druse formation
    1. transformation of the overlying RPE and
    2. deposition of materials on to Bruch’s membrane.
  - Constituents: lipids \(\rightarrow\) EC and UC, in addition to phosphatidylcholine, other phospholipids, and ceramides

- **Basal linear deposit BlinD**
  - thin (0.4-2 \(\mu\text{m}\)) layer located in the same sub-RPE
- rich in solid lipoprotein particles and lipid pools
- BlinD and Druesen are alternate forms (layer and lump) of the same entity
  - Basal laminar deposit BlamD
    - small pockets between the RPE and the RPE-BL in many older normal eyes or a continuous layer as thick as 15 µm in AMD eyes
    - containing laminin, fibronectin, type IV and type VI collagen
  - Subretinal drusenoid debris SDD
    - enriched in UC, apoE, vitronectin, and complement factor H
    - called reticular drusen in a fundus view
- **Neovascular AMD**
  - angiogenesis along vertical and horizontal vectors: vertically across Bruch's membrane, and laterally external to the RPE (CNV1), subretinal space (CNV 2), or into the retina (CNV 3)
  - VEGF stimulation of choriocapillaris endothelium, compromise to Bruch's membrane, and participation of macrophages
- **Angioid streaks**
  - ruptures in Bruch's membrane by excess calcification of the elastic layer
  - PXE → mutations of a hepatically expressed lipid transporter ABCC6
  - abetalipoproteinemia gene (MTP) deficiency
- **Thick basal laminar deposits**
  - AD: Sorsby fundus dystrophy, late-onset retinal degeneration (LORD) and malattia leventinese-Doyne honeycomb retinal dystrophy (ML-DH)
Vitreous

- 98% water and 2% structural proteins, extracellular matrix components, and miscellaneous compounds.

**Collagen**

- Type II collagen comprises 75%
- Type IX collagen accounts for up to 15% → linked with chondroitin sulfate glycosaminoglycan
- Minor collagens of vitreous is type XVIII, progenitor of endostatin, a potent inhibitor of angiogenesis
- Following vitrectomy, a type II procollagen is secreted. (*does not form gel*)

**Hyaluronan**

- Synthesized by hyalocytes, the ciliary body, and/or Müller cells
- Large polyanion

**Chondroitin sulfate**

- Versican - Wagner syndrome

**Noncollagenous structural proteins**

- Fibrillins
- **Opticin**: formerly vitrican, binds heparan and chondroitin sulfates

**Vitreoretinal interface**

1. Posterior vitreous cortex
2. The ILL of the retina
3. Intervening extracellular matrix

- Posterior vitreous cortex
  - 100-110 μm thick
• **Vogt’s or Weiss’s ring:** when peripapillary tissue is torn away during PVD and remains attached around the prepapillary hole

• **Hyalocytes** are mononuclear cells embedded in the posterior vitreous cortex 20-50 µm from the ILL posteriorly

• **highest density:** vitreous base > posterior pole > equator

2. **Internal limiting lamina (ILL) of the retina**

• type IV collagen, type VI collagen, which may contribute to vitreoretinal adhesion, and type XVIII, which binds **opticin.** Opticin binds to heparan sulfate, contributing to vitreoretinal adhesion
  
  o lamina rara externa
  
  o lamina densa

• **Retinal sheen dystrophy:** This ILL dystrophy has cystic spaces under the ILL and in the inner nuclear layer, and numerous areas of separation of the ILL from the retina with filamentous material

• **Variations at Vitreous Base**

  o Ora bays
  
  o Meridional folds
  
  o Meridional complexes
  
  o Peripheral retinal excavations
  
  o Retinal tufts: Noncystic retinal tufts, Cystic retinal tufts, Zonular traction tufts
  
  o Spiculate and nodular pigment epithelial hyperplasia
  
  o Retinal lattice “degeneration”
  
  o White-with-pressure, white-without-pressure
  
  o Verruca

**Age-Related Vitreous Degeneration**

*Liquefaction (synchysis)*
After age 40: decrease in the gel volume and a concurrent increase in the liquid volume of vitreous

Lacunae: pockets of liquid vitreous

Single, large pocket forms, the terms “bursa” or “precortical pocket

20% of vitreous is liquid in adult and by the age of 80-90 years more than half the vitreous is liquid.

Changes in collagen or the conformation of HA with subsequent cross-linking of and aggregation of fibrils into bundles

**Collapse (syneresis)**

Advanced liquefaction with thickening and tortuosity of vitreous fibers

**Posterior vitreous detachment**

PVD begins at the posterior pole, perhaps in the perifoveal region

The attachments of the posterior hyaloid to the foveal center and optic disc are the last to be released

Innocuous PVD: clean separation between the ILL of the retina and the cortical vitreous

53% after 50 years and 66% after 60

Sudden onset of “floaters” heralds the onset of PVD.

Incidence of retinal tears in patients with acute symptomatic PVD varies from 8 to 15%

18% of eyes with retinal breaks developed retinal detachment. Risk factors for progression included fresh, symptomatic, horseshoe-shaped tears; breaks suggestive of the presence of subclinical retinal detachment (RD); and pseudophakia/aphakia.

**Anomalous PVD (APVD)**

Partial thickness: VITREOSCHISIS (splitting of the posterior vitreous cortex with forward displacement of the anterior portion of the cortex, leaving the posterior layer attached to the retina) → Macular Hole (centrifugal) or Pucker (centripetal)

Full thickness but partial PVD: VMTS, VPT or Retinal tears
• Effects
  o **Vitreous:** vitreoschisis
  o **Retina:** Retinal holes
  o **Macula:** vitreomacular traction syndrome, exudative ARMD, CME, Macular cysts, Macular holes
  o **Optic Disc:** exacerbating neovascularization in proliferative diabetic vitreoretinopathy

• Macular hole opercula are rarely composed of retinal tissue, hence the name *pseudo-operculum.*

**Vitreoretinal Changes after Lens Extraction**

• **Structural:** Opacification, APVD, Vitreous incarceration in the wound and vitreoretinal traction
• Reduction of vitreous HA concentration results in decreased viscosity and shock absorption
• **PVD:**
  o 84% following ICCE
  o 76% following ECCE and surgical capsular discussion
  o 40% following ECCE with an intact posterior capsule

**Retinitis Pigmentosa**

• Previous terms: tapetoretinal degeneration” (by Leber in 1916), “primary pigmentary retinal degeneration,” “pigmentary retinopathy,” and “rod-cone dystrophy
• Typical RP: isolated
• Syndromic RP: association with systemic disease
• 1 : 5000 worldwide
• Use of the term “retinitis pigmentosa” attributed to Donders in 1855
Genetics

- Sporadic 39%, AD 20%, AR 37%, XL 4%
- Consanguinity 30-40%
- Severity: XL > AR > AD
- 45 genes cause nonsyndromic RP

**Autosomal dominant RP genes**
- codon 23 (Pro23His) of the rhodopsin gene: chromosome 3q
- peripherin/rds gene
- mutations in PIM1, on chromosome 7p

**Autosomal recessive RP genes**

**X-linked RP genes**

Typical retinitis pigmentosa

- Massof and Finkelstein Types
  - type I RP, which is associated with early diffuse loss of rod sensitivity relative to cone sensitivity and childhood-onset nyctalopia
  - type II RP, associated with regional and combined loss of both rod and cone retinal sensitivity and adult-onset nyctalopia

- Lyness Types
  - Subgroup D had diffuse loss of rod function and night blindness before the age of 10.
  - Subgroup R had regional loss of rod function, and most of these patients were unaware of night blindness until after the age of 20

- CF
  - Nyctalopia: hallmark symptom, not pathognomonic
**Visual field loss:** hallmark, progressive contraction of the visual field, 4.6% of the remaining visual field was lost per year

**Central vision loss:** CME, diffuse retinal vascular leakage, macular preretinal fibrosis, and RPE defects in the macula

**adRP are more likely to retain** central vision than arRP or xlRP

**Color vision defects**

**Photopsia and other symptoms**

**Fundus appearance**

- attenuated retinal vessels, mottling and granularity of the RPE, bone spicule intraretinal pigmentation, and optic nerve head pallor

- **RP sine pigmento or paucipigmentary RP:** no longer considered a specific subtype of RP but a stage through which many, if not most, patients with RP pass.

- **earliest features are attenuation of retinal vessels** and the appearance of fine mottling or granularity of the RPE

- Intraretinal, bone spicule pigment formations represent migration of pigment into the retina from disintegration of RPE cells with accumulation in the interstitial spaces surrounding retinal vessels.

- yellowish-white metallic tapetal-like reflex or sheen can occasionally be observed in women who are carriers for the X-linked form of RP

- “golden ring” or yellowish-white halo can often be seen surrounding the optic disc in early RP. As disease progresses, this golden ring is replaced with peripapillary mottling, hyperpigmentation, and atrophy of the RPE.

- presence or absence of macular RPE defects is of significant prognostic importance with regard to retention of visual acuity over the next 5 years

**Vitreous abnormalities**

- fine, dust-like pigmented cells

- complete posterior detachment of the vitreous

- “cotton-ball” opacities

- interwoven filaments in the retrocortical space

- spindle-shaped vitreous condensations

**Anterior-segment abnormalities**
- Cataracts: posterior subcapsular
- Keratoconus
- Glaucoma

  o Refractive status
    - High myopia and astigmatism

- **Psychophysical findings**
  
  o Perimetry
    - most reliable method of quantifying real change in visual deficit
    - relative scotomas in the midperiphery, between 30 and 50°
    - ring scotoma
    - **German adaptive thresholding estimation (GATE):** new fast thresholding algorithm, in time limit of SITA, but full field
  
  o Dark adaptometry
    - exposure to a strong adapting light → placed in the dark:
      - cone system, reaching a plateau in about 5 minutes
      - rod system 2nd plateau at 30 min
  
  o Retinal densitometry (fundus reflectometry)
    - Difference between light shone into the eye and light reflected out of the eye.
  
  o Electrophysiology
    - Karpe: 1945: ERG was “extinguished” in RP.
    - Arden: 1962 EOG
    - delays in the implicit time for cone-mediated 30-Hz flicker responses

- **Imaging modalities in RP**
  
  o Fundus photography/fluorescein angiography
    - hyperfluorescence in areas of RPE atrophy and can highlight areas of CME
    - transmission defects
Autofluorescence

- perifoveal ring of increased autofluorescence within the macula, which denotes the border between functional and dysfunctional retina
- Near-infrared autofluorescence (NIA) has also been used to image melanin present in the apical tips of the RPE

Optical coherence tomography

- CME, ERM

Adaptive optics scanning laser ophthalmoscopy

Classification

- Subdivision by inheritance type
  - arRP
  - adRP
  - X-linked recessive trait (X-linked RP)

- Subdivision by molecular defect
  - null alleles
  - dominant-negative alleles
  - toxic gain of function

- Distribution of retinal involvement
  - RP sine pigmento - RP without signs of intraretinal pigmentation, can simulate fundus albipunctatus and retinitis punctata albescens
  - Sector RP: first described by Bietti,
  - Pericentral RP: loss of visual field typically occurs between 5 and 15° from fixation
  - Unilateral RP: mostly acquired rather than genetic unilateral
    - Genetic: carrier state for X-linked RP, somatic mosaicism of a dominant gene for RP
    - In Acquired, MC is diffuse unilateral subacute neuroretinitis or DUSN
Complicated retinitis pigmentosa

- **Systemic associations**
  - greater than normal risk for thyroid disease
  - mild to severe hearing loss as adults
  - ear infections, sinusitis, and chronic recurrent respiratory tract infections

- **Usher syndrome**
  - von Graefe in 1858
  - Charles Usher for the appreciation that this condition was familial and represented a distinct entity
  - autosomal recessive deafness (most commonly congenital) with retinopathy indistinguishable from typical RP
  - most common of the syndromes associated with RP and accounts for about 18% of all patients with RP
  - type 1, with profound congenital sensorineural deafness and resultant prelingual deafness or severe speech impairment, vestibular symptoms, and childhood-onset retinopathy
  - type 2, with congenital partial, nonprogressive deafness, absence of vestibular symptoms, and milder, later-onset retinopathy.
  - The least common is type 3 Usher syndrome, which is characterized by progressive deafness starting late in the second to fourth decades, adult-onset retinopathy, and hypermetropic astigmatism.
  - Another variant, Hallgren syndrome, was defined as congenital progressive deafness, vestibular ataxia, and retinopathy

**DD**

- **Cone-rod and cone dystrophy (CRD)**
  - early loss of visual acuity and color vision, with subsequent progressive peripheral visual field loss (5 and 30° from fixation)
  - marked reduction or absence of cone ERG responses in the presence of quantitatively less reduction in rod responses
• Gene GUCY2D for guanylate cyclase-activating protein-1 (GCAP-1)

• **Leber congenital amaurosis/severe early childhood onset retinal dystrophy (SECORD)**
  - Autosomal recessive >> AD
  - 1869, Theodor Leber
  - Severely visually impaired before age 1 year, with nystagmus, poor pupillary reflexes, either normal or abnormal fundus appearance.
  - Abnormal or absent ERG
  - **Eye-rubbing - the oculodigital sign** - is a common association
  - Two types
    - Uncomplicated LCA is described as congenital blindness, nystagmus, and high hyperopia with extinguished ERG responses
    - Complicated LCA is used to group together cases of LCA associated with other ocular or systemic features
  - Retinal abnormalities: macular coloboma, “salt and pepper” retinopathy, retinitis punctata albescens, and nummular pigmentation
  - 29% keratoconus
  - Systemic: deafness, renal anomalies, infantile cardiomyopathy (Alström syndrome), hepatic dysfunction and skeletal abnormalities, Neurologic abnormalities are the most common

• **Bardet-Biedl syndrome**
  - BBS or Laurence-Moon-Bardet-Biedl syndrome
  - 5 cardinal features: retinopathy 90-100%, polydactyly 75%, and congenital obesity, mental retardation 85% and hypogenitalism 50%
  - Macular wrinkling, preretinal membrane formation, and leakage on fluorescein angiogram from paramacular capillaries
  - ERG may show a rod-cone loss
  - Absence of pigmented deposits
  - Nonocular: renal abnormalities are the most common

• **Refsum syndromes**
IRD:
- disorder of peroxisomal biogenesis that presents during infancy
- nystagmus, poor vision, retinal degeneration with

adult Refsum disease:
- disorder of a single peroxisomal enzymatic function
- cataract, miosis with poor pupil dilation, and retinopathy

Phytanic acid levels in blood and urine are always very high due to a deficiency of phytanic acid oxidation

**Neuronal ceroid lipofuscinosis (Batten’s disease)**

**Pseudo-Retinitis Pigmentosa**

**Retinal inflammatory diseases**

- Rubella retinopathy
- Syphilis
- Infectious retinitis: toxoplasmosis or herpes

**Autoimmune paraneoplastic retinopathy**

- Cancer-associated retinopathy (CAR):
  - small-cell (oat-cell) carcinoma of the lung or small-cell undifferentiated cervical carcinoma
  - first autoantigen in the human retina identified with a CAR is recoverin
  - ERG is extinguished

- Melanoma-associated retinopathy (MAR):
  - a-wave amplitude is normal, and the b-wave amplitude is severely subnormal, distinguishing this form of paraneoplastic retinopathy from CAR
  - night blindness associated with “shimmering lights”
• loss of function subserved by magnocellular cells

• **Drug toxicity**
  o *Thioridazine*: bind to melanin and concentrate in the uveal tract and RPE, higher than 800 mg/day
  o *Chlorpromazine*: binds to melanin
  o *Hydroxychloroquine*: dosage is greater than 6.5 mg/kg per day for > 5 years
  o *Quinine:*

• **Pigmented paravenous retinochoroidal atrophy**
  o 1937 as retinochoroiditis radiate
  o pigmentary changes are closely associated in distribution with retinal veins
  o ERG is generally normal, EOG is abnormal

• **Traumatic retinopathy**
  o commonest acquired retinopathy that is confused with RP

• **Diffuse unilateral subacute neuroretinitis**
  o previously called “unilateral wipe-out syndrome”
  o raccoon nematode (*Baylisascaris procyonis*)
  o *Toxocara canis*
  o signs of retinal degeneration (**mottling, edema, narrowing of retinal vessels**).
  o *Mx*
    - Retinal laser photocoagulation
    - Vitrectomy with surgical removal of the subretinal nematode
    - oral tiabendazole or ivermectin is indicated when vitritis obscures retinal detail

• **Grouped pigmentation of the retina**
  o “bear-track” pigmentation
  o **CHRPE: FAP or Gardner syndrome**
Treatment

- **INCURABLE but not UNTREATABLE**
- appropriate correction of refractive error and access to low-vision aids
- Periodic visual field examinations with compassionate explanation of visual field defects

- Cataract extraction
- CME: CAIs
- **Vitamin A supplements**: 15,000 IU/day of vitamin A
- **Docosahexaenoic acid supplements**: 400 mg/day
- **Lutein supplements**: 20 mg/day
- **Vitamin E** should not be given. It has no beneficial effect and may be potentially harmful. (Berson 1993, Survey of ophthalmology)

Hereditary Vitreoretinal Degenerations

- early-onset cataracts, vitreous anomalies, coarse fibrils and membranes, and retinal detachment.

Snowflake vitreoretinal degeneration

- **Hirose** in 1974
• autosomal dominant: chromosome 2q36.

• Ocular features
  o early-onset cataract
  o fibrillar vitreous degeneration
  o peripheral retinal abnormalities, including minute crystalline-like deposits called snowflakes
  o vascular sheathing
  o retinal detachment
  o others: guttata, ONH dysplasia

• four stages: (1) extensive white with pressure; (2) snowflake degeneration; (3) sheathing of retinal vessels and fundus pigmentation; and (4) further pigmentation and disappearance of the peripheral retinal vessels

• Investigations
  o scotopic b-wave of the electroretinogram (ERG) elicited by dim light is low in amplitude and may be almost extinguished in late stages of the disease
  o electro-oculographic light peak-dark trough ratio is abnormal

• DD
  o Stickler syndrome type I, II
  o Marshall syndrome
  o Wagner syndrome
  o Goldmann-Favre vitreotapetoretinal degeneration

• Mx
  o No specific Mx
  o risk of retinal detachment is 20% and cataract surgery of early-onset lens opacification can be difficult due to vitreous liquefaction

The chromosome 5Q retinopathies

• Wagner syndrome:
optically empty vitreous with avascular vitreous strands and veils, moderate myopia, presenile cataracts, and retinal degeneration with atrophy

- autosomal dominant, \textit{VCAN} gene, \textit{5q13-14}

- \textbf{ERVR} (erosive vitreoretinopathy)
  - \textit{AD}
  - optically empty vitreous

- \textbf{Jansen syndrome}
  - vitreoretinal and lenticular degeneration associated with retinal detachments

- \textbf{CF}
  - optically empty vitreous with equatorial avascular vitreous veils.
  - moderate myopia
  - typical dot-like cortical cataracts
  - foveal ectopia
  - abnormal retinal vessels (\textit{inverted papilla})
  - perivascular pigmentation and sheathing
  - retinal thinning as well as slowly progressive chorioretinal atrophy.
  - pseudostrabismus from congenital temporal displacement of the fovea.

\textbf{Chondrodysplasias associated with vitreoretinal degeneration}

- \textbf{Stickler syndrome:}
  - \textit{MC}
  - hereditary progressive ar thro-ophthalmopathy
  - Types I: \textit{COL2A1} gene encoding type II collagen
  - Type II: \textit{COL11A1} gene encoding type XI collagen

- \textbf{Mar shall syndrome}
I notes  RETINA  Dhaval Patel MD

- **AD**
  - **COL11A1** gene of chromosome 1p.

- **Kniest dysplasia**
  - **COL2A1** gene which encodes type II collagen,

- **Knobloch syndrome**
  - **COL18A1** gene mapped to the long arm of chromosome 21 are supposed to induce the changes in collagen XVIII

- **Weissenbacher-Zweymuller syndrome: aka** Pierre Robin syndrome with fetal chondrodysplasia

- **CF**
  - Conductive and sensorineural hearing loss, immunoglobulin deficiency, cleft palate, mid facial underdevelopment, mild spondyloepiphyseal dysplasia, and precocious arthritis
  - Congenital high myopia, cataract, and retinal problems, such as vitreous changes, radial perivascular retinal degeneration, and rhegmatogenous retinal detachment

**X-linked retinoschisis**

- **RS1** gene on Xp22
  - exclusively expressed in the photoreceptors and retinal bipolar cells
  - encodes retinoschisin \( \rightarrow \) interact with β2 laminin within the extracellular space and αB crystallin intracellularly
  - most common form of juvenile-onset retinal degeneration in males

- **CF**
  - Foveal schisis is the characteristic sign of XLRS and is present in 98-100% \( \rightarrow \) spokewheel pattern
  - **Peripheral retinoschisis**, It region, 50%
o splitting occurs in the superficial retinal layers
o Breaks occur within the inner layer
o traction or rhegmatogenous retinal detachment 5-20%

o dense vitreous hemorrhage, hemorrhage within a large schisis cavity, and intraretinal splitting involving the macula

- Vision loss is the most common clinical presentation

- Ix
  - OCT:
    - ERG: reduced b-wave amplitude with a relatively preserved a-wave, alteration of the b:a ratio
    - Multifocal ERG: reduced amplitudes and longer implicit times in the central macula

- DD
  - RD
    - cystoid macular edema, degenerative retinoschisis, acquired retinoschisis, amblyopia, Goldmann-Favre vitreoretinal degeneration, ESCS, Eales disease, and VCAN-related vitreoretinopathy

- Mx
  - Genetic counseling
  - CAIs: topical dorzolamide
  - Laser
  - Surgery: patients with severe complications
  - Gene therapy
  - Retina and/or progenitor cell transplantation

**NR2E3 related diseases**
- retinal nuclear receptor subfamily 2, group E, member 3
expression is uniquely restricted to photoreceptors

GFS, ESCS, and clumped pigmentary retinal degeneration

**Goldmann-Favre vitreotapetoretinal degeneration**
- retina, vitreous body, and crystalline lens
- early-onset nyctalopia, fibrillar vitreous degeneration, foveal cysts, peripheral retinoschisis, and retinal degeneration with clumped pigment, and an unusual ERG
- areas of clumped pigment are due to excessive accumulation of melanin granules in retinal pigment epithelial cells

**ESCS: enhanced S-cone syndrome**
- increase in the blue cone population with associated variable degeneration of the rod and red and green cone photoreceptors
- early-onset night blindness, cystic maculopathy, and peripheral retinal degeneration characterized by mild visual field loss

**CF**
- progressive loss of vision similar to retinitis pigmentosa
- night blindness

**IX**
- ERG: undetectable rod-specific response, similar photopic and scotopic responses to a standard single flash, and a 30-Hz lower-amplitude photopic a-wave response

**DD**
- X-linked retinoschisis
- Cystoid macular edema

**Macular Dystrophies**

- Always rule out these 2 before considering macular dystrophy
1. **neuronal ceroid lipofuscinosis (NCL) aka Batten disease**: fatal systemic disease of children, ERG markedly abnormal, rapidly progressive

2. **drug toxicity**: CHQ, HCHQ, Thioridazine, Chlorpromazine, Tamoxifen, Deferoxamine

**Best macular dystrophy**

- **AD/AR**
- mutations in the *BEST1*, chromosome 11q13
- Friedrich Best in 1905
- 1 in 10,000
- **Pathophysiology**
  - increased RPE lipofuscin, loss of photoreceptors (often seen over a relatively intact RPE layer), sub-RPE drusenoid material, and accumulation of cells and material in the subretinal space
  - **Bestrophin-1** is expressed in all RPE cells
- **CF**
  - known as “vitelliform” because of their egg-yolk-like appearance
  - solitary, round or horizontally oval, yellow, slightly elevated, and are centered on the fovea
  - larger lesion in childhood, smaller after 20
  - **pseudohypopyon**: the yellow material gravitates inferiorly in the subretinal space
  - **scrambled-egg lesion**: varying amounts of subretinal and sub-RPE fibrosis, RPE atrophy in addition to hyperpigmentation
  - stages given by some authors, there is not always a predictable progression
  - single or multiple lesion
  - **multifocal Best dystrophy**: multiple vitelliform lesions scattered throughout the posterior pole of both eyes
  - Visual acuity is variable but preserved in at least one eye till 6th decade, may decrease due to nodular fibrosis, choroidal neovascularization
  - **hyperopia** due to shortened axial length
- angle closure
- 4 stages

- IX
  - EOG: ratio of the light peak to dark trough (the Arden ratio) is typically less than 1.5
  - ERG: cone and rod a- and b-wave amplitudes are usually normal
  - Autofluorescence: increased amounts of lipofuscin
  - OCT: homogenous yellow material, CNVM
  - FA: hydrophobic yellow material, completely excludes fluorescein

- **Additional phenotypes associated with mutations in BEST1**
  - Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
  - Autosomal recessive bestrophinopathy (ARB)

- **Treatment**
  - recognizing choroidal neovascularization and hastening its regression with anti-VEGF therapy
  - Protective eyewear to protect the other less involved eye

**Stargardt disease**

- most common cause of AR retinal disease
- **ABCA4** mutations
- disease spectrum is determined largely by the total amount of residual ABCA4 function
- **interplay of three factors:**
  1. the severity of their **ABCA4 genotype** (and hence the rate at which toxic bisretinoids form in the photoreceptors)
  2. the relative sensitivity of the foveal cones to the genotype
  3. the relative sensitivity of the retinal pigment epithelium to the genotype

- **Pathophysiology**
remarkable lipofuscin accumulation in the RPE, photoreceptor cell inner segments

role of ABCA4 is the clearance of a retinoid intermediate of the visual cycle → Condensation of this retinoid with a second vitamin A moiety, which may occur in the photoreceptor cell or in the RPE following outer segment phagocytosis, results in the formation of A2E, a toxic detergent-like compound that can trigger death of RPE cells

CF

loss of visual acuity, which can be as mild as 20/30 or as severe as 20/200

5 years or later than 50 years

abnormal fundus appearance that is incidentally discovered

light-colored flecks at the level of the retinal pigment epithelium → more elongated than round,

pisciform (fish-tail): two adjacent flecks form an obtuse angle

many different fleck configurations

fairly reliable diagnostic sign: relative sparing of the peripapillary RPE.

quite full visual fields for many years after their acuity has fallen below the threshold of legal blindness

IX

FA/ FAF

accumulation of A2E within the retinal pigment epithelium

dark, silent, or masked choroid

retinal vessels stand out in sharp contrast

OCT

anatomic level of flecks with accuracy

full-field ERG: normal (cf: NCL, the ERG is usually severely reduced or extinguished before the age of 10 years)

Mx

no proven treatment

drugs that modulate the visual cycle

gene replacement
avoidance of cigarette smoking
- avoidance of high-dose vitamin A supplements, including AREDS vitamins, because of their potential to increase the formation of bisretinoids in the retina.

**Stargardt-like dominant macular dystrophy (SLDMD)**

- autosomal dominant
- chromosome 6
- *ELOVL4* gene: elongation of very long chain fatty acids-4
- most-characteristic features of this disease are circular zone of RPE atrophy, a pigmented spot beneath the fovea, and a ring of flecks just beyond the margin of the atrophy
- ERG is usually normal

**Pattern dystrophy**

- pigment changes at the level of the RPE.
- mutations in a single gene, *PRPH2*
- Pathophysiology
  - *PRPH2* encodes a structural protein (peripherin) → maintaining the morphology of photoreceptor outer-segment discs
- CF
  - macular photostress is important feature: central acuity will be slow to recover following exposure to bright light
  - 18% lifetime risk of choroidal neovascularization
  - butterfly-shaped pigment dystrophy: AD, pigment deposition resembling butterfly
  - adult-onset vitelliform pattern dystrophy (peculiar foveomacular dystrophy): symmetric, solitary, autofluorescent vitelliform lesions
Sjögren reticular dystrophy of the RPE: resemble a fishnet with knots or chicken wire

- fundus pulverulentus:
  - Central areolar choroidal dystrophy (central areolar retinochoroidal dystrophy)

- IX
  - ERG: normal cone and rod amplitudes and implicit times on the full-field ERG
  - EOG light-peak to dark-trough ratios are most frequently normal or only modestly subnormal

**Sorsby fundus dystrophy**

- **Pathophysiology**
  - mutations in *TIMP-3* → protein that negatively regulates MMPs
  - accumulation of lipidic and proteinaceous material between Bruch's membrane and the RPE up to 30 µm in thickness.

- **CF**
  - night blindness
  - yellow-to-gray material is present at the level of Bruch's membrane
  - bilateral subfoveal neovascular membranes
  - SFD relentlessly extends peripherally beyond arcades

- **Mx:** CNVM Mx and control

**Autosomal dominant radial drusen ADRD**

- doyne honeycomb retinal dystrophy, malattia leventinese
- *EFEMP1* gene, chromosome 2
- *Pathophysiology*
- *EFEMP1* gene → protein known as fibulin-3, poorly secreted by RPE cells and its accumulation in the endoplasmic reticulum activates the unfolded protein response

- **CF**
  - Drusen in the center of the macula and on the nasal edge of the optic disc tend to be large and round, while those at the temporal margin of the macula tend to be smaller, elongated, and radial
  - Central atrophy, scarring, and pigment proliferation that can look similar to SFD
  - Visual acuity in ADRD is typically much better than SFD
  - CNVM less common

- **ERG:** full-field ERG is usually normal but the pattern ERG is abnormal in most eyes

- **FAF:** drusen in AMD that tend to be hypoautofluorescent, the drusen in ADRD are hyperautofluorescent

### North Carolina macular dystrophy

- First described as “dominant macular degeneration and aminoaciduria”
- Chromosome 6
- **CF**
  - Lack of progression is one of the most reliable diagnostic features
  - A circular coloboma centered on fixation with a shiny concave base surrounded by a thick, white fibrotic rim

### Spotted cystic dystrophy

### Dominant cystoid macular dystrophy DCMD

- **AD**
• leaking perimacular capillaries, whitish punctate deposits in the vitreous, a normal ERG, a subnormal EOG, and hyperopia

Fenestrated sheen macular dystrophy (FSMD)

Glomerulonephritis type II and drusen

• (MPGN) type II (also known as dense-deposit disease) develop subretinal deposits with the clinical appearance of basal laminar drusen

Hereditary Choroidal Diseases

• Choroidal atrophy phenotypes
  o Central areolar choroidal dystrophy: mutation in the peripherin/RDS (retinal degeneration slow) gene, AR,
  o Peripapillary choroidal dystrophy: AR
  o Diffuse choroidal dystrophy: AD

• Gyrate atrophy of the choroid and retina:
  ▪ AR >> AD
  ▪ deficiency of the enzyme ornithine-delta-aminotransferase (OAT), which results in an increase in the plasma ornithine concentration
  ▪ hyperornithinemia, and reductions in plasma lysine, glutamine, glutamate, and creatine.
  ▪ chromosome 10
  ▪ poor night vision and constricted peripheral vision, usually begins in the second and third decades
• thinning and atrophic appearance of the RPE in which the underlying choroidal vessels may appear either normal or sclerotic

• ERG responses deteriorate and may eventually become undetectable

• EOG light peak to dark trough ratio becomes markedly reduced in the later stages

• MX
  
  • arginine-restricted diet
  
  • rigid low-protein diet, including near-total elimination of arginine with supplementation of essential amino acids
  
  • Orally administered pyridoxal phosphate

• Choroideremia

  • XR

  • CHM gene → Xq21 → Rab escort protein-1 (REP-1)

  • prevalence of 1 in 50,000

  • CF

  • defective dark adaptation, manifesting as poor visual function in dim illumination is commonly the first symptom

  • fine, peppery-like retinal pigment mottling → salt and pepper mottling → Atrophy of the choroid follows with eventual loss of the entire layer and exposure of bare sclera.

  • midperipheral retina and progress centrally

• Field: ring scotoma

• ERG is most often abnormal under both light- and dark-adapted conditions

• EOG recordings show an abnormally low light peak to dark trough ratio.

• DD

• X-linked retinitis pigmentosa (XLRP)

• Kearns-Sayre syndrome (KSS)

• Bietti's crystalline dystrophy
- Thioridazine (Mellaril) retinal toxicity
- Stargardt disease
- Pattern macular dystrophy

**Abnormalities of Cone and Rod Function**

**Cone Disorders**

**Achromatopsia**

- 1 in 30,000
- poor vision from birth and complain of poor color discrimination and photosensitivity
- monochromatism, are generally considered to lack cones and have vision worse than 20/200
- because their color vision loss is congenital, even complete achromats may be able to identify colors
- CF
  - may have a normal fundus, or have subtle granularity or atrophy of the macula
  - nerve may be normal or show some temporal pallor
- ERG: completely nonrecordable cone responses in the face of normal or near-normal rod responses
- pseudochromatic (Ishihara) color plates: Congenital achromats may be able to identify
- Farnsworth D-15 testing may reveal a scotopic axis between the deutan and tritan axes
- Sloan achromatopsia test uses an achromat's correlation of different shades of gray to various colors in order to distinguish them from normal individuals
- aptive optics scanning laser ophthalmoscopic imaging of the macular photoreceptor mosaic
- four genes: \(CNGB3>>CNGA3>GNAT2>PDE6C\)
- MX
  - No treatment currently
  - Photophobia can be reduced with tinted lenses
* Cone monochromatism and blue cone monochromatism
  
  * Progressive cone dystrophies

* Congenital stationary night blindness
  
  * nonprogressive defects in scotopic vision and/or dark adaptation with otherwise normal visual function.
  
  * AD, AR, XR

* CSNB with normal fundi
  
  * may have normal visual acuity and may not complain of night blindness
  
  * myopia and can have subnormal vision
  
  * Dx
    
    * Riggs type (also known as type I)
      
      ▪ lack a scotopic ERG, lack both an a- and b-wave on maximum bright-field stimulation ERG, and lack a rod-cone break on their dark-adaptation curve
    
    * Schubert-Bornschein (also known as type II)
      
      ▪ possess an a-wave on maximum bright-field stimulation ERG but no b-wave, hence exhibiting a negative waveform.

* CSNB with abnormal fundi

  1. Oguchi disease
    
    * Mizuo-Nakamura phenomenon: retina appears normal following prolonged dark adaptation, but on exposure to light the retina displays a golden sheen with an unusually dark macula
- Visual acuity and color vision are typically normal
- dark-adaptation curve with a cone component but no rod-cone break, and exhibit gradual recovery of full rod sensitivity after prolonged dark adaptation of 1-2 hours
- mutation in rhodopsin kinase (GRK1) or arrestin (SAG)

2. **Fundus albipunctatus**

- White or yellow dots can be seen scattered through the fundus
- night blindness early in childhood without progression
- visual acuity and color vision are typically normal
- scotopic ERG can be recorded but only after unusually long dark adaptation, whereas the cone ERG is usually normal

**Myopia**

**High Myopia**

- 1-5% in different communities
- high myopia: spherical equivalent refractive error exceeds −6 diopters (D) and/or the axial length is longer than 26.5 mm.
- Pathological myopia: high myopia with any posterior myopia-specific pathology resulting from excess axial elongation (posterior staphyloma, CNVM, foveoschisis etc.)

- **The characteristics of the OCT image in these eyes are**
  1. a relatively low signal to noise ratio
  2. deep posterior staphyloma in the presence of which the peripheral tissue often drops off from the top edge of the image
  3. poor fixation due to a large central scotoma from chorioretinal atrophy
  4. critical signs that are mostly outside the fovea.

- pearls for the OCT
I notes

**Etiology and pathophysiology**

- **Myopic foveoschisis**
  - foveal cyst in 47%, a lamellar hole in 29%, and a foveal detachment in 29%
  - hypothesis:
    - inner retina is less flexible than the outer retina due to vitreous cortex adhering to the retina, epiretinal membranes (ERMs), internal limiting membrane (ILM), and retinal vessels
    - retinoschisis at multiple levels in the outer plexiform layer, inner plexiform layer, ganglion cell layer, and nerve fiber layer
    - ILM detachments, sometimes recognized as “inner retinoschisis,” are often seen in highly myopic eyes

- **Macular hole with or without retinal detachment**
  - persistent traction at the macular hole edge after opening is critical for initiating a retinal detachment

- **Posterior retinal detachments from paravascular microholes**
incidence rates of retinal cysts and paravascular holes were 50% and 27%,

- **Clinical Features**
  - central visual distortion
  - relative central scotoma
  - Even if patients present with a macular hole, the Watzke-Allen test is usually negative.
  - OCT
    - split retinal layers normally have a bridge \(\rightarrow\) “column” which is presumed to be residual Müller cells
    - ILM detachment, and is an indicator of the tractional force from the ILM
    - IS/OS junction line is typically well preserved in the area of retinoschisis, suggesting that the photoreceptor function is well preserved in this subtype.
  - Two types of macular hole
    1. retinoschisis type:
    2. detachment type:
  - FAF: accumulated in the RPE and is an indicator of the oxidative stress level

- **Treatment**
  - vision decreased in 69% of patients, a macular hole developed in 31% after 3 years of follow-up, and in 50% of patients with retinoschisis a macular hole or retinal detachment developed after 2 years
  - postponed until the vision decreases to about 20/40 because there is still a chance of visual worsening after vitrectomy.
  - visual improvement after surgery is about 80% in cases with a foveal detachment and 50% with retinoschisis alone
  - **indications**
    - macular hole with an extensive retinal detachment
    - visual disturbance, turbulence, or visual loss
  - **prognosis**
    - favorable if no macular hole develops
Macular hole closure rate with retinoschisis or retinal detachment ranges from 30% to 50% on OCT images.

- **procedures**
- Vitreous separation
- Internal limiting membrane peeling
- Tamponade
- Macular buckling: modified silver clip

## Diabetic Retinopathy

### Epidemiology

- **Prevalence:** among persons with diabetes, the crude prevalence of diabetic retinopathy was 40% and the crude prevalence of severe vision-threatening retinopathy (pre-proliferative and proliferative retinopathy or macular edema) was 8%.

- **Incidence & Progression:** (4 year- WESDR)

<table>
<thead>
<tr>
<th></th>
<th>Younger-onset</th>
<th>Older-onset Taking insulin</th>
<th>Older-onset Not taking insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any retinopathy</td>
<td>59.0</td>
<td>47.4</td>
<td>34.4</td>
</tr>
<tr>
<td>Improvement</td>
<td>6.9</td>
<td>15.3</td>
<td>19.8</td>
</tr>
<tr>
<td></td>
<td>Younger-onset Taking insulin</td>
<td>Older-onset Taking insulin</td>
<td>Older-onset Not taking insulin</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>No change</td>
<td>55.1</td>
<td>58.1</td>
<td>71.0</td>
</tr>
<tr>
<td>Progression</td>
<td>41.2</td>
<td>34.0</td>
<td>24.9</td>
</tr>
<tr>
<td>Progression to PDR</td>
<td>10.5</td>
<td>7.4</td>
<td>2.3</td>
</tr>
<tr>
<td>Incidence of CSME</td>
<td>4.3</td>
<td>5.1</td>
<td>1.3</td>
</tr>
</tbody>
</table>

- **Gender**: no significant difference

- **AGE**
  - Under 13 years of age, diabetic retinopathy was infrequent, irrespective of the duration of diabetes
  - Age at diagnosis was not related to incidence or progression of diabetic retinopathy

- **Duration of diabetes**
  - most consistent relationship
  - 3-4 years after diagnosis of diabetes in the WESDR younger-onset group with type 1 diabetes was 14% in men and 24% in women
  - first 3 years after diagnosis of diabetes, 23% of the type 2 diabetic group not taking insulin had retinopathy, and 2% had proliferative retinopathy (PDR)

- **Glycemic Control**
  - **DCCT and UKPDS**: A1c level of 7.0% control, when achieved earlier after diagnosis of diabetes, may have greater long-term benefit in terms of reducing the incidence and progression of retinopathy
  - **NHANES III and the WESDR**: suggest that few persons with diabetes reach this targeted level of glycemic control.
  - **ACCORD and ADVANCE**: further lowering the level of glycemia does not support applying intensive glycemic control with the current technology to achieve such control in patients with long-standing type 2 diabetes who have or who are at risk of cardiovascular disease

- **C-peptide status**
most severe retinopathy were found in individuals with undetectable or low plasma C-peptide (\(<0.3\ nM\)

- exogenous insulin in itself is unlikely to be causally related to retinopathy in diabetic people with normal C-peptide levels

**Blood pressure:**

- UKPDS: each 10 mmHg decrease in mean systolic blood pressure, a 13% reduction was found for microvascular complications

- WESDR: a 10 mmHg rise in diastolic blood pressure \(\rightarrow 330%\ increased\) 4-year risk of developing macular edema in those with type 1 diabetes and a \(210%\ increased\) risk in those with type 2 diabetes

**Proteinuria and diabetic nephropathy:** association between the prevalence of diabetic nephropathy, as manifest by microalbuminuria or gross proteinuria, and diabetic retinopathy

**Serum lipids:**

- WESDR: higher serum total cholesterol was associated with higher prevalence of retinal hard exudates in both the younger- and the older-onset groups taking insulin but not in those with type 2 diabetes using oral hypoglycemic agents

- ETDRS: higher levels of serum lipids (triglycerides, low-density lipoproteins, and very-low-density lipoproteins) at baseline were associated with increased risk of developing hard exudates in the macula and decreased visual acuity

**Smoking:** most epidemiologic data show no relationship between cigarette smoking and the incidence or progression of diabetic retinopathy

**Alcohol:**

- UKPDS: increased alcohol consumption to increased severity of retinopathy

- EURODIAB: alcohol consumption was associated with a reduction in progression of diabetic retinopathy

- ADVANCE: no relation of alcohol consumption to progression of diabetic retinopathy

- WESDR: alcohol consumption was associated with a lower frequency of proliferative retinopathy in persons with type 1 diabetes

**BMI:** inversely related to the presence or severity of diabetic retinopathy only in persons with type 2

**Socioeconomic status:** ?? low socioeconomic status was significantly associated with the 6-year incidence of macular edema but not incidence or progression of diabetic retinopathy

**Hormone** and reproductive exposures in women
- **WESDR**: Menarchal status at the baseline examination was related to the prevalence and severity of retinopathy.

- **Pregnancy**, a condition associated with high levels of estrogens, is associated with more rapid progression of retinopathy.

- Risk of developing a *heart attack, stroke, diabetic nephropathy, and amputation* was higher in those with **proliferative diabetic retinopathy** compared to those with no or minimal nonproliferative retinopathy at baseline.

**Etiology**

- **Anatomic lesions**
  - **Loss of pericytes**
    - One of the earliest and most specific signs but histological
    - Pericytes loss → venous dilation and beading that is visible clinically
    - **Endothelial cell proliferation** resulting in the development of microaneurysms
    - Hyperglycemia leads to pericyte degeneration:
      - The **aldose reductase pathway**
      - Platelet-derived growth factor-beta (PDGF-β): Deficiency leads to lack of development of pericyte
  - **Capillary basement membrane thickening**
    - Deposition of fibrillar collagen and “Swiss cheese” vacuolization
    - Glycation of basement membrane collagen by enzymatic and nonenzymatic processes
  - **Microaneurysms**
    - Earliest clinically visible sign
    - Hypercellular or acellular
    - Tiny, intraretinal red dots located in the inner retina
• pericytes have antiproliferative effect, also loss of pericytes leads to weakening of walls
  
  o **Capillary acellularity**
    
    ▪ more advanced microvascular lesion in diabetic retinopathy
    ▪ not unique to diabetes
  
  o **Breakdown of blood-retina barrier**
    
    ▪ development of macular edema
    ▪ opening of the tight junctions between vascular endothelial cell processes
    ▪ VEGF leads to the breakdown of the inner blood-retina barrier appears to involve alteration of endothelial cell tight junctions
    ▪ kallikrein-kinin system: Bradykinin, via nitric oxide, induces vasorelaxation of retinal arterioles

• **Biochemical mechanisms**
  
  o **The aldose reductase theory**
    
    ▪ polyol pathway or the sorbitol pathway
    ▪ enzymes aldose reductase AR and sorbitol dehydrogenase SDH
    ▪ Elevation of intracellular glucose $\rightarrow$ AR (+NADPH) $\rightarrow$ sorbitol $\rightarrow$ SDH $\rightarrow$ fructose
    ▪ When other mechanisms of glucose metabolism becomes saturated, AR starts working but SDH is slow so sorbitol accumulates
    ▪ Also decrease NADPH $\rightarrow$ decrease the production of nitric oxide
  
  o **Advanced glycation endproduct (AGE) theory**
    
    ▪ nonenzymatic glycation and crosslinking of proteins
    ▪ AGEs is the collective name given to proteins, lipids, and nucleic acids that undergo irreversible modification by reducing sugars or sugar-derived products $\rightarrow$ *Maillard reaction*
- **early glycation**: reversible nonenzymatic binding of a sugar to amino acid groups on proteins, lipids, or nucleic acids. → Schiff bases → more stable **Amadori products** (HbA1c and fructosamine)

- cellular effect of AGEs is mediated by RAGE → of these intracellular kinases can subsequently lead to cell dysfunction
  - **Aminoguanidine** is an inhibitor of AGE formation

  - **Reactive oxygen intermediates (ROI) theory**
    - byproducts of oxidative phosphorylation include free radicals, such as superoxide anion, whose production is increased by high levels of glucose
    - damage mitochondrial DNA as well as cellular proteins

  - **Protein kinase C (PKC) theory**
    - Elevated levels of **DAG** and **PKC**
    - increased vascular permeability, disruption of nitric oxide regulation, increased leukocyte adhesion to vessel walls, and changes in blood flow
    - **ruboxistaurin** (LY333531), a PKC-β inhibitor

- **Genetic factors**
  - strong association between proliferative retinopathy and the presence of **HLA-DR phenotypes** 4/0, 3/0, and X/X (neither 3 nor 4)

- **Other ocular factors**
  - Becker: **glaucoma** was associated with a **decreased prevalence and severity** of diabetic retinopathy in affected eyes.
  - **Myopia**: decreased prevalence and severity of diabetic retinopathy

**NPDR**

- **Natural course**
  - **Diabetes mellitus without retinopathy**
  - **Microaneurysms**
■ Retinal vascular hyperpermeability
■ Capillary closure, microvascular remodeling, and retinal ischemia
■ Alterations of the vitreous gel and vitreoretinal interface

• Clinical evaluation

• Duration of diabetes mellitus:
  ■ WESDR
    ■ younger-onset group: 13% of those with less than a 5-year duration of DM and in 90% of those with a duration of 10-15 years
    ■ older-onset group using insulin: 40% of those with less than a 5-year duration of disease and in 84% of those with a duration of 15-19 years
    ■ older-onset group not taking insulin: were 24% and 53% for <5 years and 15-19 years respectively

• Hyperglycemia
  ■ retinopathy progression remained significantly lower in those who had received more intensive treatment in the DCCT than in those who had received conventional therapy. (Epidemiology of Diabetes Intervention and Complications (EDIC) study—its follow up of same patients of DCCT)
  ■ UKPDS: After 12 years, the rate of retinopathy progression was reduced by 21% and the use of laser photocoagulation was reduced by 29% in those getting intensive glycemic control compared with those getting conventional treatment.
  ■ ACCORD: In the intensive treatment group, the rate of retinopathy progression was 7.3%, compared with 10.4% in the standard therapy group

• Hypertension
  ■ UKPDS: intensive blood pressure control (<150 SBP with beta blocker or ACEI) resulted in a 37% reduction in microvascular complications of DM, predominantly a reduced risk of retinal photocoagulation, compared with less intensive control (<180 SBP)
  ■ ACCORD: Rate of progression of retinopathy was not significantly different in the two groups 10.4% of those treated intensively (<120 SBP) compared with 8.8% of those treated with standard care (<140 SBP)

• Dyslipidemia
Elevated levels of plasma triglycerides were associated with a greater risk of developing high-risk PDR in the ETDRS patients.

- Fenofibrate
- Statins

**Other extraocular factors**

- Diabetic nephropathy, as measured by albuminuria, proteinuria, or manifestations of renal failure, has been inconsistently associated with progression of retinopathy
- DR can worsen precipitously in the setting of pregnancy
- Anemia has been associated with progression of diabetic retinopathy

**Ophthalmic evaluation**

- Measurement of visual acuity and intraocular pressure; evaluation of the anterior segment by slit-lamp biomicroscopy; gonioscopy when warranted (such as in the setting of elevated intraocular pressure, neovascularization of the iris, or glaucoma); and dilated funduscopic examination

- In the absence of pupil dilation, only 50% of eyes are correctly diagnosed for the presence and severity of retinopathy

- Stereoscopic evaluation of the posterior pole and visualization of the vitreous gel and peripheral retina

**Ancillary ocular imaging**

- Fundus photography
- Fluorescein angiography:
  - Nephropathy or renal failure is not a contraindication to testing
  - FA is not indicated for classification of disease
  - Not clinically indicated to screen for mild retinopathy
- Optical coherence tomography
  - Diabetic Retinopathy Clinical Research Network (DRCR.net)
  - Pupil dilation, time-domain Stratus OCT, fast macular thickness map, which obtains 128 axial scans
- Output includes center-point thickness, total macular volume, and mean values for retinal thickness in a grid comprised of a central subfield, four inner subfields, and four outer subfields

**Classification ETDRS**

*modified Airlie House seven-field 30-degree non-simultaneous stereo color fundus photographs*

- **Mild NPDR:** At least one microaneurysm, AND criteria not met for more severe retinopathy.

- **Moderate NPDR:** Hemorrhages/microaneurysms ≥ standard photograph 2A; AND/OR cotton-wool spots, venous beading, or IRMA definitely present; AND criteria not met for more severe retinopathy

- **Severe NPDR:** Cotton-wool spots, venous beading, and IRMA definitely present in at least two of photographic fields 4 to 7; OR two of the three preceding features present in at least two of fields 4 to 7 and hemorrhages/microaneurysms present in fields 4 to 7 ≥ standard photograph 2A in at least one of them; OR IRMA present in each of fields 4 to 7 and ≥ standard photograph 8A in at least two of them; AND criteria not met for more severe retinopathy.

- **Early PDR:** New vessels; AND criteria not met for high-risk PDR.

- **High-risk PDR:** New vessels on or within one disc diameter of the optic disc (neovascularization of the disc [NVD]) ≥ standard photograph 10A (approximately 1/4 to 1/3 disc area) with or without vitreous or preretinal hemorrhage; OR vitreous and/or preretinal hemorrhage accompanied by new vessels, either NVD < standard photograph 10A or new vessels elsewhere (NVE) ≥ 1/4 disc area.

**Management**

- **Modification of systemic risk factors**
  - Control of hyperglycemia:
    - DCCT, EDIC study, UKPDS, and ACCORD
    - Hemoglobin A1C of 7.0% or lower
Control of hypertension

- **UKPDS**: <150 is better than <180
- **ACCORD**: <120 is not better than <140

Treatment of dyslipidemia

- WESDR and the ETDRS: may be beneficial
- **Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study**: role for fenofibrate in reducing risk of retinopathy progression

**Retinopathy screening and surveillance**

- **FOLLOW-UP**
  - Initial eye examination is recommended 3-5 years following diagnosis of type 1 DM, and at time of diagnosis for those with type 2 DM
  - type 1 and type 2 diabetics with no retinopathy is yearly
  - In the absence of DME, those with mild to moderate NPDR should be evaluated every 6-12 months, and those with severe NPDR should be seen every 2-4 months
  - with DME merit frequent follow-up, generally at least every 2-4 months, and sometimes monthly depending on treatment.

- **Follow up in Pregnancy**
  - prior to conception and early during the first trimester
  - pregnant patients with no retinopathy, mild NPDR, or moderate NPDR should be individualized based on the severity and recent changes in retinopathy.
  - Pregnant patients with severe NPDR should be evaluated every 1-3 months.
  - Specific circumstances, such as presence of DME, may dictate need for more frequent follow-up

- **ETDRS**
  - Aspirin (450 mg ??) use did not affect the severity of retinopathy or the risk of visual loss over 7 years
  - Aspirin remains an important therapy for control of cardiovascular risk in many diabetics, and no level of retinopathy severity, including PDR, should contraindicate its use.

- **Sorbinil Retinopathy Trial**
  - inhibitor of the enzyme aldose reductase
• sorbinil or placebo: not significantly different changes

- **Ruboxistaurin**
  - inhibitor of beta-isoforms of protein kinase C,
  - participants taking ruboxistaurin (32 mg/day) showed a significant delay in time to moderate vision loss (doubling of the visual angle) compared with those taking placebo

- **Fenofibrate**: peroxisome proliferator-activated receptor (PPAR) alpha agonist
  - Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    - fenofibrate (200 mg/day) or placebo
    - significantly higher rate of retinopathy progression in the placebo group compared with the fenofibrate group among participants with retinopathy at baseline
  - ACCORD study
    - simvastatin plus fenofibrate (160 mg/day) or simvastatin plus placebo

---

**PDR**

- *nearly 25% with type 1 and 16% with type 2 will develop PDR after 15 years of diabetes*

- four fundamental processes
  1. the cycle of proliferation and regression typical of new vessels
  2. proliferation of fibrous tissue accompanying new vessels
  3. formation of adhesions between the fibrovascular proliferations and the posterior vitreous surface;
  4. contraction of the posterior vitreous surface and associated proliferations

- **The 4-2-1 rule**
  - Severe NPDR (any one of the following)
    - H/MA ≥ Standard photograph 2A in four quadrants
    - VB definitely present in two or more quadrants
    - IRMA ≥ Standard photograph 8A in one or more quadrants
- Very severe NPDR (two or more of the above)
- Soft exudates usually disappear within 6-12 months.
- H/MA have a half-life of approximately 3 months
- **featureless retina:** after extensive capillary closure, when the number of small vascular branches decreases and some small arterioles become sclerosed with a white thread-like appearance
- New vessels most frequently seen posteriorly, within about 45 degrees of the optic disc.
- NVE had been shown to occur most frequently in the superotemporal quadrant, followed in frequency by the inferonasal
- NVD: defined as NV at or within 1 disc diameter of the disc
- For detection of early NVE: 30-degree seven standard fields of the modified Airlie House classification
- Newer Ultrawide field imaging: **Optos 200**
- **distinguishing between NVE and IRMA:**
  - NVE are more superficial location, formation of wheel-like networks, extension across both arterial and venous branches of the underlying retinal vascular network, and accompanying fibrous proliferation.
  - In unusual borderline cases, fluorescein angiography can distinguish between the profuse leakiness of preretinal new vessels and the more competent IRMA.

**Natural Course**
- treated or untreated, **PDR will eventually reach an involutional quiescent stage** which may remain stable for decades. Laser photocoagulation induces this quiescent state earlier, usually with less associated retinal damage and visual loss
- **Development and proliferation of new vessels**
  - PDR with high-risk characteristics is defined by one or more of the following lesions
    1. NVD that is approximately one-quarter to one-third disc area or more in size
    2. any amount of NVD if fresh vitreous or preretinal hemorrhage is present
    3. NVE greater than or equal to one-half disc area in size if fresh vitreous or preretinal hemorrhage is present
- **Contraction of the vitreous and fibrovascular proliferation**
Before the onset of posterior vitreous detachment, neovascular networks appear to propagate primarily on or slightly anterior to the retina.

- beginning of posterior vitreous detachment → localized or diffuse VH

- Hemorrhage in the formed vitreous tends to lose its red color and become white before absorption is complete. Absorption of a large hemorrhage from the formed vitreous is usually slow, requiring many months.

- fluid-level or “boat-shaped” hemorrhage

### Retinal distortion and tractional detachment

- With contraction of an extensive sheet of fibrovascular proliferations, distortion or displacement (“dragging”) of the macula may occur.

- NSR or even RPE may appear dragged.

- Contraction of vitreous or areas of fibrovascular proliferation may also lead to retinal detachment.

### Involutional or “Quiescent” Proliferative Diabetic Retinopathy

- the retinopathy has “burned-out”

- vitreous contraction has reached completion and the vitreous is detached from all areas of the retina except where vitreoretinal adhesions associated with new vessels prevent such detachment.

- Previously dilated or beaded veins return to normal caliber or become narrower and often appear sheathed. Fewer small venous branches are visible.

### PDR & DM

#### Prevalence

- **insulin-taking patients younger than 30**: near zero when duration of diabetes was less than 10 years and then rose rapidly to about 50% in persons with 20 years or more of diabetes.

- **older-onset (30 years or more) insulin-taking**: 2% in persons with less than 5 years of diabetes to about 25% in those with 20 years or more.

- **older-onset, noninsulin-taking (type 2) group**: less than 5% before 20 years to about 5% thereafter.

#### Proliferative diabetic retinopathy and blood glucose control
DCCT, EDIC, UKPDS demonstrated conclusively that the long-term risks for the development and progression of DR can be reduced dramatically by improving blood glucose control with intensive treatment.

ETDRS: HbA1c at baseline was a strong risk factor

- **Early worsening of retinopathy with improved glycemic control**
  - unexpected worsening of DR in the first 3-12 months
  - usually mild (development of cotton-wool spots and/or IRMA) and transient
  - clinically important early worsening (defined as development of PDR, severe NPDR, or clinically significant macular edema) was not observed in patients with no retinopathy or with microaneurysms involving only one eye, but it occurred in 6 of the 32 patients with moderate NPDR.
  - Panretinal photocoagulation prior to initiation of such treatment may be considered when factors suggest a particular need to protect against advancing severe retinopathy
  - risk factors for early worsening were higher baseline HbA1c and greater reduction of HbA1c after enrollment
  - mechanisms: alterations in retinal blood flow, decreased autoregulation of the retinal circulation, transient ischemia owing to a decrease in nutrient substrate, and insulin-induced changes in retinal homeostasis that lead to an increase in growth factors such as VEGF

- **Systemic medications**
  - glycemic control ➔ DCCT, EDIC, UKPDS, ACCORD, ADVANCE
  - lipid-lowering medications ➔ ACCORD-EYE, FIELD
  - angiotensin-converting enzyme inhibitors ➔ EURODIAB, EUCLID, ADVANCE
  - angiotensin II type 1-receptor blockers ➔ DIRECT, RASS
  - **Thiazolidinediones (rosiglitazone)**: antiangiogenic effects mediated by PPARγ agonist activity

**Management**
- two principal therapeutic approaches:
  - first, to discourage the proliferation of new vessels ➔ Medical
  - second, to prevent or relieve the effects of contraction of the posterior vitreous surface and fibrovascular proliferation ➔ Surgical
• **Pituitary ablation** ➔ Biasotti and Houssay: hypophysectomy
  o primarily of historical interest because photocoagulation is more effective and is free of the many substantial disadvantages
  o suppression of growth hormone activity and effects on insulin-like growth factor 1

**Medical Management**

• **laser therapy**

• mechanisms
  o Ischemic retina, which produces growth factors, is destroyed, thus reducing the angiogenic stimulus.
  o retinal cells may produce growth-inhibiting factors or reduce production of growth-promoting factors in response to photocoagulation injury
  o increase in oxygenation from the choroid to the inner retina that occurs through the laser scars due to the thinning of the retina in the treated area

• The DRS conclusively demonstrated that PRP significantly reduces the risk of severe visual loss (SVL) from PDR, particularly when high-risk PDR is present
  o severe visual loss: visual acuity of <5/200 at each of two consecutively completed follow-up visits, scheduled at least 4-months apart
  o Treatment reduced the risk of severe visual loss by 50% to 65% in all three groups (NPDR, PDR with HRC, PDR without HRC) at both 2 and 4 years, except for the NPDR group at 2 years
  o in the xenon group, laser attributed vision impairment were more than argon group and visual field loss were more than in argon group.

• **ETDRS and the timing of treatment**
  o scatter treatment not be used in eyes with mild to moderate NPDR but that it be considered for eyes approaching the high-risk stage (i.e., eyes with very severe NPDR or moderate PDR)
  o benefit of prompt treatment is greater in those who have type 2 diabetes or are older than 40 years of age

• **Scatter photocoagulation and macular edema**
Macular edema sometimes increases, at least temporarily, after scatter photocoagulation, and this edema may be followed by transient or persistent reduction of visual acuity.

Eyes with DME requiring scatter treatment are at less risk of visual acuity loss when focal or grid treatment to reduce the DME precedes scatter photocoagulation.

VEGF inhibitors combined with either immediate or deferred macular laser have been shown to be more effective at reducing visual loss than laser alone.

Scatter treatment should not be delayed when the risks of vitreous hemorrhage or neovascular glaucoma seem high, regardless of the status of the macula.

- **PRP and advanced PDR**
  - High-risk characteristics are definitely present, PRP should usually be carried out, despite the presence of fibrous proliferation or localized traction retinal detachment.
  - Extensive neovascularization in the anterior chamber angle is a strong indication for PRP.

- **Current techniques of PRP**

- **Regression of new vessels**
  - 3-day post-treatment visit: 20% of the 50 eyes had regressed from the high-risk stage; at 2 weeks, 50%; at 3 weeks 72%; and at 6 months, 62%. About one-third of the eyes that were still in the high-risk stage after 3 weeks were no longer high-risk at 6 months.

- **Complications of scatter (PRP)**
  - Loss of visual function
  - Damage to posterior ocular structures
  - Complications related to blood retinal barrier breakdown
  - Complications related to the destructive nature of the procedure
  - Complications related to contraction of fibrovascular tissue

- **Surgical Management**
Indications

- **Cataract**: cataract management with mx of PDR by PRP, Anti VEGF

- **High-risk retinal neovascularization**
  
  o Fibrovascular proliferations
    
    ▪ Stable or improved visual function may be achieved in 78%
    
    ▪ Good prognostic factors include younger age at baseline (<40 years), preoperative panretinal photocoagulation, better visual acuity (>5/200), no iris neovascularizations, and no iatrogenic breaks at surgery

  o Vitreous hemorrhage
    
    ▪ Waiting, head elevation or intravitreal injection of hyaluronidase
    
    ▪ Early vitrectomy, defined by the DRVS as within 1–4 months from onset, results in earlier recovery of vision and better functional outcome after 2 and 4 years

- **Macular traction and macular edema**
  
  o Vitreomacular traction syndrome, vitreopapillary traction, diabetic macular edema, epiretinal membrane or macular hole

- **Retinal detachment**
  
  o Tractional retinal detachment
    
    ▪ Diabetic tractional macular detachment therefore has been the most common indication for Vitrectomy
    
    ▪ vitrectomy reoperation rates: 24% and 47%
    
    ▪ Good prognostic factors: age <50 years, preoperative panretinal photocoagulation; visual acuity >5/200; no or few iris neovascularizations or retinal proliferations; macular detachments <30 days, and no iatrogenic breaks

  o Combined TRRD:
    
    ▪ retina appears convex in contrast to tractional
    
    ▪ often extending over the ora serrate
    
    ▪ retinal surface often shows white hydration lines, which are diagnostic of retinal holes

- **Neovascular glaucoma**
Preoperative evaluation

- should be referred to an internist or endocrinologist before surgery
- patient’s medical and glycemic status as well as coexistent problems as hypertension, hyperlipidemia, cardiovascular or renal disease
- Anticoagulants as well as antiplatelet medications must be stopped or substituted at the surgeon’s suggestion
- Preoperative electrophysiological testing

Surgical procedure

- **Cataract surgery**
- **Glaucoma surgery**
  - Aqueous shunt procedures
  - Cyclodestructive therapy
- **Pars plana Vitrectomy**
  - **Eyes with complete posterior hyaloid separation**
    - hyaloid membrane is incised and the opening enlarged
    - diathermy of neovascularizations or small bleeding sources
    - Full-scatter endophotocoagulation
    - ILM Removal
  - **Eyes with incomplete posterior hyaloid separation**
    - **Segmentation:**
      - tractions between centres of adhesions are removed
      - vertical membrane peeler-cutter scissors
    - **Delamination:**
      - connections between the posterior hyaloid and/or fibrovascular tissue and the internal limiting membrane are cut
• fibrovascular adhesions to the posterior hyaloid are excised parallel to the retinal surface with horizontal scissors
  ▪ “en bloc” technique:
    • removal of the vitreous and associated vitreoretinal membranes as a single unit
    • After an opening is made in the posterior hyaloid adjacent to vascular epicenters, membrane peeler-cutter scissors enter the subhyaloidal space. The unremoved formed vitreous provides anterior traction that helps separate the vitreous and fibrovascular tissue from the retina and helps identify sites of adhesion.

  o Eyes with subtotal posterior vitreous adhesion
    ▪ gentle suction can be used to find areas where the vitreous is lesser adherent
    ▪ areas of subhyaloidal hemorrhage or near optic disc
    ▪ centripetal dissection
    ▪ beware of posterior vitreoschisis

  o Eyes with combined tractional and rhegmatogenous detachment
    ▪ great care for not to aspirate and cut inadvertently into the retina

  o Photocoagulation
  o Tamponades
  o Wound closure

Complications

• Intraoperative complications
  o Reduced visualization:
  o Corneal edema:
    ▪ related to intraocular pressure, dryness, duration of surgery, or trauma to the epithelium or endothelium
    ▪ Debridement rate for infusion lenses was 23.8% compared with 13.0% for sew-on lenses and 15.6% for non-contact wide-angle
- **narrow pupil:**
  - after prolonged surgery, ocular hypotony or direct surgical trauma
- **lens opacification:**
  - postoperative cataract formation after vitrectomy in diabetic eyes was reported to occur in 17-37%
- **Intraocular hemorrhage**
- **Retinal breaks and detachment**
- **Subretinal perfluorocarbon or silicone oil**

**Postoperative complications**

- **Conjunctival complications:** Wound dehiscence and stitch abscess may eventually progress to conjunctivitis, scleritis or Endophthalmitis
- **Corneal complications:** epithelial defects,
- **Uveitis**
- **Iris neovascularization and neovascular glaucoma**
- **Cataract formation**
- **Intraocular pressure elevation:** \( \geq 30 \text{ mmHg} \) is about 36% in the first 48 hours after surgery
- **Fibrinoid syndrome:** 5%, breakdown of the blood-retina barrier
- **Vitreous hemorrhage:**
  - single postoperative vitreous hemorrhage occurs in about 65% of patients, whereas 35% will suffer two or more recurrences of vitreous hemorrhage
  - in association with iris or angle neovascularizations, retinal fibrovascular proliferations, or an anterior hyaloidal fibrovascular proliferation (AHFVP).
  - Only 4-10% of cases will finally require another vitrectomy
- **Anterior hyaloidal fibrovascular proliferation**
  - up to 13%
  - Risk factors for AHFVP include male gender, type I diabetes, phakic patients, insufficient panretinal photocoagulation, severe ischemia with recurrent neovascularizations, and previous surgery with placement of a scleral buckle
For treatment, cataract extraction, lensectomy, scleral buckling, extensive laser or cryopexy, and anterior dissection with eventual retinectomy

- DME is defined as retinal thickening, assessed by stereoscopic evaluation of the fundus by slit-lamp biomicroscopy or assessment of photographs. Hard exudates are a sign of present or past retinal thickening.

- In areas of vascular incompetence, DME may result from leakage of microaneurysms, or it may evolve from diffuse leakage of hyperpermeable capillaries. In areas of capillary nonperfusion on angiography, retinal thickening may result from ischemia in the absence of prominent vascular leakage, though hyperpermeable microvascular abnormalities at the borders of such regions may contribute to swelling.

- **Classification**
  - **Mild DME**: Some retinal thickening or hard exudates in the posterior pole, distant from the center of the macula
  - **Moderate DME**: Retinal thickening or hard exudates near the center of the macula but not involving the center
  - **Severe DME**: Retinal thickening or hard exudates involving the center of the macula

- **KIM's classification based on OCT**:
  - Pattern I is a diffuse increased retinal thickening, with areas of reduced intraretinal reflectivity;
  - Pattern II is CME
  - Pattern III shows posterior hyaloidal traction, which appears as a highly reflective band over the retinal surface
Pattern IV exhibits serous retinal detachment not associated with posterior hyaloidal traction, which appears as a dark accumulation of subretinal fluid beneath a highly reflective dome-like elevation of detached retina.

Pattern V shows posterior hyaloidal traction and tractional retinal detachment, which appear as a peak-shaped detachment with a highly reflective signal arising from the inner retinal surface and with an area of low signal beneath the highly reflective border of detached retina.

**Clinical evaluation**

- ETDRS defined clinically significant macular edema (CSME) as:
  1. thickening of the retina at or within 500 µm of the center of the macula
  2. hard exudates at or within 500 µm of the center of the macula, if associated with thickening of the adjacent retina (not residual hard exudates remaining after the disappearance of retinal thickening)
  3. a zone or zones of retinal thickening one disc area or larger, any part of which is within one disc diameter of the center of the macula

- Definition for CSME was based on observation that retinal thickening or hard exudation involving or threatening the fovea frequently leads to vision loss.

- Careful assessment of the distribution of retinal thickening and hard exudates and their relation to the center of the macula remains paramount to management of DME.

**Management**

- **Focal/grid laser photocoagulation:**
  - ETDRS: At 3 years, eyes with mild or moderate NPDR plus macular edema at baseline treated with immediate focal/grid laser photocoagulation showed an approximately 50% decrease in the rate of moderate vision loss (defined as a decrease of three lines or more on a logarithmic visual acuity chart, corresponding to a doubling of the initial visual angle).
  - FOCAL: “direct” treatment of all microaneurysms exhibiting leakage of fluorescein dye in regions of retinal thickening between 500 and 3000 µm from the foveal center → 50-100 µm, exposure 0.05-0.10 seconds, and intensity sufficient to whiten or darken large microaneurysms.
  - GRID: areas of diffuse leakage of fluorescein dye and areas of capillary nonperfusion in regions of retinal thickening between 500 and 3000 µm from the foveal center, with spacing between spots of at least one burn-width → size less than 200 µm, exposure 0.05-0.10 seconds, and intensity described as “mild”.
• Present standard technique: “modified-ETDRS Grid” → DRCR.net

• Pharmacotherapy with vascular endothelial growth factor (VEGF) antagonists
  - bevacizumab, a humanized murine monoclonal antibody binding VEGF-A
  - ranibizumab, a humanized murine monoclonal antibody fragment, also binding VEGF-A
  - pegaptanib sodium, an aptamer specifically inhibiting the VEGF-A 165 isoform
  - aflibercept, a human fusion protein incorporating ligand-binding elements from VEGF receptors and the Fc region of an IgG1 molecule

• DRCR.net comparison of four strategies for treatment of DME
  1. sham injection with focal/grid laser photocoagulation
  2. intravitreous injection of ranibizumab (0.5 mg) with deferral of early laser
  3. intravitreous injection of ranibizumab (0.5 mg) with early laser (within 3-10 days)
  4. intravitreous injection of triamcinolone acetonide (4 mg) with early laser

  ▪ The main outcome measure, best-corrected visual acuity, was evaluated at one year, with follow-up planned for 3 years

  ▪ RESULTS: At one year, mean change in visual acuity was significantly better in the ranibizumab plus prompt laser and ranibizumab and deferred laser groups compared with the prompt laser plus sham injection group. Mean change in visual acuity was not significantly different from the prompt laser plus sham injection group in the triamcinolone plus prompt laser group

• RESTORE study
  1. intravitreous injection of ranibizumab (0.5 mg) and sham laser
  2. injection of ranibizumab (0.5 mg) and focal/grid laser photocoagulation
  3. sham injection and focal/grid laser photocoagulation

  ▪ At 12 months, the mean change in visual acuity in the group getting ranibizumab alone (+6.1 letters) and in the group getting ranibizumab plus laser (+5.9 letters) was significantly better compared with the group getting laser alone (+0.8 letters; both P <0.0001).

• BOLT study
  ▪ intravitreous injection of bevacizumab (1.25 mg) (3 injection 6 weeks apart → PRN 6 weekly)
• modified-ETDRS focal/grid laser photocoagulation

• At 12 months, the mean change in visual acuity was significantly better in bevacizumab group (+5.6 letters) than in the laser group

• **Pharmacotherapy with corticosteroids**
  
  – **DRCR.net**
    
    1. modified-ETDRS focal/grid laser photocoagulation
    
    2. intravitreous injection of triamcinolone acetonide (1 mg)
    
    3. intravitreous injection of triamcinolone acetonide (4 mg),
    
    – primary outcome measure of mean change in best-corrected visual acuity at two years
    
    – Persistent or new macular edema was retreated every 4 months
    
    – Mean change in visual acuity at two years was **significantly better in laser-treated eyes** than in eyes receiving 1 mg triamcinolone and likewise significantly better than in eyes receiving 4 mg triamcinolone.
    
    – Cataract surgery was performed in 13% of eyes in the laser group, 23% of eyes in the 1 mg triamcinolone group, and 51% of eyes in the 4 mg group.
    
    – Intraocular pressure elevation of 10 mmHg or more from baseline at any study visit was noted in 4, 16, and 33% of eyes in the three groups

  – **Retisert**: fluocinolone acetonide intravitreal implant
    
    – 0.59 mg pellet embedded in a **nonbiodegradable** scaffold
    
    – in the vitreous cavity via a **sclerotomy** and anchored by a suture to the eye wall
    
    – releases drug at steady state between 0.3 and 0.4µg/day for approximately 30 months

  – **Iluvien**: fluocinolone acetonide
    
    – non-biodegradable cylinder (3.5×0.37 mm)
    
    – injection by 25-gauge needle
    
    – 0.2 and 0.5µg/day
    
    – 1 year

  – **Ozurdex**: dexamethasone intravitreous implant
    
    – 60 days
- **22-gauge** needle-injector system
- **350 µg and 700 µg** version

- **Vitrectomy**
  - demonstrable vitreomacular traction and epiretinal proliferation in DME

## Telescreening

- **Telemedicine** is the *exchange of medical data by electronic telecommunications technology* allowing a patient's medical problems to be evaluated, monitored, and possibly treated while the patient and physician are located at sites physically remote from each other.

- screening programs for diabetic retinopathy:
  - o **ophthalmologist-based** (with actual presence of the ophthalmologist at the site of screening)
  - o **ophthalmologist-led** (no ophthalmologist at the site of screening)

- Telemedicine for retinopathy screening is an ophthalmologist-led screening model.

- American Telemedicine Association (ATA) telehealth practice recommendations for diabetic retinopathy:
  - o four categories of telescreening programs
    - Category 1: The program allows identification of patients who have no or minimal diabetic retinopathy and distinguishes them from those who have more than minimal diabetic retinopathy.
    - Category 2: The program allows identification of patients who do not have **sight-threatening** diabetic retinopathy and distinguishes them from those who have potentially sight-threatening diabetic retinopathy.

- The **gold standard for telescreening** is the *ETDRS 7 mydriatic standard field 35 mm stereoscopic color fundus photographs*

- Picture archiving and communication systems (PACS) consists of four major components: the imaging instrumentation, a secured network for the transmission of patient information, workstations for interpreting and reviewing images, and archives for the storage and retrieval of images and reports.
Hypertension

- hypertensive retinopathy, choroidopathy, and optic neuropathy
- also a major risk factor for many other eye diseases, including the development and progression of diabetic retinopathy, retinal vein occlusion, retinal arterial macroaneurysm, and possibly age-related macular degeneration and glaucoma

Retinopathy

- Evolution and Phases
  1. **vasoconstrictive phase**: initial response to elevated blood pressure is vasospasm and an increase in vasomotor tone, with consequent narrowing of retinal arterioles
  2. **sclerotic phase**: Persistently elevated blood pressure leads intimal thickening, media wall hyperplasia and hyaline degeneration leading to manifestation of diffused and localized (focal) retinal arteriolar narrowing, arteriolar wall opacification ("silver" or "copper wiring"), and compression of the venules by structural changes in the arterioles (arteriovenous “nicking” or “nipping”).
  3. **exudative phase**: chronically sustained blood pressure elevation→ blood-retinal barrier is disrupted → of the smooth muscles and endothelial cells, exudation of blood and lipids and retinal nerve fiber layer ischemia, which results in microaneurysms, retinal hemorrhages, hard exudates, and cotton-wool spots seen in the retina.
  4. **malignant hypertension phase**: optic disc swelling which may reflect underlying hypertensive encephalopathy with raised intracranial pressure

- Classifications
  - **Keith-Wagener-Baker system**
  - **Wong and Mitchell**:
    - **None**: no detectable signs
    - **Mild**: Generalized arteriolar narrowing, focal arteriolar narrowing, arteriovenous nicking, arteriolar wall opacification (silver or copper wiring), or a combination of these signs
- **Moderate**: Hemorrhages (blot, dot, or flame-shaped), microaneurysms, cotton-wool spots, hard exudates, or a combination of these signs
- **Malignant**: Signs of moderate retinopathy in combination with optic disc swelling, in the presence of severely elevated blood pressure

**Hypertensive choroidopathy**

- **Elschnig spots** (round, deep, and gray-yellow patches at the level of the retinal pigment epithelium)
- **Siegrist streaks** (linear hyperpigmented streaks along choroidal arteries)

**Hypertensive optic neuropathy**

- Ischemia, raised intracranial pressure and hypertensive encephalopathy are all possible mechanisms that can result in papilloedema
- strongly correlated with CVD risk and mortality

**Retinal Artery Obstructions**

**CRAO**

- first described in 1859 in von Graefe's report
- 1 in 10,000
- early sixties
- CF
o monocular, painless, severe loss of vision

o premonitory episodes of amaurosis fugax

o CRAO after amaurosis fugax is estimated to be only 1% per year

o VA: counting fingers to light perception in 74-90%, preserved if Cilioretinal Artery supplying macula

o VA may spontaneously improve in up to 22% of patients with nonarteritic CRAO

o afferent pupillary defect develops within seconds following obstruction of the central retinal artery regardless of macular sparing

o anterior-segment exam is normal initially: NVI 16%, mean of 4-5 weeks

o Fundus: The classic dense, white haze of the central region in the retina with a well-marked clear patch at the yellow-spot was very well shown → cherry-red spot

o ACUTE: cherry-red spot (90%), posterior pole retinal opacity or whitening (58%), box-carrying of retinal arteries and veins (19% and 20% respectively), retinal arterial attenuation (32%), optic disc edema (22%), and optic nerve pallor (39%).

o patent cilioretinal artery supplying some or all of the papillomacular bundle is seen in approximately one-third of cases

o Retinal emboli are the most common cause of nonarteritic CRAO and BRAO

o yellow, refractile cholesterol embolus (Hollenhorst plaque)

o CHRONIC: optic atrophy (91%), retinal arterial attenuation (58%), cilioretinal collaterals (18%), macular RPE changes (11%), and cotton-wool spots (3%)

• IX

o FA: some variable residual retinal circulation with delayed and sluggish filling of the retinal vasculature

o OCT: irregular macular contour with increased reflectivity of the inner retina.

o VF: central scotoma, paracentral scotoma, Peripheral constriction

o ERG: more severe attenuation of the b-wave than the a-wave since the inner retinal layers are more affected

• Systemic associations

o from carotid artery atherosclerosis is the most common etiology

o but in < 40 years → cardiac emboli
Embolic sources
- Trauma
- Coagulopathies
- Ocular conditions
- Collagen vascular disease
- Other vasculitides and inflammatory conditions
- Miscellaneous associations

- The presence of a Hollenhorst plaque or retinal artery occlusion is associated with a low prevalence of carotid atherosclerosis requiring carotid endarterectomy

Evaluation
- rule out giant cell arteritis in patients older than 50 years
- embolic source often includes carotid Doppler imaging and echocardiography
- cardiac evaluation:
  - hypercoagulability evaluation should be considered for patients less than 50 years

Treatment
- retina suffers no damage up to 97 minutes after an acute CRAO but after 4 hours the retina suffers massive irreversible damage
- recommended within 24 hours of symptom onset
- ocular massage, sublingual isosorbide dinitrate, intravenous acetazolamide, intravenous mannitol or oral glycerol, anterior-chamber paracentesis, intravenous methylprednisolone, streptokinase, and retrobulbar tolazine.
- Ocular massage: Goldmann contact lens or digital massage to apply ocular pressure with an in-and-out movement to dislodge a possibly obstructing embolus
- mixture of 95% oxygen and 5% carbon dioxide (carbogen) can be provided to induce vasodilation and improve oxygenation
- purpose of hyperbaric oxygen is to preserve the retina in an oxygenated state until recanalization and reperfusion occur, typically at 72 hours
- Anterior-chamber paracentesis
- Nd-YAG laser arteriotomy
Corticosteroids should only be used when arteritic CRAO from giant cell arteritis is suspected.

Intravenously or intra-arterially administered thrombolytics currently in use include streptokinase, urokinase, and tissue plasminogen activator (t-PA).

EAGLE study: similarity in efficacy between groups and the higher rate of adverse events, namely cerebral hemorrhage, in the intra-arterial t-PA group.

**BRAO**

- 38% of all acute retinal artery obstructions

- **CF**
  - Monocular vision loss, which may be restricted to one part of the visual field
  - Field defects include a central scotoma in 20%, a central altitudinal defect in 13%, and sector defects in 49%
  - Fundus: sectoral pattern of retinal opacification, typically occur at vessel bifurcations, and 98% of the time the temporal
  - CHRONIC:
    - Sectoral nerve fiber layer loss and arterial attenuation may be seen
    - Artery-to-artery collaterals may also be seen and are pathognomonic for BRAO

- Visual prognosis in eyes with symptomatic BRAO is generally good, and acuity usually improves to 20/40 or better in 80% of eyes

**CLARA- Cilioretinal artery occlusion**

- 5% of retinal arterial obstructions
- 32% of the time seen in FA and fill concomitantly with the choroidal circulation
- Three distinct groups are found:
  1. **isolated CLRAO**
     - Good prognosis, with nearly 90% achieving 20/40
• presumably secondary to intact superior and inferior nerve fiber layer bundles supplying the fovea

2. CLRAO associated with CRVO

• 40% of CLRAO
• 5% of eyes with CRVO
• Visual acuity correlates with the degree of venous obstruction

3. CLRAO in conjunction with anterior ischemic optic neuropathy

• 15% of eyes with CLRAO
• Poor visual prognosis, ranging from 20/400 to no light perception

Combined retinal artery and vein occlusion

• CRVO can be seen in association with CRAO, BRAO, and CLRAO
• The visual prognosis is generally poor, with visual acuity in the hand motions range.
• After 6-8 weeks, optic nerve pallor is seen with severe arterial attenuation

Cotton-wool spots

• soft exudates is misnomer
• slightly elevated, small, yellow-white or gray-white, cloud-like, linear or serpentine lesions with fimbriated borders in the superficial retina
• usually restricted to the posterior segment of the fundus
• rarely cause vision loss unless they involve the fovea
• **resolve within 6-12 weeks** though they may last longer in diabetics
• secondary to obstruction of a retinal arteriole with resultant ischemia
• light microscopy of cotton-wool spots in the retina revealed the presence of a cytoid body, a round, dark-staining “pseudonucleus” within a grossly swollen nerve fiber layer

• **Etiologies**
  - Ischemic
  - Embolic
  - Collagen vascular disease
  - Infectious
  - Toxic
  - Neoplastic
  - Miscellaneous
  - Idiopathic

**Acquired Retinal Macroaneurysms**

• fusiform or round dilations of the retinal arterioles within the **first three orders** of arteriolar bifurcation

• at the site of an arteriolar bifurcation or an arteriovenous crossing

• supratemporal artery is the most commonly **reported**

• **Most cases are unilateral, while 10% may be bilateral**

• 1 in 9000

• sixth and seventh decades

• F >> M

• Systemic investigations for hypertension and cardiovascular disease should be done

• CF
  - decline in central visual acuity as a result of retinal edema, exudation, or hemorrhage
  - hourglass hemorrhages are typical
o Bleeding from macroaneurysms can occur in the subretinal space, into the retina, beneath the internal limiting membrane, or into the vitreous

o Circinate ring of exudates

• Ix

o FA: hypofluorescence in case of hemorrhage

o ICG: allow the light to penetrate the hemorrhage to a greater extent

o Lesions are pulsatile and contiguous with the arterial wall, pathognomonic of an insolated retinal artery macroaneurysm

• Mx

o Yellow dye laser has been considered for treatment because of its theoretical advantages

o Exudative process may progress

o Vitrectomy was performed for clearing the macular hemorrhage

o Pneumatic displacement with or without tissue plasminogen activator

o Direct laser photocoagulation of the macroaneurysm

• DD

o Diabetic retinopathy, retinal telangiectasia, retinal capillary angioma, cavernous hemangioma, malignant melanoma, and the hemorrhagic pigment epithelial detachment of age-related macular degeneration

Retinal Vein Occlusions

BRVO

• M = F

• 60-70 years

• Risk Factors

  o Systemic vascular diseases: hypertension and arteriosclerosis

  o Smoking, hyperlipidemia, glaucoma, and ocular inflammatory disease
Antiphospholipid antibodies, elevated plasma homocysteine levels, and low serum folate levels
decreased risk is present in those with higher serum levels of high-density lipoprotein and light to moderate alcohol consumption
short axial length
DIABETES is NOT an independent risk factor.

Pathogenesis
mostly occurs at arteriovenous crossings
retinal artery and vein share a common adventitial sheath
turbulent blood flow at the crossing site causes focal swelling of the endothelium and deeper vein wall tissue, leading to venous obstruction
resulting venous obstruction leads to elevation of venous pressure that may overload the collateral drainage capacity → macular edema and ischemia and intraretinal hemorrhage

CF
sudden painless loss of vision or a visual field defect
floaters from a vitreous hemorrhage
wedge-shaped distribution of intraretinal hemorrhage
ischemic BRVO: greater than a total of five disc diameters of nonperfusion on fluorescein angiography
most common location for BRVOs is in the superotemporal (larger number of arteriovenous crossings)

IX
FA:
macular leakage and edema, macular ischemia, and large segments of capillary nonperfusion that may portend eventual neovascularization
delayed filling of the occluded retinal vein
Wide-field angiography
Optos C200MA

OCT
intraretinal hemorrhages have a minimal effect on the interpretation of OCT
- cystoid edema, intraretinal hyperreflectivity from hemorrhages, shadowing from edema and hemorrhages, and occasionally subretinal fluid
- photoreceptor inner-segment-outer-segment junction abnormalities from long-standing macular ischemia and macular edema

• Cx
  o 1) macular edema; (2) macular ischemia; and (3) sequelae of neovascularization
  o BVOS: 31-41% of patients with ischemic BRVO developed neovascularization or vitreous hemorrhage, compared with 11% of patients with nonischemic BRVO

• Diagnostic Work-up
  o Young patient
    ▪ oral contraception in females
    ▪ medications that can promote a hypercoagulable state or thromboembolism
    ▪ infectious causes such as Lyme disease, syphilis, or human immunodeficiency virus
    ▪ complete blood count, prothrombin time/partial thromboplastin time/international normalized ratio, lipid panel, serum homocysteine, anticardiolipin antibodies, antinuclear antibodies with lupus anticoagulant, protein C/S, and activated protein C resistance (factor V Leiden)
  o Older patient
    ▪ idiopathic or due to hypertension or atherosclerosis.
  o Bilateral or numerous BRVO patients
    ▪ infectious or inflammatory disorder or hypercoagulopathy

• Management
  • Medical: anticoagulants are not recommended

• Laser

• BVOS for macular edema
  o Eligibility: fluorescein-proven perfused macular edema involving the foveal center, absorption of intraretinal hemorrhage from the foveal center, recent BRVO (usually 3-18 months' duration), no diabetic retinopathy, and vision reduced to 20/40 or worse after best refraction
  o argon laser photocoagulation: 0.1 second, a 100-µm diameter spot size, and a power setting sufficient to produce a “medium” white burn
• APPLICATION: grid pattern, no closer to the fovea than the edge of the capillary-free zone and no further into the periphery than the major vascular arcade

• After 3 years of follow-up, 63% of treated eyes gained two or more lines of vision, compared to 36% of untreated eyes.

• The average gain in visual acuity for treated eyes was one more Snellen line than in untreated eyes.

• BVOS emphasize waiting at least 3-6 months before considering laser therapy

• **BVOS for neovascularization**
  - large areas (>5 disc diameters) of retinal capillary nonperfusion are at risk for developing neovascularization
  - 40% of these eyes develop neovascularization, and of this 40%, about 60% will experience periodic vitreous hemorrhage → at any time within the first 3 years
  - scatter laser photocoagulation can lessen subsequent neovascularization and, if neovascularization already exists, that peripheral scatter laser photocoagulation can lessen subsequent vitreous hemorrhage
  - incidence of neovascularization can be reduced from about 40% to 20% (only after neovascularization is observed), VH from 60% to 30%
  - Iris neovascularization is a rare complication, more if DM is also there
  - APPLICATION: argon blue-green laser to achieve “medium” white burns (200-500 µm in diameter) spaced one burn width apart and covering the entire area of capillary nonperfusion

• **Steroid treatment**
  - inhibit the expression of VEGF and therefore reduce macular edema

• **SCORE (triamcinolone) study**
  - Standard care vs Corticosteroid for Retinal vein occlusion (SCORE) BRVO study
  - 3 groups: macular grid laser, 1 mg IVTA, or 4 mg IVTA
  - no significant difference in vision or the reduction of macular edema measured by OCT at the end of 12 months between each group.
  - laser group maintained a significantly greater average increase in vision (12.9 letters) compared with the two IVTA groups
  - RESULT: IVTA is not recommended as first-line therapy, considered in patients where macular grid laser or other therapies are ineffective, as the treatment was found to be relatively safe, especially in pseudophakic eyes.
• **GENEVA (dexamethasone implant) study**
  - **Global Evaluation of implantable dexamethasone in retinal Vein occlusion with macular edema**
  - Ozurdex for CRVO-BRVO
  - Ozurdex is a biodegradable copolymer of poly (d,l-lactide-co-glycolide) acid (PLGA) containing micronized dexamethasone
  - 3 groups: ozurdex 0.7 mg, 0.35 mg, and sham groups
  - At 90 days after injection, there was a significant improvement ($P < 0.001$) in central retinal thickness measured by OCT in both Ozurdex groups, compared with the sham group.

• **Anti-VEGF treatment**
  - ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), and aflibercept (Eylea).
  - ranibizumab is FDA-approved for the treatment of RVO.

• **BRAVO (ranibizumab) study**
  - Branch Retinal Vein Occlusion (BRAVO) study
  - 3 groups: sham injection, 0.3 mg ranibizumab, 0.5 mg ranibizumab
  - first 6 months
    - monthly injections
    - At month 3 to 6, a patient was eligible for rescue laser if a gain of <5 ETDRS letters, or improvement of <50 µm.
    - both ranibizumab groups gained +16.6 and +18.3 ETDRS letters (0.3 mg and 0.5 mg groups, respectively) compared with a gain of +7.3 letters in the control group.
  - After the first 6 months
    - All 3 group PRN intravitreal ranibizumab monthly if they had vision ≤ 20/40 or mean central foveal thickness ≥250 µm.
    - both ranibizumab groups maintained their vision gain at 12 months.
  - ranibizumab is superior to traditional laser.
  - current recommendation: **monthly 0.5 mg ranibizumab**

• **Other anti-VEGF inhibitors**
- **Bevacizumab**: 6 months the 1.25 mg group improved by an average +5.1 lines compared with +4.8 lines in the 2.5 mg group.

- **Pegaptanib**

- **Aflibercept**: COPERNICUS and GALILEO, 2 mg aflibercept or sham

**Experimental treatments**

- **FAVOR (iluvien) study**: sustained-release, non-erodable, intravitreal implant of fluocinolone acetonide

**Surgical management**

- **Vitrectomy with or without sheathotomy**: limited clinical use as a first-line therapy.

---

**CRVO**

- **M = F**

- prevalence of CRVO at <0.1 to 0.4%

- **risk in fellow eye is approximately 1% per year**

- **7% of persons with CRVO may develop CRVO in the fellow eye within 5 years**

- **CF**

  - sudden painless loss of vision

  - VA variable

  - retinal hemorrhages (both superficial flame-shaped and deep blot type) in all four quadrants

  - dilated, tortuous retinal venous system.

  - classic “blood and thunder” appearance

  - Optic nerve head swelling, cotton-wool spots, splinter hemorrhages, and macular edema

  - Breakthrough vitreous hemorrhage

  - cilioretinal artery occlusion can occur in association with CRVO
- presence of an afferent pupillary defect, electroretinography (a negative waveform may be seen), and Goldmann perimetry

- CHRONIC: hemorrhage may decrease or resolve, RPE Changes, Macular edema often chronically persists, ERM, OC Shunts, NVD, NVE, VH - TRRD

- **NVA 6-12% cases without any NVI**

- CVOS used an index of any 2 clock-hours of NVI or any NVA as evidence of significant anterior-segment neovascularization

- Elevated intraocular pressure associated with NVI/NVA is the hallmark of neovascular glaucoma.

**Classification**

- **perfused CRVO** (also termed nonischemic, incomplete, or partial)
  - less than 10 disc areas of retinal capillary nonperfusion
  - lesser degree of intraretinal hemorrhage
  - better initial and final visual acuity

- **Nonperfused CRVO** (also termed ischemic, hemorrhagic, or complete)
  - 10 or more disc areas of retinal capillary nonperfusion
  - greater degree of intraretinal hemorrhage, macular and disc edema, and capillary nonperfusion

- **indeterminate**
  - sufficient intraretinal hemorrhage to prevent angiographic determination of the perfusion status

**Natural history**

- In perfused, 10% developed NVI/NVA compared to 35% of eyes initially characterized as nonperfused or indeterminate

- 45% chance of developing neovascular glaucoma after onset of ischemic CRVO at 3 years

- 34% of initially perfused eyes converted to nonperfused status after 3 years

- 83% with an indeterminate CRVO at baseline were ultimately determined to be nonperfused

**Pathogenesis**

- thrombus occluding the lumen of the central retinal vein at or just proximal to the lamina cribrosa
• CRA-V branches before lamina cribrosa
• common tissue sheath
• compression from mechanical stretching of the lamina, as with increases in intraocular pressure
• compression by an atherosclerotic central retinal artery or primary occlusion of the central retinal vein from inflammation
• **Virchow's triad**: diminished blood flow, increased blood viscosity, and an altered lumen wall
• hypothesized that a less hemorrhagic, more likely nonischemic, CRVO may be due to occlusion of the central retinal vein at a site further posterior, allowing normal collateral channels to provide alternative routes of venous drainage.
• VEGF from ischemic retina → NV and macular edema

• **Risk factors**
  • Systemic vascular diseases: diabetes mellitus, hypertension, carotid insufficiency
  • Ocular diseases: open angle glaucoma, ischemic optic neuropathy, pseudotumor cerebri, tilted optic nerve heads, optic nerve head drusen
  • Hematologic alterations:
    • Inflammatory/autoimmune vasculitis: systemic lupus erythematosus
    • Medications: oral contraceptives, diuretics, hepatitis B vaccine
    • Infectious vasculitis: HIV, syphilis, herpes zoster, sarcoidosis
    • Other: after retrobulbar block, dehydration, pregnancy

• **Evaluation**
  • visual acuity, pupillary reaction, and intraocular pressure. Undilated slit-lamp examination is performed to detect NVI or NVA
  • Undilated gonioscopy
  • systemic workup is not indicated in persons older than 60
  • young patients: systemic thrombotic disease, family history of thrombosis, or other symptoms suggestive of a hematologic or rheumatologic condition, erythrocyte sedimentation rate, antinuclear antibody, antiphospholipid antibody, and fasting plasma homocysteine levels
• **Treatment**

• treating the sequelae of CRVO, particularly macular edema and neovascularization

• **Treatment of macular edema**

  o CVOS did not recommend grid laser photocoagulation for CRVO-associated macular edema

  o **OBSERVATION** is the standard of care for CRVO-associated macular edema

  o **Standard care vs Corticosteroid for Retinal vein occlusion (SCORE) study**
    
    ▪ 3 groups: preservative-free IVTA 1 mg and 4 mg, versus standard of care

    ▪ retreated with IVTA every 4 months for 1 year unless CMT, 225, VA > 20/25, adverse event (cataract and glaucoma), additional treatment needed as no improvement for 2 injections

    ▪ 1 year, 26% (4 mg) and 27% (1 mg) gained ≥15 letters at 1 year compared to 7% of untreated

    ▪ Cataract formation: 26% (1 mg) and 33% (4 mg) IVTA groups compared to 18% in the observation group

    ▪ Elevated intraocular pressure: 20% (1 mg) and 35% (4 mg), 8% in observation

  o sustained-release intravitreal fluocinolone acetonide implant (**Retisert**) for chronic refractory CME

  o **GENEVA (dexamethasone implant) study**

    ▪ **Global Evaluation of implantable dexamethasone in retinal Vein occlusion with macular edema**

    ▪ Ozurdex for CRVO-BRVO

    ▪ Ozurdex is a biodegradable copolymer of poly (D,L-lactide-co-glycolide) acid (PLGA) containing micronized dexamethasone

    ▪ 3 groups: ozurdex 0.7 mg, 0.35 mg, and sham groups

    ▪ At 90 days after injection, there was a significant improvement ($P < 0.001$) in central retinal thickness measured by OCT in both Ozurdex groups, compared with the sham group

• **Intravitreal anti-VEGF therapy**

  o **CRUISE trial**
- 3 groups: monthly intravitreal injections of 0.3 mg or 0.5 mg ranibizumab to sham-injected controls
- 0.3 mg and 0.5 mg ranibizumab gained 12.7 and 14.9 letters, respectively, at 6 months compared to a 0.8 letter gain in the sham group
  - Pegaptanib (Macugen)
  - study using a single injection of bevacizumab (OFF LABEL)
- IVTA
- **Treatment of ocular neovascularization**
- Laser photocoagulation
  - CVOS group N report compared the efficacy of PRP
  - 2 groups: early treatment (in 90 days without NVA-NVI) and delayed but prompt treatment (after NVA-NVI)
  - CVOS therefore recommended that PRP be delivered promptly after the development of NVI/NVA but not prophylactically in eyes with nonperfused CRVO
  - Prophylactic placement of PRP may be considered in eyes with nonperfused CRVO and risk factors for developing NVI/NVA (male gender, short duration of CRVO, extensive retinal nonperfusion, and extensive retinal hemorrhage) or in cases where frequent ophthalmologic follow-up is not possible.
- **Treatment of systemic medical conditions**
  - systemic hypertension and diabetes mellitus
  - **Oral pentoxifylline** is a potent vasodilator: 400 mg three times a day
- **Alternative treatments**
  - Chorioretinal venous anastomosis
  - Tissue plasminogen activator
  - Surgical treatments
    - **Vitrectomy**
    - **Radial optic neurotomy**
Macular Telangiectasia

- mac tel
- Coats disease: congenital telangiectasia
- Leber miliary aneurysms
- Gass: idiopathic juxtafoveolar retinal telangiectasis (IJRT)

**Etiopathology:**
- AD/ sporadic
  - expression of Müller cell-specific markers in the fovea, which correlated with macroscopically visible pigment depletion in this area

**Classification (mac tel study group):**
- mac tel type 1:
  - developmental or congenital
  - unilateral vascular anomaly
  - part of the larger spectrum of Coats disease
- mac tel type 2:
  - presumably acquired bilateral
  - middle-aged and older
  - macular, juxtafoveal, or perifoveal telangiectasia

**Classification GASS:**
- Group 1A and B: Leber miliary aneurysms
- group 2: common bilateral disease seen in older and elderly patients (2A), younger brothers (2B)
- group 3A: telangiectatic changes, vascular occlusion, and minimal exudation in 3 patients
- group 3B: similar retinal changes but had additional neurological changes in 3 patients also

**Yannuzzi classification:** idiopathic macular telangiectasia
- aneurysmal telangiectasia: type 1A and 1B
- type 2A (2b,3a,3b were removed because of lack of subjects)

**Epidemiology**
- Prevalence: 0.1%, *Beaver dam eye study*
- Incidence 0.0045% to 0.022%: *Melbourne collaborative cohort study*

**CF**
- Earliest: subtle loss of retinal transparency in the perifoveal region, beginning temporally
- dilation of the parafoveal capillaries in the temporal parafoveal area
- retinal hard exudates in type 1 only
- Crystalline deposits at the vitreoretinal interface
- Blunted, dilated venules, either as single or multiple vessels, are often associated with ectatic capillaries. As vessels course towards the fovea, they usually decrease in diameter but, in mac tel type 2, they dilate and may make a right-angle turn, diving into the deeper retinal layers
- yellow spot, or vitelliform lesion, in the center of the fovea with slight loss of the foveal depression may become apparent in some eyes
- neovascularization is most commonly seen temporal
- fibrovascular scar with chorioretinal anastomosis can be the endpoint of the pathogenic process

**FAF:** loss of the hypofluorescent center seen normally on blue-light FAF due to the depletion of macular pigment in this condition → **diagnostic**

**FA:** characteristic telangiectactic capillaries on FA, starting predominantly temporal to the fovea

**OCT**
- temporal enlargement of the foveal pit
- disruption of the photoreceptor inner-segment-outer-segment junction
- hyporeflective cavities in the inner retina and these may clinically be described as “pseudolamellar macular holes.”

**Adaptive optics imaging:** scanning laser ophthalmoscope, allows evaluation of the cone photoreceptor mosaic
- **Visual function:** NEI-VFQ-25
- **Microperimetry**
• Clinical Staging of Macular Telangiectasia Type 2 GASS & BLODI
  1. No biomicroscopic abnormality, no or minimal capillary dilation, mild staining of outer perifoveal retina
  2. Slight graying of perifoveolar retina, no or minimal biomicroscopically visible telangiectatic vessels, but capillary telangiectasis of outer capillary network temporally on fundus autofluorescence
  3. One or several slightly dilated and blunted retinal venules descending into outer perifovea, typically temporally
  4. Pigment hyperplasia, often surrounding right-angle venules
  5. Subretinal neovascularization, often in proximity to intraretinal pigment migration

• Differential diagnosis
  o Branch retinal vein occlusions
  o Radiation retinopathy
  o Neovascular age-related macular degeneration

• Treatment
  o No generally accepted therapies
  o Laser photoagulation or photodynamic therapy

Coats Disease

• Scottish ophthalmologist George Coats in 1908
• Initial classification of group 1, 2, 3 is now dropped
• Male 3 times more than females
• Unilateral in 80-95%
• Etiopathology
  o deficiency of Norrin, a retinal protein, in the pathogenesis of Coats disease
  o Coats disease may be part of a spectrum of related genetic disorders known as retinal hypovascularopathies which includes Norrie disease, familial exudative vitreoretinopathy (FEVR), fascioscapulohumeral muscular dystrophy (FSHD), and the osteoporosis pseudoglioma syndrome
  o Norrie disease pseudoglioma (NDP) gene on chromosome Xp11.2

• CF
  o Symptoms: Decreased visual acuity (43%): variable, strabismus (23%), leukocoria/xanthocoria (20%), pain (3%), heterochromia (1%), nystagmus (1%), no symptom (8%)
  o Anterior Segment: 90% normal, rest → cataract (8%), iris neovascularization (8%), shallow anterior chamber (4%), corneal edema (3%), cholesterol in the anterior chamber (3%) and megalocornea (2%).
  o Retinal findings: telangiectasia (100%), intraretinal exudation (99%), exudative retinal detachment (81% with 42% demonstrating partial retinal detachment and 58% with total retinal detachment), retinal hemorrhage (13%), retinal macrocyst (11%), vasoproliferative tumor (6%), and optic disc neovascularization (1%).

• Shields Staging System TEDGP
  1. Retinal telangiectasia (T) only
  2. Telangiectasia and exudation (E): Extrafoveal, Foveal
  3. Exudative retinal detachment (D): Subtotal, Total
  4. Total retinal detachment and glaucoma (G)
  5. Advanced endstage disease often with phthisis (P) bulbi

• Ix
  o FA:
    ▪ Telangiectasia, aneurysms, beading of vessel walls, and various vascular communicating channels
    ▪ peripheral retinal nonperfusion
- early and persistent leakage,
  - CT: characterize intraocular morphology, quantify subretinal densities, identify vascularities within the subretinal space through the use of contrast enhancement, and detect other abnormalities
  - MRI: distinguished from Coats disease, toxocariasis, and persistent hyperplastic primary vitreous
  - Doppler ultrasonography:
    - Blood testing: Aqueous and SRF lactic dehydrogenase

- **Coats plus syndrome:** Coats-like picture associated with varied skeletal defects, cerebellar and extrapyramidal movement disorder, epileptic seizures, leukodystrophic changes, and postnatal growth failure

- **Differential diagnosis**
  - **juvenile Coats disease:** Retinoblastoma, RD, Congenital cataract, Norrie disease, PHPV, toxocariasis, hemangiomatosis, FEVR
  - **any stage of coats:** Eales, BRVO, toxoplasmosis

- **Treatment**
  - **Mild cases:** documentation and observation
  - **Ablative therapies**
    - laser photocoagulation
    - Double freeze-thaw cryotherapy
  - **Pharmacologic therapies**
    - IVTA
    - Intravitreal anti-VEGF agents
  - **Surgery**
Hemoglobinopathies

- Hemoglobin S: valine substitutes for a glutamic acid at the sixth position within the β-globin
- Hemoglobin C (Hb C) is caused by a glutamic acid to lysine mutation in the β-globin molecule.
- SCD remains the most common inherited blood disorder

**Pathophysiology**

- Hydrophobic polar valine takes the place of a nonpolar strongly hydrophilic glutamic acid residue
- Polymerization results in the generation of rigid fibers of Hb S
- Decreased erythrocyte deformability and increased rigidity can cause increased capillary transit time
- Sickleled erythrocytes display increased adhesion to vascular endothelium matrix proteins, such as laminin

**Systemic manifestations**

- Intravascular hemolysis, thrombosis, tissue necrosis, and ischemia, causes a myriad of systemic complications, including cerebrovascular accident, acute chest syndrome, pulmonary hypertension, splenic sequestration, priapism, osteonecrosis, cholelithiasis, pneumonia, leg ulcers, aplastic crisis, renal disease, need for recurrent transfusions, episodic, painful vaso-occlusive crises, and death
- Visual impairment: more in hemoglobin SC (33%) than in hemoglobin SS (3%)
  - Hb SS may not live long enough to manifest the ophthalmic disease
  - Higher hematocrit and cell density, and the lower Hb F, of individuals with Hb SC

**Ophthalmic clinical features**

- **Retrobulbar and orbital involvement:** periorbital swelling, lid edema, fever, facial pain, proptosis, restriction of motility, and resultant diplopia
- **Anterior-segment involvement:**
  - Saccular and sausage-like dilatations of the tiniest conjunctival vessels,
  - Segmental iris atrophy and pupil abnormalities
  - Hyphema in a patient with SCD and in those with sickle-cell trait represents a sight-threatening emergency, as even modest elevations of intraocular pressure (IOP)
have resulted in vision loss from central retinal artery occlusion or macular branch retinal artery occlusion

- Repetitive use of carbonic anhydrase inhibitors, for example, is contraindicated in SCD patients with hyphema

- **Posterior-segment involvement**

- Vitreoretinal interface:
  - peripheral retinal whitening: just like *white without pressure*
  - flat, brown, ovoid lesions in the retinal periphery: *dark without pressure*

- **Optic nerve**
  - Dark, dilated capillaries at the optic nerve head appear as small red dots → precapillary arterioles plugged with sickled erythrocytes

- **Macula**
  - *macular depression sign*: oval depression of the bright foveal or parafoveal reflex as a result of macular thinning due to ischemic atrophy
  - enlarged foveal avascular zone (FAZ)
  - “splaying,” or blunting of the foveal contour on SD-OCT in asymptomatic patients with SCD

- **Angioid streaks**
  - 1-2%
  - irregular, reddish subretinal bands → benign course in HbSS

- **Retinal vasculature**
  - Vascular tortuosity caused by arteriovenous anastomoses may be more commonly observed in Hb SS
  - peripheral retinal nonperfusion
  - Retinal arteriole “silver-wiring” represents permanently occluded arterioles

- **Nonproliferative sickle retinopathy**

  - *Salmon patch hemorrhages*: blowout” of an occluded arteriole

  - *Iridescent spots*: small schisis cavity may develop after the intraretinal portion of the hemorrhage resolves.
- **Black sunburst**: flat, stellate, or round areas of hyperpigmentation, and result when intraretinal hemorrhage tracks into the subretinal space → **sunburst sign**

- **Proliferative sickle retinopathy**
  - Resembles marine invertebrate, *Gorgonia flabellum*
  - Peripheral retinal arteriolar occlusions → growth factors → neovascular fronds
  - Sea fans are predisposed to hemorrhage into the vitreous, and to cause vitreous membrane formation, tractional retinoschisis, and tractional or combined rhegmatogenous-tractional retinal detachment

- **Goldberg classification**
  1. Peripheral arterial occlusions
  2. Peripheral arteriovenous anastomoses
  3. Neovascular and fibrous proliferations: Sea-fan fronds are the hallmark of stage III PSR
  4. Vitreous hemorrhage: more commonly in the Hb SC than the Hb SS genotype (23% versus 3%)
  5. Retinal detachment: TRD

- **Incidence/prevalence**
  - 43% subjects with Hb SC disease and in 14% subjects with Hb SS disease

- **Risk factors**
  - Unstable type IIa border (hairpin loop) conferred an increased risk for PSR.
  - Hb SS: high total hemoglobin in males and a low Hb F in both males and females
  - **Hb SC**: High total hemoglobin and high MCHC

- **Progression**
  - Spontaneous regression of PSR may occur in 32%
  - **unilateral PSR** had a 16% (11% Hb SS, 17% Hb SC) probability of regressing to no PSR and a 14% (16% Hb SS, 13% Hb SC) probability of progressing to bilateral PSR.
  - **bilateral PSR** had an 8% (both Hb SC and Hb SS genotypes) probability of regressing to unilateral PSR and a 1% (0 Hb SS, 2% Hb SC) probability of regressing to a PSR-free state

- **Treatment**
Radiation Retinopathy

- Stallard in 1933
- Slowly progressive, delayed-onset *occlusive microangiopathy* of the retinal vasculature that occurs with variable latency after exposure of the retina to ionizing radiation.

**Etiopathogenesis**

- Ionizing radiation of the retina induces an acute transudative as well as a slowly progressive occlusive vasculopathy
- Fundamental abnormality, is retinal vascular endothelial cell injury and loss
- Loss of capillary cellularity leads to the development of microaneurysms, and hemodynamic alterations produce fenestrated telangiectatic retinal vessels.
- Closure of blood vessels is the single most characteristic finding on FA.
- In contrast to diabetic retinopathy, in which pericytes are initially affected, RR exhibits an early loss of endothelial cells.

**CF**

- Microaneurysms
- Intraretinal hemorrhages, macular capillary dilation and nonperfusion, and nerve fiber layer infarcts
- Retinal edema, hard exudates, telangiectasia, and perivascular sheathing
- FA: presence of severe retinal capillary nonperfusion, capillary dilation, and microaneurysms, frequently in combination with macular edema or ischemia

**Classification**

- Nonproliferative radiation retinopathy
- Proliferative radiation retinopathy
Clinically significant macular edema
Macular ischemia

- **Finger and Kurli prognosis-related classification**
  1. extramacular ischemic changes
  2. macular ischemic changes
  3. additional macular edema and retinal neovascularization
  4. vitreous hemorrhage and at least 5 disc areas of retinal ischemia, whether macular or extramacular

- **Horgan OCT-based grading scale**
  1. extrafoveolar, noncystoid edema
  2. extrafoveolar cystoid edema
  3. foveolar noncystoid edema
  4. mild-to-moderate foveolar cystoid edema
  5. severe foveolar cystoid edema

- **Risk factors**
  - Internal: concomitant vascular disease
  - External: Chemotherapy, pregnancy,

- **Incidence and dosimetry**
  - *Radiation type:* plaque, proton beam irradiation, gamma knife treatment
  - *Treatment modality:* EBRT are less likely than plaque
  - *Total radiation dose:* does not usually occur at total doses <45 Gy
  - *Fractionation schedule:* per fraction below 1.9 Gy/fraction has been shown to decrease the incidence of retinopathy
  - *Volume of retina irradiated:* more than 50 Gy to greater than 60% of the retina have been shown to be more likely to develop RR
  - *Total elapsed time:* most commonly occurs between 6 months and 3 years

- DD
diabetic or hypertensive retinopathy

- Bone marrow transplant retinopathy
- multiple branch retinal artery occlusions, multiple retinal venous occlusive episodes or retinal telangiectasia from other causes

- Prevention and treatment
  - Retinal laser photocoagulation remains the gold standard in the treatment of most forms of ischemic retinopathies.
  - Corticosteroids have both angiostatic and vascular antipermeability properties
  - anti-VEGF agents
  - Treatment of Radiation Retinopathy (TORR) trial: intravitreal ranibizumab (0.5 mg) or intravitreal triamcinolone acetonide (4.0 mg) is associated with improved visual acuity at 1 year, as compared to natural history
  - predictors of poor visual acuity at long-term follow-up following plaque radiotherapy included patient age ≥60 years, tumor base ≥10 mm, tumor thickness >8 mm, radiation dose to the tumor base of ≥33 300 cGy, and increasing radiation dose to the optic disc

Ocular Ischemic Syndrome

- 1963, Kearns and Hollenhorst: venous stasis retinopathy
- Dr. Larry Magargal: ocular ischemic syndrome
- 5% of patients with severe carotid artery insufficiency or thrombosis
- 50-80 years
- M:F= 2:1
- 20% bilateral

- Etiology
  - 90% or greater stenosis of the ipsilateral carotid arterial system
- CF
  - visual loss: gradual, sudden in 12%
- VA: variable
- cherry-red spot present on funduscopic examination
- Prolonged light recovery: ischemia of the macular retina
- Scintillating scotomas:
  - Amaurosis fugax
- Pain: 40% → ocular angina
- External collaterals:
  - Anterior segment changes: 66% cases NVI, only 50% develop increase IOP (Impaired ciliary body perfusion)
  - Posterior segment findings:
    - Retinal arteries are usually narrowed and the retinal veins are most often dilated, but not tortuous
    - Retinal hemorrhages: midperipheral
    - NVD 35%, NVE 8%
    - VH 4%
    - cherry-red spot is seen in approximately 12%
    - cottonwool spots in 6% of eyes, spontaneous retinal arterial pulsations in 4%, and cholesterol emboli within the retinal arteries in 2%.
- FA:
  - Delayed and/or patchy choroidal filling 60%
  - Prolonged retinal arteriovenous transit time 95%
  - Retinal vascular staining 85%
  - Macular edema 17%
  - Other signs: Retinal capillary nonperfusion, Optic nerve head hyperfluorescence, Microaneurysmal hyperfluorescence
- Electoretinography
- diminution of the amplitude, or absence, of both the a- and b-waves
  - Carotid angiography: typically discloses a 90% or greater obstruction of the ipsilateral internal or common carotid artery
  - VEP:
  - Ophthalmodynamometry
- DD
  - CRVO
  - DR
- Treatment
  - poor long-term outcome
  - if rubeosis: 90% are blind in 1 year
  - Total carotid artery obstruction: extracranial to intracranial bypass surgery → superficial temporal to middle cerebral artery (STA-MCA) bypass
  - Less than total carotid artery obstruction: carotid endarterectomy,

**ROP**

*Read everything from [www.focusrop.com](http://www.focusrop.com), best concise review.*

- First identified by Terry in 1942 → retrolental fibroplasia
- term ROP was coined by Heath in 1951.
- 1951, Campbell suggested that toxic effects of uncontrolled oxygen to newborns
- First epidemic: 1950, due to use of oxygen
- Second Epidemic: 1970-80, due to increased survival of very low birth premature infants
- Third or Mixed Epidemic: Asian countries, due to extremes of health cares, combination of first and second epidemic
- 1983: International Classification of Retinopathy of Prematurity, John Flyrm
Epidemiology

- Childhood blindness prevalence of 0.7 (+ 0.3)/1000 in India
- Upto 3.35 percent of all premature children.
- Low incidence of ROP in India is due to low or no survival rate of children <1200 gm in rural, unawareness amongst ophthalmologists and neonatologists, and lack of experience and infrastructure for ROP screening.
- Incidence: 2.3% (<1600 gm) [azad et al]

Pathogenesis

- 6 weeks (5 mm): hyaloid artery enters the globe
- Upto 16 weeks: choroidal vessels alone nourish both outer and inner retina
- 16 weeks: first blood supply to inner retina appears in the form of mesenchymal “Spindle cells” arising from the adventitia of the hyaloid artery
- Rate of growth of the advancing spindle cells is 0.1 mm/ day and reaches normal ora serrata by the 7th or 8th month and then temporal ora serrata by the 9th month of gestational

- The classical theory:
  - Arhton and Patz
  - Elevated arterial P0₂ → causes retinal vasoconstriction → vascular closure → if sustained → permanent vascular occlusion occurs → Endothelial cell proliferation → neovascularization.

- Spindle cell theory
  - Kretzer
  - Spindle cells are exposed to hyperoxic environment due to increased oxygen diffusion through choroidal vasculature → Oxygen free radical: a cytotoxic agent attacks compromised spindle cells, which has deficient anti-oxidative system → prevents migration of cells and canalization.

- Role of VEGF is also proposed.
• Bilateral
  o Retinoblastoma
  o Retinal dysplasia
  o Norrie's disease
  o Waller Warbtug syndrome
  o Trisomy13
  o Fundus coloboma
  o X-linked retinoschisis
  o Falciform folds
  o Incontinentia pigmenti
  o Intrauterine catastrophes
  o Anterior encephaloceles in Asians
  o Cataracts
• Unilateral
  o (PHPV) Persistent hyperplastic Primary vitreous
  o Coats’ disease
  o Retinal vascular anomalies
  o Parasitic endophthalmitis
  o Prenatal infantile trauma
  o Trauma (child abuse syndromes)

Classification
• Zones
o Zone I (Posterior pole or inner zone): The limits of zone I are defined as twice the disc fovea distance in all directions from the optic disc.

o Zone II: Extends from the edge of zone I peripherally to a point tangential to the nasal ora serrata.

o Zone III: It is a residual temporal crescent of retina anterior to zone 2.

o Extent: The extent of the disease is coded by the number of clock hours with ROP. The extent of the disease is further described as contiguous clock hours of ROP or noncontiguous clock hours.

- ICROP Staging
  o Stage 1: Demarcation line
  o Stage 2: Ridge
  o Stage 3: Ridge with extraretinal FVP (Mild/Moderate/Severe)
  o Stage 4: Subtotal RD
    - A: Not involving macula
    - B: Involving macula
  o Stage 5: Total retinal detachment (anterior and posterior- open -close types)

- ICROP Revisited
  o Pre-Plus disease is defined as vascular abnormalities of the posterior pole that are insufficient for the diagnosis of plus disease but that demonstrate more arterial tortuosity and venous dilatation than normal and may later progress to plus disease.

  o Aggressive posterior ROP is a new term for Rush disease or type 2 fulminant ROP in which there is posterior pole vessels show increased dilatation and tortuosity in all 4 quadrants out of proportion to peripheral retinopathy, progresses rapidly, does not progress through classic stages 1-3 and may appear only as a flat network of neovascularization at the deceptively featureless junction of vascularized and non-vascularized retina.

- Rush disease: Characterized by engorgement of the posterior pole vessels whose most anterior development was still in the posterior pole and it was associated with broad anterior avascular retina

- Plus disease: Schaffer, Quinn and Jhonson recognized this feature when they noted that posterior polar dilation and tortuosity constituted an important sign related to
the severity of the disease. Associated with it was the iris vessel dilation and engorgement, which resulted in poor pharmacological dilation of the pupil. This was called the plus disease.

- **Prethreshold ROP:**
  - Any stage of ROP in zone I with plus disease
  - ROP stage 3 with plus disease with 3 contiguous or 5 interrupted dock hours of involvement of retina in zone II but less than threshold.

- **ETROP Study (Early Treatment of ROP) Sub-classification**
  - Type 1 ROP defined as zone 1 ROP, any stage ROP with plus disease; zone 1, stage 3 ROP without plus disease; or zone 2, stage 2 or 3 ROP with plus disease-perform retinal ablation.
  - Type 2 ROP defined as zone 1, stage 1 or 2 ROP without plus disease or zone 2, stage 3 ROP without plus disease. These eyes should be considered for treatment only if they progress to type 1 or threshold ROP.
  - Threshold Disease: Zone I or II: ROP stage 3 more than 5 contiguous or 8 cumulative clock hours with plus disease present. This is the stage in which the treatment is mandatory since the chances of progression to retinal detachment are 50 percent if left untreated.

**Risk Factors**

- **Definite and Well Accepted**
  - Prematurity /Gestational Age/Birth Weight
  - Oxygen Supplementation

- **Associated Factors**

- **Scoring for BW and GA available: 0,1,2,3**
• **Regressed ROP:**
  o Peripheral and posterior changes
  o Vascular
    ▪ Failure to vascularize peripheral retina
    ▪ Abnormal, nondichotomous branching of retinal vessels
    ▪ Vascular arcades 'With circumferential interconnection
    ▪ Telangiectatic vessels
  o Retinal
    ▪ Pigmentary changes
    ▪ Vitreoretinal interface changes
    ▪ Thin retina
    ▪ Peripheral folds
    ▪ Vitreous membranes with or 'Without attacluent to retina
    ▪ Latticelike degeneration
    ▪ Retinal breaks

**Screening**

1. Screen all premature infants less than 1500 gram birth weight
2. Screen all babies born at less than or equal to 32 weeks of post-conceptional age or 4 weeks from birth whichever is earlier.
3. Special criteria *(the THIRD Criteria, proposed by AZAD et al especially for developing countries like India): Neonatologist is to be cautioned to include all babies for screening who they consider most sickly survivors because of sepsis, multiple blood transfusions, RDS, pneumonitis, Extraordinary oxygen support.*

**Management**
• CRYOTHERAPY/ LASER
  o Threshold ROP
  o Prethreshold ROP (Type 1)

• WHEN NOT TO DO LASER
  o Less than prethreshold ROP
  o Type 2 prethreshold
  o Lack of consent

ADVANCED STAGES
Stage 4a: Focal Traction, No RD \(\rightarrow\) follow up
  Generalised traction, No RD \(\rightarrow\) follow up +- buckling
  Generalized traction with RD \(\rightarrow\) buckling/ lens sparing Vitrectomy
Stage 4b: Lens sparing Vitrectomy
Stage 5: Combined lensectomy and vitrectomy or vitrectomy with lens conservation

Sequelae of ROP

• Progressive ROP
• Spontaneous regression
  o Refractive Errors
  o Strabismus and motility defects
  o Changes in ocular dimensions
  o Cataract
  o Anterior segment change
  o Visual field changes
ARMD

Epidemiology

- prevalence and incidence rates differ by race/ethnicity
- different studies available

Prevalence

- Total prevalence 6.5% in 40 years or older
- Late AMD 1.6% overall (exudative maculopathy 1.2%, geographic atrophy 0.6%)
- Late AMD 7.1% in persons who were 75 or older.

Incidence

- Early AMD increased from 3.9% in individuals aged 43-54 years to 22.8% in persons 75 years of age and older
- Overall 5-year incidence of late AMD was 0.9%

Quality of life

- Greater emotional distress, worse self-reported general health, and greater difficulty carrying out daily activities.
- Higher rate of depression

Socioeconomic risk factors

- Age
  - 30% of individuals 75 years of age or older had early AMD
  - 7.1% had late AMD after 75 years of age
- Gender
- no overall difference
- males had lower AMD than females

- **Race/ethnicity**
  - early AMD is common among blacks and Hispanics than whites
  - Asians have rate comparable to whites

- **Socioeconomic status**
  - Less education and lower income groups have higher prevalence

- **Ocular risk factors**
  - **Refractive error**
    - association between AMD and hyperopia
  - **Iris color**
    - Higher levels of ocular melanin may be protective against light-induced oxidative damage to the retina
  - **Lens opacities, cataracts, and cataract surgery**
    - history of cataract surgery has been found to be associated with an increased risk for advanced AMD
  - **Cup-to-disc ratio**
    - larger cup-to-disc ratios had a reduced risk of exudative AMD

- **Behavioral and lifestyle factors**
  - **Smoking**
    - 25 or more cigarettes per day had a relative risk (RR) of 2.4
  - **Antioxidants, vitamins, and minerals**
    - vitamin C (ascorbic acid), vitamin E (alpha-tocopherol), and the carotenoids (including alpha-carotene, beta-carotene, cryptoxanthin, lutein, and zeaxanthin)
    - AREDS: zinc supplement included zinc (80 mg) as zinc oxide, and copper (2 mg) as cupric oxide; the antioxidant supplement included vitamin C (500 mg), vitamin E (400 IU), and beta-carotene (15 mg).
• three or more servings of fresh fruit per day have an RR of 0.64 (95% CI 0.44-0.93) compared to those who consumed less than 1.5 servings per day
  
  o **Alcohol intake**
    
    ▪ evidence to date suggests that alcohol intake does not have a large effect
  
  o **Obesity and physical activity**
    
    ▪ BMI between 25 and 29 had an RR of 2.32
  
  o **Sunlight exposure**
    
    ▪ no significant association??
  
  o **Medications**
    
    ▪ increased risk of early AMD with use of beta-blockers
    ▪ decreased rate of CNV among AMD patients taking aspirin or statins

• **Cardiovascular-related factors**
  
  o **Cardiovascular diseases**
    
    ▪ 4.5-fold increased risk of late AMD associated with plaques in the carotid bifurcation and a twofold increased risk associated with plaques in the common carotid artery
    ▪ positive association between AMD and cerebrovascular disease
    ▪ many CVD risk factors are associated with AMD
  
  o **Blood pressure and hypertension**
    
    ▪ Unclear association
  
  o **Cholesterol levels and dietary fat intake**
    
    ▪ the relationship with dietary fat is more consistent
  
  o **Diabetes and hyperglycemia**
    
    ▪ no significant relationships.

• **Hormonal and reproductive factors**
  
  o EDCCS showed a marked decrease in the risk of neovascular AMD among postmenopausal women who used estrogen therapy
- **Protective effect of estrogen on AMD is possible**

- **Inflammatory factors**
  - Inflammation is also associated with angiogenesis and may play a role in the neovascularization seen in the advanced forms of AMD
  - CRP
  - SNPs in the *CFH* gene
  - Intravitreal compstatin/POT-4: a C3 inhibitor
  - Intravitreal use of ARC1905: C5 inhibitor
  - Systemic administration of the anti-C5 antibody, eculizumab, is being investigated for geographic atrophy

- **Genetic factors**
  - Y402H in the *CFH* gene, chromosome 1q31
  - Variation in the *ARMS2/HTRA1* locus on chromosome 10 has been convincingly associated with AMD
  - LIPC and tissue inhibitor of metalloproteinase 3 (*TIMP3*)
  - Data from the Rotterdam study showed that first-degree relatives of affected individuals are at 25% greater risk of developing disease than individuals in the general population without any affected family members.
  - A higher prevalence of AMD is found in identical twins compared to fraternal twins

**Pathogenesis**

1. **RPE**
   - Primary lesion is in RPE which causes secondary changes in photoreceptors and choriocapillaries.
   - RPE cells are responsible for phagocytosis of membranous discs shed by rods and cones. But Molecular degradation does not always go to completion and Residues of incomplete digestion gradually accumulate—LIPOFUSCIN GRANULES
Incomplete degradation due to → reactive oxygen intermediates
  - High oxygen tension
  - Exposure to irradiation
  - PUFA in cell membranes of photoreceptors

Accumulated lipofuscin causes →
  - Mechanical distortion
  - Reduces phagocytic ability
  - Reduced activity of catalase, superoxide dismutase
  - Reduces glutathione levels
  - N-retinyl N-retinylidene ethanolamine or A2E a component of lipofuscin induces apoptosis
  - Increases susceptibility of RPE to ROI

RPE is progressively engorged with lipofuscin and so normal metabolism disrupted

Altered secretion of materials from basal aspect causing
  - Basal laminar deposits
  - Basal linear deposits

2. Bruch’s

Progressive increase in lipid content

AGE’s

Change in GAG’s - ↑Heparan sulfate

IMPEDANCE OF DIFFUSION → Disrupts RPE function → The abnormal deposits in the Bruch’s membrane still have their origin from RPE - Basal Linear Deposits

Basal laminar deposits: BLamD
- Between plasma membrane and basement membrane of RPE
- Widely spaced collagen, 100nm, most prevalent marker

- Basal Linear deposits: BLinD
  - In the Inner collagenous layer of Bruch’s membrane
  - Widely spaced collagen and lipids, most specific to AMD

- Constituents of drusen
  - Denatured mitochondria, cytoplasmic debris, pigment granules, photoreceptor remnants
  - Mucopolysaccharide and lipids.
  - IgG, complement components, complement inhibitor clusterin

- Types of drusen
  - Hard
    - Hyalinized material with membrane bound bodies external to RPE
    - Formed from entrapment sites or microdrusen
  - Hard drusen cluster
    - Amorphous material lines the druse and contains globular material
  - Soft cluster driven
    - Fusion of hard drusen with disruption of amorphous rim
  - Soft membranous
    - Focal accentuation BlinD.
  - Basal Laminar drusen
    - Diffuse accumulation of hyalinized material internal to RPE with nodularity
    - Not a/w AMD
PATHOGENESIS OF CNV

- Surgically excised CNV contains RPE, Bruch’s membrane, photoreceptors, vascular endothelium, fibroblasts, stem cells, macrophages, collagen and basal laminar deposits.

- CNV
  - VASCULAR COMPONENT
  - EXTRA VASCULAR COMPONENT

- Stages of CNV
  - INITIATION:
    - VEGF
    - Macrophages
    - Insulin like growth factor
    - Nitric Oxide
    - Angiostatin
    - Endostatin
    - Pigment epithelium derived factor
    - CCR3/CD193
  - ACTIVE INFLAMMATION
    - Matrix Metalloproteinase
    - Tissue factor
    - Angiopoietin - 2, Tie1 , Tie 2
    - b-Fibroblast growth factor
    - TGF-beta
    - Activation of complement
    - PDGF-B
  - INVOLUTION
    - TGF-BETA
Structural Changes

Choroid

- density of the choriocapillaris is decreased with age in eyes without AMD
- in advanced AMD, loss or narrowing of the choriocapillaris occurs
- diffusely thickened Bruch's membrane represented a barrier to diffusion of VEGF towards the choroid resulting in changes in the capillary bed

Bruch's membrane

- PED: reduction of the hydraulic conductivity of Bruch's membrane would hamper movement of water towards the choroid thus causing it to accumulate in the sub-RPE space
- There is considerable lipid trafficking through Bruch's membrane and lipids are believed to accumulate as they fail to pass freely through a thickened Bruch's membrane

The retinal pigment epithelium

- quadratic relationship exists between age, and both autofluorescence and residual body quantity in RPE
- those with high autofluorescence levels had a diet high in vitamin A.

Outer retina

- photoreceptor cell loss occurs progressively in early AMD
Role of Cytokines

- **Angiogenesis** refers to the creation of new blood vessels from existing blood vessels.
- **vasculogenesis** seen characteristically in utero in which vessels are created de novo.
- VEGF plays a principal role (it’s a putative factor X first postulated by Michaelson)
- other cytokines may play an important role as well, including fibroblast growth factor (FGF), pigment epithelial-derived factor (PEDF), the integrins, angiopoietins, and matrix metalloproteinase inhibitors.

**VEGF**

- MOA: increases in hydraulic conductivity of isolated microvessels that are mediated by increased calcium influx and likely changes in levels of nitric oxide caused by induction of nitric oxide synthetase (NOS).
- 45 kDa
- 121, 145, 165, 183, 189, and 206, amino acids respectively after signal sequence cleavage
- VEGF_{165} exists in both soluble and bound forms
- 165 is the principal isoform involved in pathologic neovascularization
- (1) induction of angiogenesis through endothelial proliferation, migration, and new capillary formation, and (2) enhancement of vascular permeability
- two highly related receptor tyrosine kinases (RTKs) VEGFR-1 and VEGFR-2
  - VEGFR-1: important during embryogenesis
  - VEGFR-2: pathologic neovascularization as well as in hematopoietic bone marrow-derived cells and neural signaling
- VEGF is also suspected to mobilize and augment endothelial progenitor cells (EPC) from bone marrow

Angiogenesis

Naturally occurring upregulators of angiogenesis

- *Fibroblast growth factor and integrins*
- *Platelet-derived growth factor*
• **Angiopoietins**

• **Matrix metalloproteinases and tissue inhibitors of metalloproteinases**

**Naturally occurring downregulators of angiogenesis**

• **Pigment epithelial-derived factor**

• **Other cytokines**
  
  o Thrombospondin 1 (TSP-1) has been described as both an up- and downregulator of VEGF

  o Angiostatin, is a 38 kDa internal fragment of plasminogen, it has inhibitory effects on vascular endothelial proliferation

  o Endostatin, a cleavage product of collagen XVIII, is structurally related to and shares homology with angiostatin, and inhibits tumor-associated angiogenesis

**Non-neovascular AMD**

• International Epidemiological Age-related Maculopathy Study Group defined **Early ARM** as

  o Soft drusen (intermediate >63 µm, ≤125 µm; large >125 µm) drusen. When occurring alone, soft, indistinct drusen are considered more likely to indicate AMD than soft, distinct drusen, and drusen over 125 µm have greater importance than smaller drusen.

  o Areas of hyperpigmentation associated with drusen but excluding pigment surrounding hard drusen.

  o Areas of depigmentation or hypopigmentation associated with drusen. These areas, which commonly occur as drusen fade, are most often more sharply demarcated than drusen, but do not permit exposure of the underlying choroidal vessels.

  o Visual acuity is not used to define ARM or AMD because advanced changes may be present without anatomically affecting the fovea.

• **Late stages of ARM** will be called **Age related macular degeneration** which can be dry or wet

  o **DRY/EARLY:**
    
    ▪ A sharply demarcated area of de/hypopigmentation in which choroidal vessels are more visible and the area is at least 175 microns in diameter
- **WET/LATE**
  - RPE detachments
  - Subretinal/Sub RPE neovascular membrane
  - Epiretinal/Subretinal/Intraretinal/Sub RPE scar or glial tissue
  - Subretinal haemorrhage
  - Hard exudates in macular area with any of the above

- **AREDS CLASSIFICATION**
  - No AMD (AREDS category 1)
    - No or a few small (<63 micrometres in diameter) drusen
  - Early AMD (AREDS category 2)
    - Many small drusen or a few intermediate-sized (63-124 micrometres in diameter) drusen, or macular pigmentary changes
  - Intermediate AMD (AREDS category 3)
    - Extensive intermediate drusen or at least one large (≥125 micrometres) drusen, or geographic atrophy not involving the foveal centre
  - Advanced AMD (AREDS category 4)
    - Geographic atrophy involving the foveal centre (atrophic, or dry, AMD)
    - Choroidal neovascularisation (wet AMD) or evidence for neovascular maculopathy (subretinal haemorrhage, serous retinal or retinal pigment epithelium detachments, lipid exudates, or fibrovascular scar).

- **Neovascular AMD**
  - Clinical features & histopathogenesis overall 10% of AMD patients have the wet form of AMD. This includes CNV and associated manifestations like RPED, RPE tears, disciform scarring, and vitreous
hemorrhage. Majority of AMD patients with vision, <20/200 have wet form of AMD. Most patients with CNV complain of blurred and/or distorted vision, central scotomas leading to difficulty in reading & recognizing faces. After noting the visual acuity, the scotomas should be mapped on an Amsler grid in order to have a fair idea of the patient's handicap & for planning low vision aids for the patient.

- **CNV**: Clinically on slit lamp biomicroscopy CNV appears as grey-green elevation deep to retina with overlying neurosensory detachment, however, this characteristic appearance may not always be present in CNV due to AMD. In such scenarios the presence of CNV is indicated by any one of the following:
  - Subretinal blood or lipids
  - RPED with or without overlying subretinal fluid.
  - Occasionally a shallow neurosensory serous RD may be the only presenting sign of underlying CNV.
  - The CNV capillary network becomes more apparent after the atrophy of overlying RPE. CNV has been classified into classic and occult depending upon the angiographic appearance (described later). Depending upon its location CNV may be subfoveal, juxtafoveal (between 1&199μm from the centre of FAZ), or extrafoveal (>200μm from FAZ centre). Histologically CNV is growth of abnormal, fragile new vessels between the Bruchs membrane & RPE or between the latter & neurosensory retina. These vessels sprout from the chorio capillaries & proceed inwards through the defects in the Bruchs membrane.
  - **Classic**: classic subretinal neovascular membrane (SRNVM or CNVM) presents a fluorescein angiographic picture characterized by early onset of hyperfluorescence from the arterial phase of the FA, during which a neovascular net may also be seen. This lesion shows progressive increase in the intensity of the hyperfluorescence in the late phase of the FA, with a blurring of the margins of the lesion.
  - **Occult CNVM**
    - three common presentations
      - The first is a late leakage from an unknown source. In these lesions, the early phase of the FA does not show any well defined lesion but by the mid phase of the FA, an area of increasing hyperfluorescence begins to get visualized. The intensity of the hyperfluorescence and even the extent of the lesion increases over time upto the late phase of the FA. In order to be able to make a diagnosis of these lesions conclusively, it is mandatory to take photographic frames.
during fluorescein angiography from the arterial phase upto at least 8 minutes after the fluorescein injection.

- The second presentation of an occult CNVM is that of a fibrovascular pigment epithelial detachment, which presents with an irregular elevation of the RPF showing stippled hyperfluorescence within 1-2 minutes after fluorescein dye injection, with persistent staining or leakage in the late phase frames of the fluorescein angiogram.

- The third common presentation of an occult CNVM is of a serous retinal pigment epithelial detachment, which presents clinically as a dark blister type of lesion with a ring halo around it. On fluorescein angiography, this lesion shows hyperfluorescence which is relatively uniform and well defined and starts in the early phase of the FA. The hyperfluorescence become uniform and more intense in the late phase of the angiogram but the margins continue to remain well defined.

- **RPEDs**: appear as sharply demarcated, dome shaped elevations of RPE. If filled with serous fluid they transilluminate. Three types of PEDs are seen & can be differentiated on the basis of their Angiographic pattern (described later)
  - Drusenoid PED -does not have CNV
  - Fibrovascular PED-is a form of occult CNV
  - Serous PED-may or may not overlie CNV

- Overlying serous RD, lipid & blood within or surrounding a PED implies the presence of CNV. Sub RPE blood is seen as green or dark red mound.

- **RPE tear**: or rip occurs as a complication in serous or fibrovascular PED. It occurs at the border of attached & detached RPE due to stretching forces of the underlying fluid or from the contractile forces of the fibrovascular tissue. Clinically it is seen as area of hypopigmentation with hyperpigmented wavy border on one side due to rolling in of the free edge of torn RPE.
Massive sub retinal hemorrhage and breakthrough vitreous hemorrhage though unusual complications of AMD, are seen sometimes and result in sudden profound visual loss both central as well as peripheral.

*Disciform Scar:* is the last stage in the evolution of neovascular AMD just as geographic atrophy is in dry AMD. CNV is a fibrovascular tissue; however, the fibrous component is not readily appreciated in the early stages of CNV due to immaturity of the fibrous tissue & also due to the overwhelming signs like serous RD, subretinal lipids and/or blood, of the vascular component. When the fibrous tissue becomes apparent clinically then the fibrovascular complex is called disciform scar. Clinically it appears as white to yellow subretinal scar with intervening areas of hyperpigmentation. If the vascular component has died its own death then the scar does not grow, however, it can expand with neovascularization occurring along the edges.

**Pharmacotherapy**

**Non-neovascular AMD**

1. *Netraceuticals*
2. *Prevent photoreceptors and RPE loss*
3. *Reduce toxic metabolites*
4. *Suppress or modulate inflammation*

*Antioxidants, vitamins, and cofactors*

- AREDS and related supplements
  - Write trials and results
- Othera Eye Drops (antioxidant, anti-inflammatory and anti angiogenic) - *Omega study*
Pills for Dry AMD - Acucela (ACU-4429): ENVISION Clarity trial in geographic atrophy

- Copaxone (glatiramer acetate)
  - weekly vaccination with the drug Copaxone. This is NOT an injection in the eye.
  - Macular degeneration, Alzheimer’s disease and Multiple sclerosis

- **Visual cycle inhibitors**
  - intended to reduce the accumulation of toxic fluorophores such as A2E in RPE
  - Fenretinide: in circulating retinal binding protein (RBP) and retinol by displacing retinol from RBP
  - Accutane: inhibits the conversion of all-trans-retinyl esters (in retinosomes) to 11-cis-retinol and the conversion of 11-cis-retinol to 11-cis-retinal
  - most common adverse events
    - dyschromatopsia (32%), unspecified visual disturbance (29%), night blindness (18%), blurred vision (11%), and photophobia (8%).

- **Complement modulators**
  - Role of CCR3 (chemokine receptor): Anti-CCR3 antibodies may prevent tube formation prior to vascularization and reduce the proliferation of CECs following laser-induced injury.
  - Complement C5aR Inhibition
  - CNTF in Dry AMD
    - Protein that effects apoptosis and is classified as a “neuroprotective” agent

- **Cell Based Therapy**
  1. **Regenerative**: Isolated Stem cells → expanded differentiated cell therapy product
    - Corneal limbal stem cells for chemical injury
    - Not used for AMD now
  2. **Trophic**: Isolate → Expanded but not differentiated (this is now used)
- **CNTF Implant for Atrophic AMD** (modified allogenic RPE cells secrete CNTF)
- **First used for RP**
- Microcathetre gided delivery system: iTRACK and iLumin fibreoptic illuminator
- **Razel pump** for rate-controlled delivery of stem cells

**Neovascular AMD**

- **VEGF inhibitors**
- **Direct VEGF inhibitors**
- **Monoclonal antibody: bevacizumab (Avastin)**
  - humanized monoclonal antibody (IgG1) against human VEGF-A
  - amino acid sequences which are about 93% human and 7% murine
  - **systemic bevacizumab (5 mg/kg)** was shown to reduce leakage from CNV, decrease OCT central retinal thickness measurements, and significantly improve vision in exudative AMD
  - intravitreal dose: 0.05 ml (1.25 mg) to 0.1 ml (2.5 mg) [500 times less dose]
  - concerns about retinal penetration are now disproved
  - **SANA**: Systemic Avastin for Neovascular AMD
    - two to three intravenous infusions of bevacizumab (5 mg/kg)
    - too small to establish the safety
  - half-life of 3 days and was likely to provide complete intravitreal VEGF blockade for a minimum of 4 weeks
- **ABC trial**
  - intravitreal bevacizumab (three loading doses every 6 weeks, followed by additional injections at 6-week intervals as needed) to standard therapy, defined at the time of recruitment as verteporfin PDT for predominantly classic CNV, or pegaptanib injection or sham injection for minimally classic or occult CNV.
- first level 1 evidence of the efficacy of bevacizumab for the treatment of AMD.
- bevacizumab group improved by 15 letters compared with the standard therapy group (32% vs 3%, P < 0.001)

- **Antigen binding fragment: ranibizumab (Lucentis)**
  - Ranibizumab is a humanized anti-VEGF-A recombinant Fab fragment
   - **MARINA**
     - assessed the response of minimally classic or occult CNV to ranibizumab.
     - sham injection:
       - 0.3 mg ranibizumab
       - 0.5 mg ranibizumab
     - 90% of ranibizumab-treated patients had lost less than 15 letters on the Bailey-Lovie (ETDRS) chart as compared to 53% of the sham-injected patients.
   - **ANCHOR study**
     - predominantly classic CNV
     - verteporfin-PDT plus sham
     - sham PDT plus injection of 0.3 mg ranibizumab
     - sham PDT plus injection of 0.5 mg ranibizumab
     - 95% of ranibizumab-treated patients lost less than 15 letters of vision versus 64% in the verteporfin active-treatment control group.
     - Forty percent of patients treated with 0.5 mg ranibizumab gained at least 15 letters vision versus 6% in the verteporfin treatment cohort
   - **PIER**
     - subfoveal CNV
     - sham injection
     - 0.3 mg ranibizumab
     - 0.5 mg ranibizumab
- Monthly for 3 months and then 3 monthly up to 12 months
- Injecting patients with ranibizumab every 3 months (after an induction phase of three monthly injections) does not produce the same chance for visual benefit as monthly injection, at least during the first 12 months of therapy
  
  o **EXCITE study**
  
  - At month 12, the visual acuity gain in the monthly treatment cohort was higher than that of the quarterly regimens.

*PrONTO, SUSTAIN, SAILOR were PRN dosage study.*

- **SUSTAIN study**
  
  - Three initial monthly injections of ranibizumab (0.3 mg) and thereafter pro re nata (PRN) retreatment for 9 months

- **PrONTO**: Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intraocular Lucentis
  
  - 0.5 mg ranibizumab at entry, month 1, and month 2
  - OCT done monthly, FA every 3 months
  - Retreatment with ranibizumab was done only if one or more of the following conditions was observed: (1) CRT increased 100 µm; (2) ≥5 letter visual loss associated with subretinal fluid (3) New onset classic CNV; (4) new macular hemorrhage; (5) Persistent fluid 1 month after the previous injection.
  - OCT-guided variable-dosing regimens with intravitreal ranibizumab were capable of achieving visual acuity outcomes comparable

- **SAILOR study**
  
  - Numerically higher rate of cerebrovascular stroke with 0.5 mg ranibizumab compared with 0.3 mg ranibizumab (1.2 vs 0.7%), which was not statistically significant

- **Comparison of Armd Treatments Trial (CATT)**
  
  - Bevacizumab and ranibizumab
3 questions
  - one treatment offer superior visual outcomes to another?
  - optimal treatment regimen and interval?
  - safety profile of bevacizumab comparable to that of ranibizumab?

- ranibizumab 0.5 mg monthly
- bevacizumab 1.25 mg monthly
- ranibizumab PRN
- bevacizumab PRN

1st year result
  - bevacizumab as needed, when compared to ranibizumab or bevacizumab monthly, yielded inconclusive results, all other groups showed similar efficacy.
  - Rate of systemic adverse events was significantly higher in the bevacizumab group than in the ranibizumab group

2nd year result
  - very similar visual outcomes to patients maintained on as-needed therapy since study enrollment for both medications.
  - Similar about complications also..

- Soluble receptor: aflibercept (VEGF-TRAP EYE)
  - Regeneron
    - soluble fusion protein → extracellular components of VEGF receptors 1 and 2 fused to the Fc portion of IgG1
    - 200-fold higher affinity for VEGF
    - also binds VEGF-B and PI GF.
  - CLEAR-IT 1 (CLinical Evaluation of Anti-angiogenesis in the Retina Intravitreal Trial)
    - functional and anatomical improvement with a dose of 0.5 and 2 mg
- **CLEAR-IT 2**
  - biologic effects and safety of aflibercept during a 12-week fixed-dosing period in patients with exudative AMD followed by PRN dosing out to 1 year

- **VIEW 1 and VIEW 2: VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD**
  - aflibercept 0.5 mg monthly
  - aflibercept 2 mg monthly
  - aflibercept 2 mg every 2 months (following three monthly loading doses)
  - ranibizumab administered 0.5 mg every month
  - at 1 year, no difference in the outcomes when the three aflibercept groups were compared with the ranibizumab group

- **Combination therapy: SUMMIT**
  - evaluate if Visudyne combined with Lucentis was not inferior (with a non-inferiority margin of seven letters) to monthly Lucentis monotherapy
  - **MONT BLANC** is the European study
    - standard-fluence Visudyne with Lucentis 0.5 mg can deliver VA improvements (2.5 letters from baseline) that are non-inferior to a Lucentis monotherapy regimen
  - **DENALI**: USA and Canada
    - both combination therapy and Lucentis monotherapy were well tolerated
  - **EVEREST**: Asia
    - Visudyne therapy, with or without Lucentis, may lead to complete regression of the polyps that can cause vision loss in patients with PCV, a potentially devastating eye disease.

- **KH902**
- Adeno-associated viral vector (AAV) gene transduction
- Oligonucleotide aptamer (pegaptanib - Macugen)
  - first VEGF inhibitor approved for use
• **aptamer against VEGF isoform 165**
  - not used now

• **Small interfering RNA (siRNA)**
  - double- rather than single-stranded RNA
  - presence of siRNA results in the inhibition of protein synthesis
  - phase I study of Sirna-027
  - Bevasiranib - **Gene Silencing**: Phase I and Phase II trials of Bevasiranib have been completed and a Phase III clinical trial is now recruiting.

• **PDGF/PDGFR inhibitors**
  - PDGF-B pegylated aptamer, E10030
  - Pazopanib (GlaxoSmithKline) is a tyrosine kinase inhibitor that blocks the action of PDGFR, as well as VEGFR-1, -2, and -3, kit, and FGFR-1

• **TrpRS**

• **Protein kinase C inhibitors**

• **Complement inhibitors**
  - **Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)**
    - Unrestrained complement activation has been recently identified to be one of the key mechanisms in the pathogenesis of AMD. It has also been demonstrated that complement activation plays a crucial role in the development of CNV. Therefore, the use of intravitreal complement inhibitors may be beneficial in participants subjects with neovascular AMD. This prospective, uncontrolled, non-randomized, dose-escalating, pilot Phase I study will provide initial safety and tolerability information on intravitreal complement inhibitor (POT-4) therapy in AMD patients with subfoveal CNV as a single intra-vitreal injection.

• **PTK787 Pill for AMD**: This Phase I/II study looked at the safety and tolerance of a tablet of Vitalanib, taken over three months and the effect on wet macular degeneration. The study is completed and no data is available as yet.

• **Talaporfin Sodium PDT**: This Phase I trial was undertaken to determine the safety of photodynamic therapy (PDT), using the drug talaporfin sodium (LS11). Twenty-seven patients were enrolled and the study was completed in January 2006
• **Gene therapy in Wet AMD**
  
  o **AAV2-sFLT01**. This experimental study drug uses a virus to transfer a gene (genetic code) into cells within the eye. The gene codes for a protein that is intended to diminish the growth of abnormal blood vessels under the retina. The duration of the gene’s effect is currently unknown, but might last for years. This phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration is ongoing.

• **EMERALD trial**, is designed to evaluate the therapeutic potential of Sirolimus in combination with Lucentis in wet AMD

• **Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration (AMDB1)**

• **HARBOUR Study**
  
  o 0.5 mg Ranibizumab monthly
  
  o 0.5 mg Ranibizumab PRN
  
  o 2 mg Ranibizumab monthly
  
  o 2 mg Ranibizumab PRN
  
  o At 24 months, in view of VA and total number of injections, 2 mg dose was not any better than 0.5 mg standard dose.

• **RADICAL Study**: Reduced fluence PDT AntiVEGF Dexamethasone In Combination for AMD Lesion
  
  o Its basically a triple Therapy
  
  o AntiVEGF used was Ranibizumab
  
  o 4 arms
  
  o All group has similar result

**PDT**

• PDT procedure is relatively contraindicated in patients with severe liver disease, unstable heart disease or uncontrolled hypertension. The dye should not be administered if the patient is allergic to porphyrin, suffers from porphyria or has received any photosensitizing drug within the last two days.

• Photodynamic therapy (PDT) involves the intravenous infusion of a drug (photosensitizer) and the application of a continuous nonthermal laser light directed at the CNVM. The
wavelength of the laser light used corresponds to the absorption peak of the drug, but it is not strong enough to produce any thermal (photocoagulation) damage.

- **Mechanism of action:** The drug gets concentrated in the immature endothelium of CNVM, and light-activation induces a photochemical reaction in the target area that causes immunologic and cellular damage, including endothelial damage of new vessels. Endothelial damage and the resulting platelet adhesion, degranulation, and subsequent thrombosis and occlusion of the vasculature might be the predominant mechanism by which light-activated drugs work. Since the photosensitizer accumulates predominantly in the CNV, a fairly selective damage to the CNV is expected.

- **To date, only PDT with the photosensitizer Verteporfin has been proven to decrease the risk of visual loss in patients with neovascular ARMD. Verteporfin (a benzoporphyrin derivative monoacid, BPD-MA; Visudyne, Novartis AG) is a light-activated drug. The application of photodynamic therapy with verteporfin involves two main steps: intravenous infusion of the drug and activation of the drug by light at a specific wavelength (689 nm) with a low-power, nonthermal laser. The therapy includes retreatment as often as every 3 months if leakage from choroidal neovascularization is detected on follow-up fluorescein angiograms.**

- **Procedure**
  - The intravenous infusion of verteporfin is given throughout a 10-minute period.
  - Then, 15 minutes after the start of the infusion the laser light is applied for 83 seconds. Guidelines for the treatment of patients with ARMD and subfoveal CNV with PDT have been recently published. In these guidelines, treatment with PDT is recommended for patients with predominantly classic CNV and for those with occult and no classic CNV with recent disease progression (e.g., presence of blood associated with the CNV, growth of the CNV, or deterioration of the visual acuity within the past 12 weeks) and a lesion size of four or fewer disk areas or a lesion size greater than four disk areas associated with low levels of vision (i.e., approximately in the level of 20/50 Snellen vision). In these guidelines, it is also recommended to treat juxtapfoveal lesions that are so close to the fovea that conventional laser photocoagulation almost certainly would extend under the center of the FAZ, and extrafoveal lesions that are contiguous to the optic nerve provided that treatment spots do not overlie the optic nerve. The recommendations included a 3-month interval follow-up for at least 2 years from the time of initial treatment in all patients, except in those in whom no treatment was recommended for two consecutive visits (6-month period). Patients should receive retreatments as often as every 3 months if there is any fluorescein leakage from CNV noted.

- **Although no data are currently available on the treatment of pregnant or nursing women and patients with moderate or severe liver disease, the guidelines suggest to carefully consider PDT in these patients. Photodynamic therapy is contraindicated in patients with**
porphyria. Patients must be warned, however, that they will be sensitive to direct sunlight or bright indoor lights for 24 to 48 hours after drug infusion and that they should avoid direct sunlight for about 2 to 5 days after treatment.

**Macular Photocoagulation Study (MPS)**

In Patients with well-defined extrafoveal CNVM after a follow-up of 5 years, 64% of eyes assigned to no treatment compared with 46% of eyes randomized to argon laser experienced severe visual loss (six or more lines of visual acuity loss using Bailey-Lovie visual acuity charts). The difference was statistically significant. Although the risk of severe visual loss was reduced in treated patients, a high rate of persistent and recurrent CNVM was observed.

The recurrence rate observed in treated eyes at 12, 24, and 60 months were of 41%, 51%, and 54%, respectively. Patients with well-defined juxtafoveal CNV were treated with krypton red laser. At 3 years after randomization, 49% of laser-treated eyes experienced severe visual loss compared with 58% of untreated eyes.

**Surgical Therapy**

- **Exudative AMD**
  - Removal of the submacular choroidal membrane and/or hemorrhage
  - MTS360: machemar
  - LMT: De Juan
  - Displacement with TPA and Gas
  - Transplantation of an autologous graft of RPE, Bruch's membrane, choriocapillaris, and choroid: Peymen

- **Epiretinal Brachytherapy (NeoVista)**
  - Administred via PPV
  - Strontium 90 device (Epi Rad 90)
  - 24 Gy delivered over 4 minutes
- Peak dose directly to macula
- Rapid radiation dissipation
- 10% drop-off for every 0.1 mm from source
- **NVI 111 protocol**: Epi Brachytherapy and Bevacizumab
  - 74% subjects received no additional injections
  - Mean number of injections: 12 months: 2.2; 24 months: 2.4
  - Major complication was cataract
  - This led to another trial CABERNET
- **CABERNET trial** (CNV Secondary to AMD Treated with BEta Radiation Epiretinal Therapy)
  - Strontium-90 Beta Radiation Implant Trial
  - CABERNET is a multicenter, randomized, controlled study that has enrolled over 490 subjects at 45 sites worldwide and is evaluating the safety and efficacy of NeoVista’s therapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis® (ranibizumab) versus Lucentis alone
- **MERITAGE-I Study**
  - Examine NeoVista’s novel Epimacular Brachytherapy procedure when used in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Neovascular Age-Related Macular Degeneration (Wet AMD)
- **Macular EpiRetinal Brachytherapy versus Lucentis Only Treatment** (*MERLOT*) study
- **External beam radiation**
  - **IRay system** (oraya technologies)
    - Office based radiation
    - 2-3 fractionated dose of 8Gy
- **IMT- Implantable Miniature Telescopes**
  - The Implantable Miniature Telescope (IMT) is implanted into the eye in the same position that an intraocular lens would be placed after a cataract extraction (patients in the study
have their cataract or lens removed). It enlarges images up to three times, but only in the center. The peripheral vision of that eye is eliminated by the placement of the telescope. In the clinical trials, the implant is placed in the better eye. The FDA did not approve the device and required more research because of damage to the cornea in some of the patients.

- **X ray:**

  -

- **Dry AMD**

  - recreate a functioning RPE underlayer of the macula: autografts versus allografts; cells in suspension versus cell sheets or patches; RPE versus iris pigment epithelium (IPE) cells

  - **Surgery**

  - **Keyhole approach**

    - Paramacular vertical retinectomy (as suggested by F. Devin) is currently preferred because this retinotomy has less tendency to enlarge towards the fovea and the graft is inserted more easily

**Epiretinal Membranes**

- cellular proliferation on the inner retinal surface

**Prevalence**

  - BDES & BMES 7-11.8%, with a 5-year incidence of 5.3%

  - Bilateral in 19.5-31%, with a 13.5% 5-year incidence

**Classification and Grading**

- **Classification**

  - Idiopathic
o Secondary
  - Retinal vascular disease
  - Vascular occlusion, e.g. BRVO, CRVO
  - Diabetic retinopathy
  - Telangiectasias, Macroaneurysm
  - Sickle cell retinopathy
  - Intraocular inflammation
  - Trauma, Retinal detachment and retinal tears, Intraocular tumors
  - Retinitis pigmentosa

o Iatrogenic
  - Postoperative, Cataract, Retinal detachment, Silicone oil, Retinopexy, Laser or cryotherapy

• Gass’ Grading System
  o Grade 0 (also termed cellophane maculopathy):
    - translucent membrane with no underlying retinal distortion
    - asymptomatic
  o Grade 1: irregular wrinkling of the inner retina
    - distorted or blurred vision
    - loss of binocularity, central photopsia, and macropsia
  o Grade 2: opaque membrane causing obscuration of underlying vessels
    - marked full-thickness retinal distortion
    - Increasing vascular tortuosity and size of vessel involved
    - CME in 20–40%

• PVD is present in approximately 60-90% of patients at the time of diagnosis
Pathogenesis

- represents a reactive gliosis in response to retinal injury or disease involving inflammatory and glial cells.

- Components
  - extracellular matrix: collagen, laminin, tenascin, fibronectin, vitronectin
  - cells: glial cells, neurites, retinal pigment epithelium, immune cells and fibrocytes

- secondary ERM: RPE Cells

- Idiopathic ERM: glial cells

CF

- ophthalmic and general medical history

- distinguish an idiopathic ERM from one that is secondary

- according to gradings as described

DD

- Vitreomacular traction
  - VMT is said to differ from ERM by the degree of vitreous separation in the mid-periphery
  - ERMs may coexist with VMT in 26-83%
  - In VMT with ERM the vitreous in the mid-periphery is detached, whereas in ERM without PVD the vitreous is attached

- Cystoid macula edema
  - no distortion of the microvasculature, it is always centered on the fovea and may be seen on fluorescein angiography as a ‘star pattern’ in late pictures

Ix

- OCT
  - diagnostic capabilities up to 90%
  - hyper-reflective layer on the surface of the retina
underlying corrugation of the retinal surface, blunting of the foveal contour, increased retinal thickness and intraretinal cysts

- FFA
  - in cases where an underlying vascular event or choroidal neovascular membrane is suspected.
  - highlight the extent of retinal wrinkling, degree of retinal vascular tortuosity and presence of macular edema

Management
- vital dyes
- ICG
  - greater affinity for ILM than ERM and may be more useful when viewed as a negative stain
  - toxicity has been more commonly demonstrated with a solution that has an osmolarity <270 mOsm, a concentration above 0.5% and incubation time >30 seconds
- Brilliant blue (0.25 mg/mL).
  - stains ILM
  - less toxic
- Trypan blue
  - highlights ERMs due to its strong affinity for glial cells
  - no evidence of RPE toxicity

- engaging and peeling ERMs
  - edge visible \(\rightarrow\) end-grabbing forceps
  - edge not visible \(\rightarrow\) surgical pick, a bent-tipped microvitreoretinal (MVR) blade or a diamond-dusted scraper
  - ILM peeling along ERM: controversial issue

complications
- Intraoperative
  - petechial hemorrhages from the perifoveal capillary bed
Peripheral retinal breaks are observed intraoperatively in 4-9%

- **Lens touch**

- **Postoperative**
  - **Cataract:** most common complication, 6-100%
    - alterations in oxygen tension and glucose concentrations
    - disruption of the anterior vitreous in the retrolental area
    - orientation of the infusion cannula at the time of surgery
  - **Retinal detachment**
    - 2-14% of eyes
    - unidentified entry site breaks at the time of surgery.
  - **Recurrence**
    - less than 20%
  - Other rarer complications include endophthalmitis, retinal toxicity from the use of vital dyes, phototoxicity, visual field defects and subretinal neovascularization

**Macular Hole**

- first described in 1869 by Knapp
- Ogilvie (1900) was the first to use the term hole at the macula
- **Epidemiology**
  - **Prevalence**
    - 1-3 per 1000
    - female-to-male ratio of 3.3 : 1
    - MH was bilateral in 11.7% of patients
  - **Incidence**
    - In the fellow eye without PVD is 5% to 16%.
- No MH in fellow eye with PVD

- **Risk factors**
  - age of ≥65
  - female gender

- **Pathogenesis**
  - **Vitreomacular traction:** anteroposterior traction of vitreous fibers on the fovea played a role in the formation of MH
  - **Foveal cyst:** foveal cyst formation due to vitreous traction was the first step in MH formation
  - **Contraction of the premacular vitreous cortex: GASS,** tangential contraction of the prefoveal “posterior hyaloid membrane” resulted in the detachment of the central photoreceptors and then in the opening of the fovea
  - **SD-OCT based theory of pathogenesis:**
    - Shows changes substantiate the concept of Stage 0 MH proposed by Chan et al. in 2004

- **Staging**

  - **Stage 0 MH:**
    - slight changes in the foveolar structure long before the occurrence of the early foveal cyst that characterizes Stage 1 MH or impending hole
    - Minor changes in the cone outer segment tips (COST, or Verhoeff membrane), line at the foveal center, or subtle changes in the reflectivity of the center of the foveola, along an anteroposterior axis extending from the ILM to the IS/OS junction line

  - **Stage 1A**
    - Impending macular hole
    - central yellow spot and loss of the foveal depression associated with no vitreofoveal separation
    - due to early serous detachment of the foveolar retina
    - inner foveal cyst.
• **Stage 1B**
  o occult hole
  o yellow ring in the fovea, the absence of vitreofoveal separation and the loss of the foveal depression.
  o yellow ring is due to the edematous border of the disrupted outer retina

• **Stage 2**
  o eccentric oval, crescent or horseshoe-shaped retinal defect inside the edge of the yellow ring
  o tear in the contracted pre-foveolar vitreous tissue bridging the round retinal hole, with no loss of foveolar retina
  o neuronal elements formed a constitutive part of the operculum at least in some cases

• **Stage 3**
  o central round retinal defect more than 400 µm in diameter
  o with a rim of elevated retina, with or without pre-foveolar pseudo-operculum and without a Weiss's ring

• **Stage 4**
  o complete PVD with a Weiss's ring.
  o presence of the Weiss's ring on **biomicroscopy (not just OCT)** therefore remains the valid indicator for this

**Differential diagnosis**

• **Lamellar macular hole**
  o Gass in 1975: opening of the central cyst of a cystoid macular edema.
  o **Histology:** thinning of the foveal tissue leaving the RPE and photoreceptor layers intact, but causing partial loss of the inner nuclear layer
  o **Biomicroscopy:**
    ▪ rarely round but rather bi- or tri-lobulated
    ▪ edge is thin whereas the FTMH edge is thick and elevated
    ▪ Watzke test negative
• aiming beam test: beam perceived unlike MH
  o OCT: defects in the inner fovea due to the avulsion of the roof of a foveal cyst

• **Macular pseudoholes**
  o Allen and Gass in 1976
  o OCT: thickening of the macula contracted by an ERM, and the U or V shape of the fovea. There is no loss of retinal tissue at the umbo of the fovea

• **Foveal cysts of various origins:** cystoid macular edema, X-linked retinoschisis, or foveal cysts of type 2 macular telangiectasia.

• **Microholes**
  o Cairns 1988
  o dark-reddish lesions in the center of the fovea ranging from 50 to 150 µm in diameter
  o break in the photoreceptor layer at the foveal center. What have been called “microholes” might therefore not be FTMH but in some cases, spontaneously closed FTMH

• **Non-idiopathic (secondary) MH**
  o Orbital trauma and high myopia
  o High myopia
  o Other rare causes

**Management**

• **Principles and techniques**

• Posterior hyaloid detachment

• Extensive Vitrectomy

• Epiretinal membrane peeling

• Internal limiting membrane peeling
  o Eckardt et al. in 1997
  o Maculorrhexis
• **Vital dyes**
  - Chromovitrectomy
  - *Indocyanine green and infracyanine*
    - selective affinity for the ILM
    - concentration was reduced to 0.125% and even 0.05%
    - 0.05%, 290 mOsm and no more than 30 seconds with the retina, seems to give no sign of RPE toxicity
    - *Infracyanine*, an *iodine-free* product, diluted in 5% *glucose*, results in an iso-osmolar solution, which might be safer for the retina
  - *Trypan blue*
    - stains the ERM well but the ILM less effectively
    - must be used after fluid-gas exchange
    - no signs of toxicity for the RPE
  - *Brilliant Blue*
    - selective affinity for the ILM
    - iso-osmolar solution of 0.25 mg/mL

• **Gas**
  - most MH close within 3–7 days of tamponade
  - bubble large enough to insulate the macula from intraocular fluid during this period

• **Use of silicone oil in MH surgery**: anatomic results were no better with silicone oil than with gas

• **Use of healing adjuvants**: TGF-β, autologous platelet concentrates

• **A nonsurgical treatment**
  - Ocriplasmin (ThromboGenics NV, Leuven, Belgium)
  - Stage 2 MH <400 µm
  - success rate for the ocriplasmin group was 40.6% compared with 10.6% in the placebo
  - MH with a diameter of ≤250 µm, the success rate rose to 58.3%, but for holes with a diameter of 250–400 µm, it was only 24.6%
• Results
  o Today the closure rate is currently 85% or more
  o 92% for MH <400 µm but only 56% for MH of ≥400 µm, as measured on OCT
  o Tornambe: 79% success for hole closure without any facedown positioning

• Complications
  o **Retinal detachment:** under 2%
  o **Cataract:** rate of pseudophakia at 3 or 5 years is commonly 85-98%
  o **Visual field defects:** attributed to retinal nerve fiber layer damage to the nasal portion of the optic nerve rim, probably due to traction during cortical vitreous peeling, upto 23%
  o **Reopening of macular holes:** 5-7% of cases

**MH Indices**

a = base diameter  
b = minimum linear dimension (MLD)  
e = maximal hole height  
f = macular hole inner opening

• **Hole Form Factor (HFF)**

Determine extent of Base diameter (a) and MLD (b)

Hole Form Factor = \( \frac{c + d}{a} \)

No correlation found between HFF and postop gain in lines

HFF:
HFF > 0.9: good surgical prognosis
HFF < 0.5: 25% MH closure rate

- **Macular Hole Index (MHI)**
  
  \[ MHI = \frac{e}{a} \]
  
  MHI was associated with postoperative vision

- **Diameter Hole Index (DHI):** ratio of minimum diameter of MH to base MH diameter
  
  indicator of extent of tangential traction

- **Tractional Hole Index (THI):** ratio of the maximal height of MH to minimum diameter
  
  indicator of A-P traction and retinal hydration

  \[ THI = \frac{e}{b} \]

  THI correlated significantly with postop vision

- **Closure:**

  Grade 0: IS/OS junction absent under the fovea
  
  Grade 1: IS/OS junction present under the fovea; abnormal
  
  Grade 2: IS/OS junction present under the fovea and normal

- **VITAL DYES:**

  1. **Indocyanine green (ICG):** Toxicity reports for 0.125%-0.50%
     
     Visual field defects
     
     RPE damage
     
     OCT based RNFL damage
mf ERG (0.125%)  
2. BBG: 0.25 %  
3. Tryptan Blue: 0.15%  
4. Triamcinolone:

- OCT imaging preoperatively and postoperatively has provided additional prognostic data for visual recovery following macular hole surgery. Factors on OCT predictive of good visual acuity macular hole surgical outcome are as follows:
  1. Size of macular hole (minimum diameter < 311 µm)
  2. Traction on macular hole edges as defined by various parameters (e.g., macular hole height)
  3. Development of a normal photoreceptor inner segment and outer segment junction, which can occur as early as 1 month postoperatively but typically by 6 months postoperatively as shown in the images below.
  4. MH minimum diameter of <311 microm or a THI >1.41 are predictive factors for a good visual prognosis after MH surgery.

CME - VMT

Pathophysiology

- **cystoid macular edema**
  - predisposed to develop edema: extremely high cell count with increased metabolic activity and a central avascular zone, creating a watershed arrangement between the choroidal and retinal circulation which decreases resorption of extracellular fluid
  - In the foveal region, these fibers of the outer plexiform layer demonstrate a loose arrangement allowing accumulation of fluid leaking from perifoveal capillaries
leakage from the perifoveal capillaries

- **tractional macular edema**
  - increased water influx into the retinal tissue by decreased fluid clearance through glial and RPE cells
  - hypothesis of VMT: Vitreous fibers, which adhere to Müller cell end-feet at sites of vitreoretinal attachments after partial detachment of the vitreous, exert tractional forces onto the cells; this activates Müller cells and results in cell hypertrophy, proliferation, and vascular leakage
  - breakdown of the BRB
  - growth factors such as VEGF, IL-6, PDGF, and others are secreted in large amounts into the vitreous during proliferative vasculopathies

- **CF**
  - loss in distance visual acuity, contrast sensitivity, color vision, reading acuity to a reduction in reading speed
  - marked reduction in central retinal sensitivity with either a relative or absolute scotoma during active macular edema
  - cysts are characterized by an altered light reflex
  - retroillumination can help to delineate the polycystic spaces
  - subclinical foveal edema: 201-300 microns, difficult to identify clinically
  - thickness appears to be most closely correlated with visual acuity
  - leakage on fluorescein angiography is not directly correlated with reduced visual acuity.

- **Ix**

- **FFA:**
  - Early: capillary dilation can be detected in the perifoveal region
  - Late: fluorescein pools in cystoid spaces located in the outer plexiform layer (Henle's layer)
  - Foveal area: classic petaloid staining pattern
  - outside the perifoveal area: honeycomb appearance
- **FAF**: cysts as hyperautofluorescent because of the displacement of macular pigments that naturally attenuate the autofluorescent signal
- **ICG**: not considered a very useful tool
- **OCT**:
  - **CME**: amount of reflectivity within these cystoid spaces is due to higher concentration of protein associated with the breakdown of the inner blood-retinal barrier
  - **VMTS**: 2 patterns
    - **foveal cavitation** defined as the formation of cystoid cavity located in the inner part of the central fovea secondary to mechanical forces
    - **CME** that was defined as **intraretinal cyst**-like cavities extending beyond the foveal region

**Management**

**treatment of tractional macular edema**

- **Vitrectomy**
  - **Tractional origin of macular edema**: Newton’s third law,
  - **Nontractional origin of macular edema**:
    - oxygenation of the posterior segment of the eye is increased after Vitrectomy
    - growth factors such as VEGF, IL-6, platelet-derived growth factor, and others are secreted in large amounts into the vitreous which are removed
  - **internal limiting membrane peeling**
    - diffusion of oxygen from the fluid in the vitreous cavity into the retina would be retarded by a thickened ILM
    - absence of ILM would further speed up this clearance of cytokines

- **Pharmacologic vitreolysis**: chondroitinase, dispase, hyaluronidase, plasmin, and microplasmin.
  - **Plasmin**
    - nonspecific serine protease
- promote PVD acting on a variety of glycoproteins and activating endogenous metalloproteinases
- anatomic and functional improvement after intravitreal injection
- Microplasmin is recombinant the agent that shows the greatest clinical potential
- 125 µg dose that was repeated up to three times, released adhesion in 58% of patients with VMTS, 28 days after the final injection
- MIVI-IIT trial:
  - MIVI-TRUST (Traction Release without Surgical Treatment) trial:

**Clinical entities with cystoid macular edema**
- DME
- CRVO
- BRVO
- Uveitic macular edema
- Postoperative macular edema
- VMTS
- ERM
- ERM
- VMT in ARMD
- RP

**CNVM**
- Gass’ Types
  1. within Bruch's membrane and beneath the RPE → typical of AMD
2. proliferate anterior to native RPE in the subneurosensory retinal space → typical of histoplasmosis

- **Submacular surgery trials:** surgery should not be recommended for ARMD but may be recommended for OH

- **Current indications for surgical removal of CNV**
  - large peripapillary CNV unresponsive to anti-VEGF agents and/or photodynamic therapy
  - too large for thermal laser photocoagulation

### Submacular Hemorrhage

- **Etiology**
  - most often caused by CNV
  - 80% were due to AMD with retinal arterial macroaneurysms
  - CNV due to histoplasmosis, angioid streaks
  - idiopathic submacular hemorrhage being less common

- **Natural history**
  - etiology was the most important factor in predicting the final visual outcome
  - 19% of eyes gained two or more lines of vision during follow-up, while loss of two or more lines occurred in 59% and 36% experienced severe vision loss of 6 lines or more

- **Management**
  - **Surgical removal of blood and CNV:** generally not beneficial
  - **Vitrectomy, injection of subretinal TPA, and aspiration of liquefied blood**
    - tPA (12.5 µg/mL) injected into the subretinal space
  - **Intravitreal TPA with pneumatic displacement**
    - Heriot 1997
    - 50 µg or 100 µg of tPA and injection of a long-acting gas bubble (C₃F₈ or SF₆)
    - intravitreal tPA is controversial
  - **Subretinal injection of TPA with pneumatic displacement**
    - subretinal injection of tPA (25-50 µg/mL) using a bent 36-gauge needle
- maximal chemical lysis of the clot via subretinal injection of tPA

- **Anti-VEGF agents**

---

**Cystoid Macular Edema**
The presence of fluid in the macula was first described in diabetic retinopathy by Appolinaire Bouchardat from Paris in 1875. Subsequently, a similar appearance of the retina was noted in a number of other conditions, and in 1950, Hruby drew attention to the occurrence of macular edema after cataract extraction. This was followed 3 years later by Irvine's classical paper on cystoid macular edema (CME), occurring after intra- and extracapsular cataract extraction complicated by incarceration of vitreous in the anterior segment. These changes in the macula were further described by Gass and Norton, a decade later, using fluorescein angiography.

Using fluorescein angiography, the following classification has been suggested:

0 = no edema
1 = capillary leakage
2 = partial petalloid ring
3 = complete petalloid ring

Another classification scheme has been proposed using focal macular electoretinograms.

1. Eyes with a type I response have reduced amplitudes of the oscillatory potentials with normal a- and b-wave responses.

2. In type II, the eyes have reduced amplitudes of the oscillatory potentials and b-waves.

3. In type III reduced amplitudes of the oscillatory potentials, a-waves, and b-waves are observed.

The least reduction in visual acuity is seen in type I, while the most severe reduction is present in type III.

Giant Retinal Tear

- Giant retinal tear: a retinal tear of more than 90° circumferential extent. Since the posterior vitreous is detached, the vitreous gel is adherent to the anterior flap. Hence, the posterior flap has a tendency to fold over.
• **Giant retinal dialysis:** the retina is either torn at the ora serrata or there is a break in ciliary epithelium, with the vitreous being adherent to the posterior retina. Thus, the posterior flap does not have the tendency to fold over, since it is supported by the vitreous gel.

• **Etiology**
  - 0.091 patients per 100,000
  - Idiopathic 55%
  - M >> F
  - High myopia
  - Marfan syndrome
  - Stickler syndrome
  - Ehlers-Danlos syndrome, lens coloboma, and aniridia
  - **Iatrogenic giant retinal tear**
    - During a cataract surgery misadventure
    - During vitreoretinal surgery
    - After pneumatic retinopexy
    - After refractive surgery in the form of LASIK

• **Pathogenesis**
  - Central vitreous liquefaction is associated with condensation in the peripheral vitreous base that leads to traction on the peripheral retina
  - White-without-pressure
  - Transvitreal contraction of the cortical gel occurs, tearing the retina along the vitreous base in a zipper fashion
  - Multiple horseshoe-shaped tears may form along the posterior vitreous base and coalesce to form a giant retinal tear.

• **Evaluation**
  - Corneal problems such as generalized haze due to edema, opacity, Descemet’s membrane folds, etc.
  - The lens could be subluxated due to the blunt trauma and could be also cataractous.
posterior vitreous will be found to be detached in cases of giant retinal tear, unlike in dialysis.

extent of retinal detachment

vitreous could be incarcerated in the wound

macular hole can coexist

USG:

- discontinuity noticed anteriorly in the retinal echo and extending more than one quadrant
- Double linear echo would be seen near the disc due to the close proximity of the two layers of the retina

Proliferative vitreoretinopathy

Role of nonsurgical treatment

- Laser barrage photocoagulation
- Outpatient fluid-gas exchange followed by cryopexy or laser photocoagulation

Role of simple scleral buckling

Management

pre-PFCL era

- Scleral buckles: shallow, but broad buckle
- rotate the patient and to reposition the retinal flap with the help of an air bubble
- retinal tacks or sutures: divide the giant retinal tear into smaller segments by pinning the edge of the tear
- fluid-air exchange in prone position.

PFCL era

- Vitreous surgery

Role of an encircling band: fresh GRT can be managed without band, some degree of PVR should be managed with band
o **Lens management**
  - leave it untouched
  - lensctomy and leaving the eye Aphakic
  - lens removal and keeping the posterior capsule intact for future IOL placement
  - lens removal and IOL placement at the same time

o **Management of intraocular lens**

o **Visualization**

o **Vitrectomy**

o **Radical excision of the vitreous base**

o **Mobilizing the retina and management of anterior retinal flap**

o **Eyes with PVR**

o **Conversion to a 360° tear**

o **Perfluorocarbon liquids**
  - During membrane dissection to stabilize the posterior pole
  - for facilitating internal limiting membrane removal around macular hole in detached retina
  - for reattachment of the mobilized retina without fear of posterior slippage
  - for medium-term tamponade.

o **Retinopexy**

o **Internal tamponade**

o **PFCL-air exchange**

o **PFCL-silicone oil exchange**

- **Results**
  o pre-vitrectomy era: 15-20%
  o Vitrectomy and gas: 43%
  o vitrectomy and silicone oil: 80-90%
Management of fellow eye

- 14% incidence of giant retinal tear and 36% incidence of other retinal tears
- High-risk fellow eyes
  - high myopia
  - eyes with progressively increasing white without pressure areas with sharp posterior margin and increased vitreous condensation
  - patients with Wagner-Stickler syndrome
- prophylactic mx: only cryopexy or laser photocoagulation without scleral buckling

Angioid Streaks

- Doyne in 1889
- Knapp’s striae as he first coined the term in 1892
- 1917: Kofler correctly determined that they represented changes at the level of Bruch’s membrane
- irregular breaks in calcified and thickened Bruch’s membrane radiating outwards from optic nerve in all directions like blood vessels
- peripapillary in 27% of cases when it is confined to two disc diameters from optic nerve or more widespread in 73% of cases where the streaks radiate for varying distances in the fundus, however never going past the equator
- colour of streaks varies from red to dark brown depending on colour of the fundus and overlying retinal pigment epithelial (RPE) atrophy
- associated fundus findings
  - Peau d’orange changes
  - Salmon spots
  - Optic disc drusen - They are seen in around 10% of patients.
  - Fresh haemorrhages.
o Paired red spots along streaks.

o Cracked egg shell appearance of fundus- diffuse type of angioid streaks.

- course and complications
  o Choroidal neovascularisation (CNV) - It is the most common and serious complication seen in 72-86% of patients
  o Macular degeneration- It is seen in 72% of these patients
  o Traumatic membrane ruptures
  o RPE tears have also been reported in angioid streaks

- Systemic associations
  o pseudoxanthoma elasticum (34%), Paget’s disease (10%), hemoglobinopathies (6%). Upto 50% cases are, however, idiopathic

- Dx
  o clinical examination
  o FFA: window defect’ in FA due to RPE atrophy adjacent to them
  o ICG:
  o OCT

- Management
  o use eye protection and avoid contact sports
  o Therapy is possible and indicated only whenever a CNV has developed
  o Prophylactic photocoagulation of angioid streaks may stimulate CNV formation and is contraindicated.
  o Laser photocoagulation
  o Photodynamic therapy
  o Anti VEGF
  o transpupillary thermotherapy
Infectious Endophthalmitis

- Exogenous Endophthalmitis: when the outer wall of the eye sustains a break
- Endogenous Endophthalmitis: less common, when the microorganisms spread to the eye from a source elsewhere in the body, usually through the blood stream
- 90% of all cases are caused by bacteria

Etiology

Postoperative (70%)

Acute postoperative (<6 weeks after surgery)

Ninety-four percent Gram-positive bacteria including coagulase-negative staphylococci (70%), Staphylococcus aureus (10%), Streptococcus species (11%); only 6% Gram-negative organisms

Delayed postoperative (>6 weeks after surgery)

Propionibacterium acnes, coagulase-negative staphylococci, and fungi (Candida species)

Conjunctival filtering bleb associated

Streptococcus species (47%), coagulase-negative staphylococci (22%), Haemophilus influenza (16%)

Posttraumatic (20%)

Bacillus (B. cereus) species (24%), Staphylococcus species (39%), and Gram-negative organisms (7%)

Endogenous (2-15%)

Rare, usually fungal (Candida species); bacterial endogenous is usually due to Staphylococcus aureus and Gram-negative bacteria. Occurs in debilitated, septicemic, or immune-compromised patients, especially after surgical procedures.

- Bacteria
  - Gram-positive cocci
- **Staphylococci:**
  - *S. aureus*: 2nd MC
  - **CONS**: *S. epidermidis* is MC (*exopolysaccharide* or “slime”)

- **Streptococci**
  - **Gram-positive bacilli**
    - *Bacillus*: IV drug use, sickle-cell disease, foreign bodies including IV catheters, immunosuppression from malignancy, neutropenia, corticosteroid use, AIDS
  - *Corynebacterium diphtheria*
  - *Listeria monocytogenes*
  - *Clostridium species*
    - *Propionibacterium*: most common clinical isolate of Gram-positive, nonsporulating bacteria, chronic granulomatous nature, IOL associated

- **Gram-negative cocci**
  - *Neisseria*
  - *Moraxella*

- **Gram-negative bacilli**
  - *Actinobacter*
  - *Haemophilus influenza*
  - *Pseudomonas*
  - *Enterobacteriaceae*
  - *Klebsiella*
    - **Higher bacteria**: Mycobacteriaceae, Actinomycetaceae, and Nocardiaceae.

- **Fungi**
  - *Candida*
  - *Aspergillus*
  - *Histoplasma capsulatum*
  - *Blastomyces dermatitidis*
• **Helminths**

• **Protozoa**

• **Ectoparasites**

**Clinical Features**

• **Postoperative infection**
  
  o **Cataract extraction**: 0.03% to 0.1%
    
    ▪ pain 1-7 days after
    
    ▪ conjunctival chemosis and increased injection, often with a significant amount of yellowish exudate
    
    ▪ More severe initial findings suggest infection with Gram-negative bacteria, *Streptococcus* or *Staphylococcus aureus*
    
    ▪ Postoperative filtering blebs, wound leaks, and vitreous wick are also found more frequently in infected eyes
  
  o **Corneal transplantation**: 0.11% and 0.08%
  
  o **Glucoma filtration surgery**:  
    
    ▪ similar to the risk following cataract
    
    ▪ inferior location to the bleb and use of antifibrotic agents increase the likelihood
  
  o **Pars plana Vitrectomy**:  
  
  o **Intraocular injection**: 0.014% up to 0.87%
  
  o **Scleral buckling procedure**
  
  o **Strabismus surgery**

• **Post-traumatic Endophthalmitis**
  
  o 20-30% of the cases of endophthalmitis
  
  o 2-17%

• **Endogenous Endophthalmitis**
  
  o 5-7% of cases
I notes

RETINA

Dhaval Patel MD

- diabetes mellitus or renal therapy, immunosuppressive disease and therapy, IV drug use, or systemic septicemia
- **Bilaterality** is common
- **Fungal** causes are found in 50-62% of cases
- More alarming is the mortality rate, which has been reported to vary from 5% to 29%

**Therapy**

- To overcome the problem of poor penetration, intravitreal injection of antibiotics was studied by von Sallmann et al and by Leopold with further development by Peyman and Forster

- Characteristics for ideal drugs
  - Bactericidal properties
  - Broad spectrum of coverage
  - Excellent therapeutic ratio
  - Good therapeutic ratio after IV injections
  - Favorable pharmacokinetic properties

- **Dosing**
  - Vancomycin 1 mg/0.1 mL
  - Cefazolin 2.25 mg/0.1 mL
  - Amikacin 0.2-0.4 mg/0.1 mL
  - Ceftazidime 2 mg/0.1 mL
  - Dexamethasone 4 mg/0.1 mL
  - traumatic endophthalmitis with vegetable matter: Amphotericin B 5 µL/0.1 mL
Retinal Tumors

Cavernous Hemangioma

- Etiopathology
  - tumor arising from the inner half of the retina
  - multiple endothelial-lined, thin-walled aneurysms
  - multiple endothelial-lined, thin-walled aneurysms
  - Genotyping for the three known CCM genes can establish its hereditary nature.

- CF
  - clusters of saccular aneurysms filled with dark blood
  - isolated, one to two disc diameters in size, and resembles an intraretinal cluster of grapes
  - pseudohypopyon in retina: layering of the red blood cells within the aneurysms causes a plasma-erythrocytic separation
  - characteristic “cluster-of-grapes” appearance
  - unilateral
  - symptomatic when they are located in or adjacent to the macula which has been reported in approximately 10%
  - can cause simultaneous subretinal, intraretinal, and preretinal hemorrhage

- DD
  - lack of intraretinal exudate distinguishes this tumor from Coats disease
  - Leber miliary aneurysms is a progressive condition
  - capillary hemangioma (von Hippel disease) is a discrete tumor with characteristic feeder vessels
  - Racemose hemangioma (Wyburn Mason syndrome): dilation of the larger retinal vessels with direct arteriovenous anastomosis is seen

- FAF: autofluorescence of the gray-white epiretinal membrane overlying the tumor
- FFA: aneurysms will fill slowly and often incompletely up to 30 minutes after dye injection.
- Mx
- Conservative and follow up
- Laser or cryo in case of VH

**Metastases**
- 10% of patients who die of cancer have been found to have intraocular metastases
- average age at diagnosis of retinal metastases was 52 years

**Metastatic cascade**
- dissociate from the primary tumor
- invasion of the surrounding connective tissue components
- intravasation
- dissemination: hematogenous or lymphatic
- extravasation and angiogenesis

**CF**
- decreased or blurred vision
- Floaters
- pain, diplopia, and red eye
- can be asymptomatic
- Metastatic melanoma: pigmented lesion within the retina with irregular borders and flat appearance
- Carcinomas: non-pigmented, white or yellow
- Intraretinal/ Subretinal hemorrhage
- Perivascular infiltrates and exudates
- subretinal fluid
- Vitreous cells: “brown spherules” or “globular vitreous opacities” → melanoma

**Differential diagnosis**
- non-pigmented white retinal lesions: carcinoma, the differential includes inflammatory and infectious diseases
pigmented lesions: metastatic melanoma, metastatic choroidal tumors, neovascular macular degeneration

**Diagnostic evaluation**
- history and physical exam, with review of systems,
- metastatic workup
- Blood work,
- markers for infectious disease
- B-scan ultrasonography:
  - FFA: not diagnostic, it is helpful in differentiating metastatic tumors from non-neoplastic conditions
- OCT

**Management**
- systemic chemotherapy
- Surgical resection for some tumors has been described
- Plaque radiotherapy
- Photodynamic therapy

**Paraneoplastic Retinopathy**

**Effects of Cancer**
- mass effect
- metastatic
- due to RT or CT
- paraneoplastic syndrome

**Cancer-associated retinopathy CAR**
- **Klingele**: termed this “paraneoplastic retinopathy”
• subacute visual loss resulting from circulating antibodies against retinal proteins in the presence of systemic cancerous tumor growth

• Etiopathology
  o hormone-like substance ??
  o autoimmune basis ??
  o 23 kDa serum antiretinal ganglion cell antibodies → recoverin, a calcium channel photoreceptor protein → recoverin-associated retinopathy
  o 46 kDa antigen identified as human alpha-enolase, a glycolytic enzyme

• CF
  o decreased vision, a halo of missing peripheral vision, positive visual phenomena (“sparkles”), photosensitivity, impaired color vision and night blindness
  o mean of 5 months in up to 50% of cases
  o Tonic pupils
  o ERG: extinguished a and b waves or rod responses larger than cone responses
  o OCT: Reduced macular thickness

• most common malignancies related to CAR are carcinomas, and over half of all these patients have a pulmonary malignancy with the most common being small cell carcinoma of the lung

**Cutaneous melanoma-associated retinopathy MAR**
• 1984 by Gass as “an acute Vogt-Koyanagi-Harada-like syndrome.”

• Paraneoplastic acquired night blindness

• Etiopathology
  o antibodies against transducin, aldolase A and aldolase C have also been documented in patients with MAR

• CF
  o differentiated from CAR syndrome by being nonprogressive, causing central visual loss (versus ring scotomas), a sensation of shimmering or pulsating light and being associated with vitiligo in up to 20%.
  o In contrast to patients with CAR syndrome and the “acute Vogt-Koyanagi-Harada-like syndrome,” patients with MAR syndrome demonstrate a substantial elevation of rod
absolute thresholds and selective reductions in the rod and cone ERG b waves, resembling those of patients with congenital stationary night blindness.

- The photoreceptor function is intact but signal transmission between the photoreceptors and second-order interneurons appears to be defective.
- MAR syndrome, unlike CAR syndrome, is more likely to be visually symptomatic in more advanced stages of disease and, in general, does not manifest before the clinical diagnosis of cutaneous malignant melanoma.

Management of paraneoplastic retinopathy

- ERG should be considered in any adult patient who has symptoms of central or paracentral positive visual phenomena (“shimmering” or “dancing” lights), photopsias, and minimal retinal findings
- ERG is abnormal or extinguished, then a chest X-ray is a common “next step,”
- panel of autoantibody tests for CAR, MAR
- possible role for immunosuppression therapy

bilateral diffuse uveal melanocytic proliferation BDUMP

1. Development of multiple, slightly elevated (usually only up to 2 mm), pigmented, and nonpigmented uveal melanocytic tumors, as well as evidence of diffuse thickening of the uveal tract
2. Multiple, round or oval, subtle, red patches at the level of the RPE in the posterior fundus
3. A striking pattern of multifocal areas of early hyperfluorescence on fluorescein angiography corresponding with these patches
4. Exudative retinal detachment
5. Rapidly progressing cataracts

Melanocytoma of the Optic Disc

- Zimmerman
- specific variant of melanocytic nevus, located in the optic disc or anywhere in the uveal tract, characterized clinically by a dark brown to black color, and composed histopathologically of deeply pigmented round to oval cells with small, round, uniform nuclei
• melanocytoma appears to have an equal incidence in all races, whereas uveal melanoma is uncommon in black people

• CF
  o slight visual loss related to the tumor can occur in about 26%, usually due to mild retinal exudation and subretinal fluid.
  o Marcus Gunn pupil 10-30%
  o usually unilateral
  o dark brown to black lesion that is located partly in the optic disc
  o relatively small and confined to the disc in 15%
  o some degree of disc edema (25%), intraretinal edema (16%), subretinal fluid (14%), yellow intraretinal exudation (12%), focal hemorrhage (5%), vitreous seeds (4%), and retinal vein obstruction (3%).

CHRPE
• asymptomatic congenital hamartoma
  o solitary
  o grouped
  o multiple: FAP, Gardner, Turcot

• 3 per 2400 prevalence

• FAP
  o adenomatous polyposis coli (APC) gene
  o chromosome 5
  o Attenuated FAP (AFAP, <100 colorectal adenomas)
  o Severe FAP (>1000 adenomas)
  o intermediate FAP (100-1000 adenomas)

• Clinical Features

• Solitary CHRPE
  o flat, round, hyperpigmented lesion with smooth or scalloped margins
I notes

RETINA

Dhaval Patel MD

- light gray, brown to black
- marginal halo of depigmentation may surround the lesion
- punched-out inner lacunae with hypopigmentation
- size may vary
- predominance in the superotemporal and equatorial region

- **Grouped CHRPE**
  - arranged in a cluster, resembling the footprint of an animal (‘bear tracks’),
  - 3-30 lesions, which may vary in size from 100 to 300 µm lesions
  - possible pigmentary mosaicism in both the eye and skin

- **Multiple CHRPE**
  - generally smaller (50-100 µm in diameter) compared with solitary
  - depigmented halo, mottled RPE
  - More than four widely spaced lesions per eye or bilateral involvement are suggestive of FAP

- **Ix**
  - FFA ICG: no leaks
  - ERG-EOG: normal

**Differential diagnosis**

- choroidal malignant melanoma: elevated, less homogeneously pigmented and less sharply demarcated compared with CHRPE

- Choroidal nevi are flat and located below the RPE

- Melanocytomas of the choroid: homogeneously black color

- sickle cell retinopathy: Black sunburst lesions

**CHRRPE**

- Combined hamartomas of the retina and retinal pigment epithelium
• benign tumors that may cause significant visual loss
• solitary, unilateral lesions located at the optic disc or posterior pole.
• mean age at the time of diagnosis was 15
• CF
  o painless visual loss → choroidal neovascularization, vitreous hemorrhage, exudative retinal detachments, retinoschisis, and macular hole formation
  o strabismus, floaters, leukocoria and ocular pain
  o elevated pigmented mass involving the RPE, retina and overlying vitreous with extension of fanlike projections towards the periphery
  o vascular tortuosity within the lesion in 93% of patients, hyperpigmentation in 87%, slight elevation in 80%, epiretinal membrane formation in 78%, and exudation in 7%
  o Bilateral CHRRPE lesions have been identified in patient with neurofibromatosis 1
• Ix
  o FFA: degree of hypofluorescence parallels the degree of hyperpigmentation, tortuous vessels usually leak in late phase
  o OCT: elevated lesion with high reflectivity of the inner retina, hyporeflective shadowing of the underlying tissue, and obscuration of the normal retinal layers
• DD
  o Epiretinal membrane
  o Pigmented choroidal lesions
  o Miscellaneous: Morning-glory disc anomaly, retinoblastoma, choroidal neovascularization, retinoschisis, and capillary hemangioma
• Mx
  o anti-VEGF agents for CNVM
  o surgical removal

Primary Vitreoretinal Lymphoma
• **PCNSL and PIOL**
  
  - PCNSL is a variant of extranodal non-Hodgkin lymphoma (NHL) that is predominantly a high-grade B-cell malignancy associated with a median survival ranging from 1–8 years depending on factors such as age and Karnofsky performance status.
  
  - Primary intraocular lymphoma (PCNSL-O or PIOL) is a variant of PCNSL with predominantly ophthalmic involvement. In contrast to other ocular lymphomas that affect the orbit, conjunctiva, and uveal tract, PCNSL-O is characterized by vitreoretinal involvement and is therefore referred to as primary vitreoretinal lymphoma (PVRL).

• exact incidence is unknown

• **Etiopathogenesis**

  - originate from late-germinal center or post-germinal center lymphoid cells

• **CF**

  - painless, decreased visual acuity or floaters

  - bilateral in 80% of cases

  - hallmark: presence of fine vitreous cells or clumps of cells and sub-retinal pigment epithelium (RPE) deposits comprised of aggregated lymphoma cells

  - keratic precipitates, iris nodules, aqueous cells, and flarefocal, multifocal, or diffuse choroidal, retinal, or chorioretinal infiltrates

---

**Phakomatoses**

• oculoneurocutaneous syndromes

• phakoma was first used by Van der Hoeve in 1932

• **Hamartia**: is a nontumorous anomaly of tissues normally present at the location where it develops

• **Hamartoma**: is a tumorous malformation of tissues normally present at the location where it develops (eg: VHL)

• **Chorista**: is a nontumorous anomaly composed of elements that are not normally present at the site where they develop

• **Choristoma**: is a tumorous malformation composed of elements that are not normally present at the site where they develop (eg: limbal dermoid)
- Most phakomatoses display an AD inheritance except encephalofacial hemangiomatosis (Sturge-Weber) and racemose hemangiomatosis (Wyburn-Mason) in which germline heredity does not appear to play a role.

Capillary Hemangioblastoma - VHL
- Retinal capillary hemangioblastomas RCH = retinal angiomas
- a sign of the systemic condition, von Hippel-Lindau disease (VHL).
- AD
- 1 in 36,000
- CNS: brain, spinal cord, inner ear, and retina
- visceral organs: the kidney, adrenal gland, pancreas, epididymis and broad ligament

Genetics
- germ line mutation in the VHL gene, which is located on the short arm of chromosome 3, 3p25-26
- VHL gene’s protein degrade particular transcription factors called hypoxia inducible factors (HIFs)
- pVHL, the VHL suppressor gene product, is known to downregulate vascular endothelial growth factor (VEGF) expression. With the absence of pVHL, VEGF is upregulated, resulting in neovascularization on and around these retinal capillary hemangioblastomas

CF
- initial appearance: subtle red or grayish dot no larger than a few hundred microns
- later: proliferation progresses, secondary alterations occur to produce a distinctive clinical appearance that is often nodular
- tumors are located predominantly in the retinal periphery and less frequently on or around the optic disc
- tumors are located predominantly in the retinal periphery and less frequently on or around the optic disc
- retinal hard exudates can develop

FFA: early leakage and marked hyperfluorescence and this may persist or decrease in the late phases of the study.

Treatment
- laser photocoagulation, cryotherapy, radiation, photodynamic therapy, or by surgical excision.

- **ablative fugax**: photocoagulation and cryotherapy of peripheral tumors can often lead to massive retinal hard exudate accumulation and retinal edema in the macula, contributing to further decrease in vision following treatment.

- **SU5416**, an intravenously administered inhibitor of VEGF receptor-2,

- **bevacizumab**, a humanized anti-VEGF antibody, was also used systemically, resulting in a transient reduction in exudation, but no improvement in visual outcome

- Diagnosis of von Hippel-Lindau disease
  1. A positive family history and a CNS hemangioblastoma (including retinal hemangioblastomas), pheochromocytoma, or clear cell renal carcinoma is sufficient for diagnosis
  2. If there is no family history, for diagnosis, the individual must have two or more CNS hemangioblastomas, or one CNS hemangioblastoma and a visceral tumor (with the exception of epididymal and renal cysts, which are frequent in the general population

---

**Tuberous Sclerosis**

- Bourneville syndrome

- **AD**

- Hamartomatous tumors of the brain, skin, viscera, and eye

- Classic triad included seizures, mental retardation, and cutaneous angiofibromas

- **CF**

  - **Neurological**: infantile spasms” or “salaam attacks

  - **Cognitive and behavioral disability**

  - **Skin features**: butterfly distribution of adenoma sebaceum aka Facial angiofibromas, ash-leaf lesion → **Wood's lamp**, Shagreen patches

  - **Visceral features**: Renal angiolipomas, Cardiac hamartomas

  - **Skeletal features**: Sclerotic calcified areas

  - **Ocular**
    - **Retinal**
Solitary astrocytic hamartomas: (1) large, whitish (calcified) nodular masses or (2) flat, translucent (noncalcified) smooth tumors

- vitreous hemorrhage, retinal vascular abnormalities (including telangiectasia, neovascularization, and exudation), and vitreous seeding

- **Optic nerve phakomas**

- **Ocular adnexal lesions**: adenoma sebaceum, poliosis

**Differential diagnosis**

- Retinal astrocytoma
- Retinoblastoma
- Myelinated nerve fibers
- Coats disease

**Neurofibromatosis**

- **Type 1**
  - peripheral neurofibromatosis or von Recklinghausen syndrome
  - chromosome 17
  - peripheral and cutaneous manifestations
  - 1 in 3000
  - at least two of the following seven criteria should be present for diagnosis
    1. Café au lait
    2. Freckles in axilla or inguinal region
    3. Skin neurofibroma
    4. Optic nerve glioma
    5. Iris Lisch nodules
    6. Osseous lesion
7. Relative (1st degree) with NF1 by above criteria
   
   - type 2
     - central or bilateral acoustic neurofibromatosis
     - chromosome 22
     - CNS tumors and early onset of posterior subcapsular cataract
     - MISME syndrome, a mnemonic referring to related tumors of MIS (multiple inherited schwannomas), M-meningiomas, and E-ependymomas
     - at least one of the three
       1. Bilateral 8th cranial nerve tumors confirmed on magnetic resonance imaging or computed tomography
       2. Unilateral 8th cranial nerve tumor with relative with NF2
       3. Two of following → Meningioma, Glioma, Schwannoma, Juvenile posterior subcapsular lens opacity with relative with NF2

sturge-weber syndrome

- 1 per 50,000 persons

- Roach diagnostic scale
  1. Classic Sturge-Weber syndrome
  2. Sturge-Weber syndrome
  3. Sturge-Weber syndrome forme fruste

wyburn-mason syndrome

- Racemose hemangiomatosis
• midbrain and ipsilateral retina
• 30% of patients with the retinal findings have brain findings.
• 8% of patients with brain findings have retinal findings
• Archer classification
  1. Abnormal capillary plexus between the major vessels of the arteriovenous malformations
  2. Arteriovenous malformations lack any intervening capillary bed between the artery and vein
  3. Extensive arteriovenous malformations with dilated and tortuous vessels and no distinction between artery and vein

Choroidal Melanoma

Epidemiology
• incidence of 5-6 cases per 1 million population per year
• 60-70 years
• only 5% of all melanomas
• most common primary intraocular malignancy
• sunlight has been proposed as an environmental risk factor
• Heavily pigmented individuals rarely get skin or posterior uveal melanoma

Risk factors
  o Age: median age at diagnosis is 55 years
  o Sex: slight predominance of males
  o Race: relative risk for white males compared with African American males of 7.4
  o Genetics:
    ▪ Familial clusters are there but it’s not common
    ▪ Mutations in G-α proteins
o **Hormones and reproductive factors**
  ▪ increased risk for women in their childbearing years
  ▪ the seemingly adverse influence of pregnancy on prognosis
  ▪ hormonal effect from estrogens or melanocyte-stimulating hormone ??

o **Eye and skin color**
  ▪ blue or gray eyes were found to have three times the risk of disease
  ▪ relative risk of 3.8 comparing light to darker skin color

o **History of nonocular malignancy**
  ▪ elevated risk of ocular melanoma among women with a history of invasive ovarian cancer, suggesting a possible common hormonal etiology

o **Sunlight exposure**: possible role

o **Diet and smoking**: smoking and alcohol consumption were not associated with an increased risk for uveal melanoma

o **Geography**: inconclusive about latitude and altitude

o **Occupational and chemical exposures**: associations are weak

o **Mobile phone use**: not associated with risk

o **Other environmental exposures**:

---

**Prognosis**

- **Clinical prognostic indicators**:
  o Tumor size: 6-year survival rates dropped with increasing tumor diameter from 87% for tumors 10 mm or less, to 30% for tumors larger than 12 mm

- **Histopathologic prognostic indicators**
  o The presence of epithelioid cells, extravascular matrix patterns that reflect the arrangement of tumor microcirculation, high microvascular density and large numbers of tumor-infiltrating macrophages in primary uveal melanoma, are independently associated with shorter time to metastatic death
Histopathology

Callender described five histologic types: spindle cell subtypes A and B, epithelioid, fascicular, and mixed cell-type tumors composed of both spindle cells and epithelioid cells.

10-year mortality ranged from 11% to 19% in spindle A tumors; 21-36% in spindle B tumors; 63-79% in mixed-cell tumors, and 72-100% in epithelioid tumors.

Tumor microvasculature

Presence of networks of three or more contiguous closed vascular loops was highly predictive.

10-year survival was 50.7% when networks were present and 88.3% in the absence of networks.

Extrascleral extension

5-year survival rate was 26% in patients with orbital extension and 78% in those without extension.

Molecular prognostic indicators

- Loss of chromosome 3 is associated with a poor prognosis.
- Gains in chromosome 8 are associated with a worse prognosis.
- Abnormalities in chromosome 6 are associated with a good prognosis.

Molecular Genetics

- Cutaneous melanoma
  - Activating mutations in Ras and B-Raf → activation of MEK1/ERK (or the mitogen-activated protein kinase (MAPK) pathway), thereby promoting cell proliferation and survival.

- Uveal melanoma

- Genes in uveal melanoma
  - Half of uveal melanomas exhibit mutations in the gene encoding for Gαq (GNAQ).
  - Other half shows mutation in the gene encoding for the related protein, Gα11 (GNA11).
  - Gαq/11 family → stimulation of phospholipase C-β (PLCβ) → protein kinase C (PKC) → activates downstream intracellular signaling pathways, including the MAPK signaling pathway.

- Chromosomal abnormalities in uveal melanoma
gain of chromosome 6p

- loss of one copy of chromosome 3
- gain of copies of chromosome 8q

**Pathology**

- **Gross appearance**
  - oval or fusiform shape when confined by Bruch’s membrane.
  - collar-button/mushroom configuration when the tumor has broken through Bruch’s membrane.

- **Histopathologic features**
  - **Cytologic**
    - Callender classification: spindle cell subtype A; spindle cell subtype B; epithelioid type; fascicular type, and mixed cell type (consisting of mixtures of spindle and epithelioid cells)
    - modified Callender classification: Mclean
      - three different types
      - spindle cell melanoma (composed of spindle B cells); epithelioid cell melanoma, and melanoma of mixed-cell type
    - Further modification also done with newer proposed classification
      - **Spindle A cells**: fusiform, cohesive cells with poorly defined cell borders
      - **Spindle B cells**: plumper than spindle A cells, most common cell type in choroidal melanoma.
      - **Epithelioid cells**: non-cohesive cells with defined cell borders
      - **Intermediate cells**: small epithelioid cells, are a frequent cell type intermediate between spindle B cells and epithelioid cells
  - **Immunohistochemical**
    - Melan A stains melanocytes in general
    - HMB45 is predominantly expressed in “activated” melanocytes and is therefore more suggestive of malignant melanocytic lesions
    - S100 is expressed in different types of cells including melanocytes and very often used in combination with HMB45 as a marker for uveal melanoma
- Microphthalmia transcription factor (MITF) is essential for the development and survival of melanocytes
- Tyrosinase is an enzyme that is involved in the metabolism of melanocytes and was recently introduced as a melanoma marker
- Ki67 antigen - a proliferation marker expressed in the nucleus - is suitable to detect the proliferative activity in tumors and has prognostic relevance
- **Electron microscopy:** cell types can also be differentiated by transmission electron microscopy
- **Tumor stroma:** intratumoral vessels and vascular-like structures" - nine different morphologic patterns
- Melanoma-associated spongiform scleropathy (MASS)” is a degenerative, noninflammatory process in the sclera underlying the tumor that occurs in 38% of enucleated eyes harboring uveal melanoma
- **Tumor extension:**
  - **Degenerative changes:** Secondary drusen and orange pigment

- **Special types of uveal melanoma**
  - Diffuse uveal melanoma
  - Multifocal unilateral uveal melanoma
  - Bilateral uveal melanoma
  - Balloon cell melanoma
  - Necrotic melanoma
  - Retinoinvasive melanoma

- **Histologic differential diagnoses**
  - Nevus
  - Melanocytoma
  - Other choroidal neoplasms
  - Choroidal metastases
  - BDUMP (bilateral diffuse uveal melanocytic proliferation)
  - Choroidal neovascularization (CNV) with hemorrhage
Management

- methods of management today include observation, transpupillary thermotherapy (TTT), radiotherapy, local resection, enucleation, orbit exenteration, and various combinations of these methods

Systemic Evaluation

- Physical examination
  - history of weight loss, subcutaneous nodularity or abdominal pain

- Serology: liver function tests
  - gamma-glutamyl transpeptidase, lactate dehydrogenase, alkaline phosphatases, aminotransferases and bilirubin
  - should be used for metastases screening only as a complement to radiographic imaging

- Radiologic assessment: CT, MRI, USG
  - Contrast-enhanced magnetic resonance imaging (MRI) is considered to be the most sensitive

- Positron emission tomography/computed tomography
  - discrimination between inflammatory and neoplastic tumors
  - those at high risk for metastatic uveal melanoma (e.g., T3 and T4 tumors)

Periodic observation

- small melanocytic tumors are best managed by periodic fundus photography and ultrasonography

- risk factors for metastasis include greater tumor thickness, tumor proximity to the optic nerve, presence of visual symptoms from the melanoma, and prior documented growth
Photocoagulation
- xenon photocoagulation achieved better tumor control but argon laser was associated with fewer complications
- TTT has largely replaced argon laser

Transpupillary thermotherapy
- transpupillary thermotherapy” (TTT) was introduced by Journée-de Korver
- thermotherapy is different from hyperthermia, which by definition is heating the tumor to a temperature of 42-44°C to enhance the cytotoxic effect of ionizing radiation on tumor cells. In TTT, temperatures of approximately 45-60°C within the tumor are reached with irreversible cytotoxic effects so that additional radiotherapy may be not required
- delivers heat to the tumor in the infrared range using a modified diode laser delivery system
- Infrared or near-infrared light penetrates deeper into the choroidal tissue than light from argon blue-green lasers theoretically avoiding undesirable coagulation effects in the retina.
- In contrast to other wavelengths, the absorption of ocular media for infrared is very low (approximately 4-7%).
- A laser beam with a spot size of 3 mm and a maximal power density of 12 W/cm² is used. At the second half of the exposure time of at least 1 minute, a grayish discoloration of the tumor tissue should be visible, indicating a temperature of the target tissue of 60-65°C
- Indication
  - largest tumor diameter of <12 mm and not more than 4 mm thickness located posterior to the equator
- Leiden Group suggested “sandwich therapy” (brachytherapy of the tumor base and TTT of the tumor apex) for the treatment of choroidal melanoma

Radiotherapy
- two major radiotherapeutic techniques for the treatment of uveal melanomas: radioactive plaques sutured on the sclera over the area of the tumor, and external beam irradiation using charged particles such as protons, helium ions and the gamma knife.
- Brachytherapy
  - suturing a radiation source to the eye → Moore in 1930
- Iodine-125 is currently the most commonly used isotope
- Iodine-125 and Ruthenium-106 plaques have largely replaced Cobalt-60 at most institutions
- **indications for plaque brachytherapy include:**
  - selected small choroidal melanomas exhibiting growth or malignant transformation
  - medium-sized choroidal (thickness between 2.5 and 10 mm, as well as a maximal basal diameter <16 mm) and ciliary body melanomas in eyes with visual potential
  - large melanomas with dimensions up to 16 mm in diameter and 8-10 mm in thickness;
  - larger melanomas, especially in monocular patients
  - juxtapapillary tumors (touching or located within 1 mm from the optic nerve)

- **Dosimetry**
  - range between 50 and 100 Gy
  - COMS modified the prescription dose to deliver 85 Gy to the tumor apex with a delivery rate of 43-105 cGy/hour

- **Isotope selection**
  - most commonly used: iodine-125, palladium-103, and ruthenium-106
  - HVL, half-value layer: thickness of water required to reduce exposure (dose) from the nuclide to 50% (narrow beam).
  - TVL, tenth-value layer: thickness of lead required to reduce exposure (dose) from the nuclide to 10% (broad beam)
  - inverse-square law largely governs the radiation penetration in tissue

- **Plaque design**
  - gold plaque that is approximately 0.4 mm thick with a lip around its perimeter that resembles a smooth bottle cap
  - Within the gold plaque is a soft, pliable plastic (Silastic) seed carrier insert with evenly spaced troughs that accept the iodine-125 seeds

- **charged particle irradiation:**
  - charged particles such as protons, helium ions and the gamma knife.
  - **helium ion irradiation** is no longer in use due to its high cost
- **gamma knife** do not appear to be as attractive as those of proton irradiation
  - **Protons** are positive, singly charged particles that have minimal scatter and a well-defined, finite, and energy-dependent tissue range
    - positive, singly charged particles
    - well-defined, finite, and energy-dependent tissue range
    - inherent Bragg peak at the end of the beam path

- **Patient selection**
  - patients with larger tumors located at the peripheral fundus

- **technique**
  - tumor is localized by transillumination, indirect ophthalmoscopy
  - four tantalum rings, 2.5 mm in diameter, are sutured to the sclera at the margins of the tumor
  - patient positioning with a headholder attached to the proton beam collimator
  - standard dose administered for most tumors is 70 cobalt Gy equivalents (CGE) delivered in five equal fractions in 5 days

- **Results**
  - Disappearance of the lesion, or formation of a flat scar is observed in 15%

**Photodynamic therapy**
- cytotoxic effect of singlet oxygen radicals by photosensitizers when exposed to visible light

- The first generation of photosensitizers used was hematoporphyrin derivatives (HpD). HpD-based photodynamic therapy, however, had numerous disadvantages, among which was a high rate of recurrences (probably related to the poor tissue penetration of 630 nm laser light into tumor tissue), secondary glaucoma, and severe systemic side-effects (patients had to avoid sunlight for weeks to prevent deleterious phototoxic effects on the skin) which led to rejection of this therapeutic approach
  - Benzoporphyrin-derived photosensitizers like verteporfin → better tissue penetration and fewer systemic side effects with regard to skin toxicity and has been proven to be effective in the treatment of choroidal hemangioma
Local resection

• either by **en bloc resection**, through a scleral trapdoor (“exoresection”), or in a piecemeal fashion using a vitreous cutter passed transretinally (i.e., “endoresection”).

• Meyer-Schwickerath: penetrating sclero-uveo-retinectomy

• Foulds and Damato: partial lamellar sclerouvectomy

• **Exoresection**
  
  o **Indications**: large tumor size, anterior location, and the presence of exudative retinal detachment

  o **Contraindications**: (1) a tumor diameter >18 mm; (2) tumor extension to within a disc diameter of the optic disc margin; (3) extensive retinal invasion or any retinal perforation; (4) extraocular extension; (5) involvement of more than 2 clock-hours of ciliary body or angle; and (6) general health precluding hypotensive anesthesia

• **Endoresection**
  
  o **Indications**: 1) radiotherapy is unlikely to conserve useful vision, because the tumor has perforated retina or extends close to optic disc, and (2) the patient is highly motivated to retain vision and understands the controversial nature of this operation.

  o

Enucleation

• **Indications**
  
  o **primary enucleation** are large tumor size, neovascular glaucoma, optic nerve invasion, blind painful eye, localized extrascleral extension, and patient preference

  o **secondary enucleation** are local treatment failure and ocular pain secondary to radiation-related complications.

• **no touch enucleation**:
  
  o to minimize the amount of surgical trauma and theoretically to lessen the chance of tumor dissemination at the time of surgery

  o to freeze the venous drainage from the tumor prior to cutting the optic nerve
o **recently fallen into disuse**

- **Implant description**
  - two general categories: solid spheres and porous, integrated implants.
  - Solid spheres include silicone and polymethyl methacrylate (PMMA)
  - porous implants include coralline hydroxyapatite and porous polyethylene

- **Implant sizing**
  - Most adult patients require at least a 20 mm implant
  - contralateral eye axial length measurements subtracted by 2 mm or by 3 mm for hyperopia
  - Another algorithm subtracts the volume of an ideal 24 mm eye by the volume of sclera and 2 mL to determine implant volume

**Orbital exenteration**
- in cases of orbital extension

**Chemotherapy or immunotherapy**
- no current method of preventing metastasis in the early stages
- no current evidence that chemotherapy or immunotherapy are effective
Choroidal Tumors

Choroidal Nevi

- benign-appearing atypical uveal melanocytes called nevus cells
- **nevus**: benign acquired or congenital tumors of neural crest-derived cells, including atypical melanocytes
- **Halo nevus**: depigmented annulus that surrounds the central pigmented portion of the nevus
- **Giant choroidal nevus**: basal diameter greater than or equal to 10 mm
- Nevus cells are believed to be modified, or atypical, melanocytes
- melanization starts between the 24th and 27th weeks of gestation, proceeding anteriorly until birth
- **Melanocytoma**: nevus that are composed mostly of uniform, densely pigmented, and plump polyhedral cells (magnocellular nevi)
- **Ocular melanocytosis**: congenital hyperpigmentation of the uveal tract
- **nevus of Ota**: oculodermal melanocytosis, ocular along with trigeminal distribution
- Prevalence
  - Nevus: 1-6%
  - Halo nevus: 4.7%
  - Giant choroidal nevus: 1.5%
  - Melanocytoma: 0.05%
  - Ocular melanocytosis: 0.038%

- **systemic disease**
  - neurofibromatosis
  - Dysplastic nevus syndrome: 1) ill-defined or irregular borders; 2) irregular pigmentation; 3) accentuated skin markings, and 4) large size (>5 mm).[1] They tend to occur on sun-shielded skin (e.g., the scalp or bathing trunk area)
Bilateral diffuse uveal melanocytic proliferation (BDUMP):

**Histopathology**

- Immunohistochemical staining against S-100 antigen is the most sensitive
- Four main cell types
  - Plump polyhedral nevus cells
  - Slender spindle nevus cells
  - Intermediate nevus cells
  - Balloon cells
- Malignant transformation was described in 4.6% of the reported cases of nevus of Ota and, with rare exception, the melanoma occurred in the pigmented eye

**CF**

- Most nevi are incidental findings
- Visual field defects,
- Visual loss
- Flat or slightly elevated slate-gray tumors, with defined but not sharply demarcated margins
- Retinal pigment epithelial and Bruch's membrane changes
- Serous detachment
- Choroidal neovascular membrane

**DD**

- Freckles: flat foci of increased choroidal pigmentation with irregular borders
- Subretinal hemorrhages:
- CHRPE
- Small melanomas: A melanoma should be suspected if
  - the thickness of the tumor is >2 mm
  - there is orange pigment overlying the tumor
• a neurosensory detachment is present without evidence of choroidal neovascularization,
  • visual symptoms are present

• The presence of any two of the following features is considered evidence of a suspicious nevus
  1. largest diameter between two and five disc diameters
  2. thickness >2 mm
  3. significant effects on the overlying structures with most importantly, the presence of orange pigment on the tumor surface

• Shields: The mnemonic TFSOM UHHD for the phrase: “To Find Small Ocular Melanomas Using Helpful Hints Daily” correlates to
  o Thickness >2 mm
  o subretinal Fluid
  o visual Symptoms
  o Orange pigment
  o tumor Margin within 3 mm of the optic disc
  o Ultrasonographic Hollowness
  o absence of a surrounding Halo
  o absence of Drusen

• Factors predictive of metastases include posterior tumor margin touching the optic disc, documented growth, and greater tumor thickness.

• Mx
  o Nonsuspicious nevi: observation yearly
  o Suspicious nevi: fundus photographs and ultrasound every 6 months
  o Serous detachment and CNVM: anti VEGFs

Choroidal Metastases
• most common of adult intraocular tumors
• 10% of cancer patients have ocular metastases
• 20-40% are bilateral
• multifocal involvement of one eye occurs in approximately 20%

• CF
  o Asymptomatic
  o painless visual loss by involvement of the macular area or peripapillary retina or because of an associated, generally exudative, retinal detachment
  o painful visual loss as a result of neovascular glaucoma or metastatic iritis
  o blurred vision in 80%; pain in 14%; photopsias in 13%; red eye and floaters in 7%; field defects in 3%, and photophobia in 1%
  o **most common location:** posterior pole of the globe
  o present as yellow or white lesions (contrast to choroidal melanomas which are generally darkly pigmented)
  o often flatter than choroidal melanomas

• **primary cancer site**
  o women as follows: breast, 68%; lung, 12%; unknown, 12%; gastrointestinal, 2%; skin, 1%; renal, <1%; and other, 4%.
  o men, primary sites were: lung, 40%; unknown, 29%; gastrointestinal, 9%; prostate, 6%; renal, 6%; skin, 4%; breast, 1%; and other, 4%

• Ix
  o FFA
  o OCT
  o USG
  o FNAB

• **Differential diagnosis**
  o choroidal melanoma
  o choroidal osteoma
• choroidal hemangioma
• choroidal neovascularization with disciform scar
• posterior scleritis

• **Management**

  o **Conventional external beam radiation therapy**
    - D-shaped field designed to cover the posterior globe, bony roof, floor of orbit, and a portion of the optic nerve but shield the cornea and lens

  o **Brachytherapy plaques**

  o **Stereotactic radiosurgery**

  o **Protons**

---

**Choroidal Osteoma**

• choroid and the retinal pigment epithelium are the most common sites for bone formation within the eye

• Intraocular ossification most often occurs as a dystrophic process

• choroidal osteoma is an unusual form of benign intraocular ossification containing healthy bone

• **healthy** young females in the second or third decades of life

• **pathogenesis**
  
  o speculated pathogeneses: inflammatory, traumatic, hormonal, metabolic, environmental, or hereditary

  o The mass is composed of dense bony trabeculae with endothelial-lined large cavernous spaces and small capillary blood vessels

• **Clinical features**
  
  o Asymptomatic

  o mild to severe visual blurring, metamorphopsia, and visual field defects corresponding to the location of the tumor
unilateral in approximately 75%

- tends to be located in the juxtapapillary or peripapillary area, often with extension into the macula

- location anterior to the retinal vascular arcades is RARE (idiopathic sclerochoroidal calcification: benign multifocal, bilateral process that typically occurs anterior to the retinal vascular arcades)

- yellow-orange in color

- Serous subretinal fluid can occur overlying choroidal osteoma

- Choroidal neovascular membrane overlying osteoma has been found in 31% of cases by 5 years, 31-47% by 10 years, and 46-56% by 20 years

- **Ix**
  
  - FFA: mild patchy early hyperfluorescence of the tumor that evolves to a diffuse intense late staining, lacy early hyperfluorescence due to overlying choroidal vessels

  - ICGA: early hypofluorescence of the choroidal mass

  - USG: high-intensity echo spike, **pseudo-optic nerve appearance**

  - OCT

  - FAF

  - Roentgenography

  - Computed tomography: radiopaque plaque of bone density

  - Magnetic resonance imaging

  - Radioactive phosphorus uptake

  - Laboratory studies

- **Differential diagnosis**
  
  - amelanotic choroidal melanoma

  - amelanotic choroidal nevus

  - metastatic carcinoma to the choroid

  - circumscribed choroidal hemangioma

  - disciform macular degeneration

  - posterior scleritis
• Management
  o no known systemic metabolic or hormonal method for altering the growth of the choroidal osteoma
  o PDT
  o Laser

• Prognosis
  o prognosis is variable but the systemic prognosis is good.

Circumscribed Choroidal Hemangioma

• benign vascular hamartomas which occur in two forms: circumscribed and diffuse
  o circumscribed form is typically an isolated finding without systemic associations
  o diffuse form generally occurs in association with Sturge-Weber syndrome

• mean age at diagnosis 38 to 47 years

• Pathology
  o Hamartomas

• Clinical features
  o orange-red elevated masses
  o accumulation of lipofuscin pigment (orange pigment) over the lesion, though this is often difficult to distinguish except with fluorescein angiography
  o majority are posterior to equator
  o usually solitary and unilateral
  o Overlying subretinal fluid or serous retinal detachment
  o Cystoid macular edema
  o exudates, epiretinal membrane, and retinal hemorrhages
blurred vision in up to 81%, visual field deficits, metamorphopsia, and floaters

- **Differential diagnosis**
  - choroidal nevus, amelanotic choroidal melanoma, choroidal metastasis, choroidal osteoma, and central serous chorioretinopathy

- **Ix**
  - FFA: mild early lacy hyperfluorescence of the tumor in the pre-arterial and arterial phase, followed by moderate hyperfluorescence during the arteriovenous phase, and increasing hyperfluorescence through the late phase with variable amounts of late leakage
  - ICGA: characteristic pattern of rapid onset of fluorescence around 30 s which occurs much earlier than in other choroidal tumors, “wash out” phenomenon in late frames, the tumor demonstrates loss of dye resulting in a hypofluorescent appearance
  - USG: acoustically solid mass, dome-shaped
  - MRI: hyperintensity in contrast to vitreous on T1-weighted images, and hyperintensity or isointensity to vitreous on T2-weighted images
  - OCT: macular edema, epiretinal membranes, and subretinal fluid
  - enhanced depth imaging (EDI) technique:

- **Treatment**
  - Photodynamic therapy
  - Radiation
  - Transpupillary thermotherapy
  - Laser photocoagulation
  - Anti-VEGF injection

## Retinal Detachment

### Types

- separation of the neurosensory retina from the retinal pigment epithelium
- 3 major types
Rhegmatogenous retinal detachment

- one or more full-thickness retinal breaks.
- three factors needed
  1. existence of abnormal mobility of partially liquefied vitreous gel
  2. tractional forces that can precipitate a retinal break
  3. presence of a retinal break that will allow the passage of liquefied vitreous into the subretinal space
- convex, even bullous, surface,
- Subclinical retinal detachments are defined as having less than 1-2 disc diameters of associated subretinal fluid and usually do not progress, if asymptomatic
- Dialyses, in general and following trauma, are more common in the inferotemporal quadrant although most of the dialyses in the superonasal quadrant are associated with a definite history of preceding trauma

Traction retinal detachment

- tractional forces that mechanically pull the retina away from the underlying RPE
- diabetic retinopathy, PVR, penetrating trauma, branch retinal vein occlusion, and retinopathy of prematurity (ROP).
- traction is associated with a clinically apparent membrane. Such membranes typically have fibroblasts and glial and RPE cells as cellular constituents
- more concave surface and is likely to be more localized, often not extending to the ora serrata

Combined TR RD

- full-thickness retinal break and a significant tractional component
• often not bullous and have a concave appearance

• Combined tractional-rhegmatogenous retinal detachments are often seen in proliferative diabetic retinopathy, PVR, proliferative sickle-cell retinopathy, and penetrating intraocular injuries.

Exudative RD
• absence of a retinal break or vitreoretinal traction
• secondary to diseases of the choroid and RPE or of the retina itself

Nonrhegmatogenous Retinal Detachment

• three potential sources for fluid accumulation within or under the retina: vitreous fluid, retinal vessels, and choroidal vessels.
  o The main route for vitreous water turnover is by way of the retina, choroid and the vortex veins.
  o Choriocapillaries of the choroidal circulation, a single-layered capillary structure with numerous fenestrations on the vessel walls are freely permeable to the intravascular fluid.
  o The main mechanisms for keeping the retina in a dehydrated state are the presence of inner and outer blood-retinal barriers, and the fluid movement across the retinal pigment epithelium (RPE).

Central serous chorioretinopathy (CSCR)
• area of serous detachment of the posterior retina usually in young and middle-aged healthy persons
• mostly self-limiting
• atypical manifestations: acute bullous retinal detachment and chronic CSCR.
• Bullous retinal detachment
  o long-term corticosteroid taken for systemic diseases; regular taking of herb drugs or be under steroid treatment for presumed Harada disease
  o acute onset with simultaneous or sequential involvement of the two eyes
- multiple areas of serous RD in the posterior retina with lower bullous RD
- multiple RPED
- FA: shows multiple hyperfluorescent spots or patches with late enlargement; intense fluorescein leakage from the edge of the RPE detachment
- ICG
- OCT
- CX: large RPE tear; broad retinal folding; submacular plaques or fibrotic bands; peripheral paravascular exudates; peripheral retinal telangiectasia, occlusion, or even fibrovascular proliferation
- Mx
  - steroids should be discontinued
  - keep the head elevated during sleep
  - FA-guided laser to the leaking points
  - external drainage of SRF
  - pars plana vitrectomy with perfluorocarbon liquid injection
  - bevacizumab injection
  - Photodynamic therapy (PDT) with reduced fluence
- DD
  - Harada disease
  - PCV
- Chronic CSCR
  - Aka RPE decompensation, diffuse retinal pigment epitheliopathy
  - chronic steroid usage.
  - poorly defined areas of chronic persistent or recurrent retinal detachment in the posterior pole
  - FA: multiple areas of RPE disturbance with late staining or mild leakage
  - Mx
    - Conventional laser or the more recently developed MicroPulse laser
- PDT with reduced fluence
- Intravitreal bevacizumab

**Uveal effusion syndrome**
- middle-aged men with normal ocular size, presenting with unilateral or bilateral serous choroidal, ciliary, and retinal detachment

- **CF**
  - episcleral vessel dilatation; the anterior chamber is usually free of cells; intraocular pressure (IOP) is normal; there may be blood in the Schlemm's canal; vitreous cells
  - concentration of the subretinal fluid is 2.5-3 times that of the normal plasma
  - FA: in late stage, the leopard-spot pattern, which was not obvious in fundus examination; choroidal perfusion may be slow, and focal leaking areas in multiple places may be seen
  - UBM can clearly demonstrate ciliochoroidal detachment

- **Pathogenesis**
  - possibly related to congenital anomaly of the sclera and vortex veins hypoplasia
  - GAG accumulate within the sclera → decreased drainage of extravasated protein through scleral emissary channels

- **Mx**
  - Vortex vein decompression with scleral resection
  - Gass: partial-thickness sclerectomies or full-thickness sclerectomies.

- **Other Causes:** nanophthalmos, dural arteriovenous fistula, scleritis, Harada disease, diffuse tumors of the uveal tract, prolonged hypotony

**Coats disease**
- non-familial developmental retinal vasculopathy
- young children-adults, unilateral

- **CF**
  - All vessels, arteries and veins alike, would be affected, showing telangiectasis combined with a large amount of hard exudates;
  - Exudates
hemorrhagic retinopathy is occasionally seen

- other abnormalities such as progressive facial hemiatrophy, facial scapulohumeral muscular dystrophy and deafness, or Alport syndrome

- somatic mutation on the NDP gene on chromosome Xp11.2.

- Treatment
  - laser or cryo aiming at the lesions to decrease exudates and preserve vision
  - Scleral buckling
  - Sector panretinal photocoagulation (PRP)
  - intravitreal injection of bevacizumab

Accelerated hypertension and pregnancy-induced hypertension

Proliferative Vitreoretinopathy

Pathogenesis

- complex cellular reaction representing a vitreoretinal wound-healing response that results in a characteristic clinical appearance

- 5-10% of RRD, 10-45% of post trauma cases

- most common cause of ultimate failure of a surgery for RRD

- initially, assumed to be primarily due to changes in the vitreous gel (“massive vitreous retraction”, “massive preretinal retraction”).

- involvement of cells was recognized, and the condition was re-termed “massive periretinal proliferation”

- Retina Society Classification 1983: did not reflect prognosis and surgical difficulty

- Cologne classification

- Silicone Oil Study classification
• pathological **hallmarks** of the advanced PVR include **periretinal membrane formation**, causing development of surface wrinkling and single or multifocal star-folds

• **retinal break** is a prerequisite for the development of PVR.

• it takes 4-8 weeks for PVR development after surgery

• **Composition of membranes**
  
  o **Hallmark**: formation of periretinal fibrocellular membranes and intraretinal fibrosis
  
  o retinal glial cells, epithelial cells from the RPE and ciliary body, hyalocytes, blood-borne immune cells, fibrocytes, and finally myofibrocytes
  
  o **RPE cells**: epithelial-mesenchymal transition (EMT), proliferation, and directional migration of transformed RPE cells, resulting in the formation of traction-generating fibrocellular membranes in the vitreous and on both surfaces of the retina.
  
  o **Glial cells**: Müller cell gliosis
  
  o **Blood-borne cells**: Inflammation, macrophages and fibrocytes

• **Stimulation of cellular proliferation and migration**
  
  o **Blood components**: Serum, Thrombin, Fibronectin,
  
  o **Platelet-derived growth factor (PDGF)**: PDGF-C
  
  o **Transforming growth factor-B**: tissue contraction
  
  o **Monocyte chemotactic protein-1 (MCP1)**: migration of RPE cells
  
  o **Basic fibroblast growth factor (bFGF)**: Fibroproliferative membranes
  
  o **Hepatocyte growth factor (HGF)**: scattering of retinal cells, chemotaxis and EMT
  
  o **Connective tissue growth factor (CTGF)**
  
  o **Epidermal growth factor (EGF)**
  
  o **Vascular endothelial growth factor (VEGF)**: cellular proliferation and vascular permeability
  
  o **Cytokines**: IL-6, IL-1β, TNF-α and interferon gamma

• **Biomarkers**
- MMP-2 and -9
- α1-antitrypsin, apolipoprotein A-IV, serum albumin, and transferrin

**vicious cycle of proliferative retinopathy**: The breakdown of the retinal integrity is accompanied by breakdown of the blood-retinal barrier (BRB) and inflammatory tissue reaction. These processes result in an influx of blood-derived cells and soluble factors including growth and inflammatory factors, serum, fibrin, and metalloproteinases into the vitreous and retina. The factors stimulate the scattering, migration and proliferation of the cells of retinal and extraretinal origins followed by periretinal membrane formation. Myofibroblastic transdifferentiation of cells within the fibroproliferative membranes during epithelial-mesenchymal transition and extracellular matrix remodelling cause membrane contraction resulting in fixed (re)detachment of the retina.

**Risk factors**
- previous retinal detachment repair
- Previous trauma, prolonged inflammation of the posterior segment, viral infections
- retinal detachments with more than two quadrants involved
- coexisting choroidal detachment.
- large retinal breaks or giant tears, vitreous hemorrhage associated with retinal tears, multiple previous eye surgery, previous trauma to the posterior segment and pre-existing signs of localized PVR such as fixed folds
- detachments associated with a variety of systemic conditions such as Wagner disease, Stickler syndrome, Marfan syndrome, and familial exudative vitreoretinopathy
- **The greatest risk period is 4-12 weeks after detachment surgery**

**CF**
- cellular dispersion in the vitreous and on the retinal surface
- localized fibrocellular membranes
- fixed folds
- funnel-shaped detachment
Classification

Retina Society PVR Classification (1983)

A. Vitreous haze, vitreous pigment clumps
B. Wrinkling of the inner retinal surface, rolled edge of retinal break, retinal stiffness, vessel tortuosity
C. Full-thickness retinal folds in
   C-1 One quadrant
   C-2 Two quadrants
   C-3 Three quadrants
D. Fixed retinal folds in four quadrants
   D-1 Wide funnel shape
   D-2 Narrow funnel shape (anterior end of funnel visible by indirect ophthalmoscopy with 20 diopter lens)
   D-3 Closed funnel (optic nerve not visible)

Updated PVR Grade Classification (1991)

A. Vitreous haze, vitreous pigment clumps, pigment clusters on inferior retina
B. Wrinkling of the inner retinal surface, retinal stiffness, vessel tortuosity, rolled and irregular edge of retinal break, decreased mobility of vitreous
C.
   CP 1-12 Posterior to equator, focal, diffuse or circumferential full-thickness folds, *subretinal strands
   CA 1-12 Anterior to equator, focal, diffuse, or circumferential full-thickness folds, *subretinal strands, *anterior displacement, *condensed vitreous strands
Updated PVR Contraction Type Classification (1991)

**Focal** → Posterior → **Star fold posterior** to vitreous base

**Diffuse** → Posterior → Confluent star folds posterior to vitreous base; optic disc may not be visible

**Subretinal** → Posterior/anterior → Proliferation under the retina; annular strand near disc; linear strands; motheaten-appearing sheets

**Circumferential** → Anterior → Contraction along posterior edge of vitreous base with central displacement of the retina; peripheral retina stretched; posterior retina in radial folds

**Anterior** → Anterior → Vitreous base pulled anteriorly by proliferative tissue; peripheral retinal trough; displacement ciliary processes may be stretched, may be covered by membrane; iris may be retracted

**Demerits of Retina Society Classification**

- it ignores antero-posterior epiretinal proliferation and hence the importance of anterior traction in PVR
- says nothing about the degree of cellular proliferative activity at the time of the grading

**Prevention**

- Laser probably causes less breakdown of the blood-retinal barrier than cryopexy
- signs of early PVR may indicate the need for combined vitrectomy and scleral buckling rather than one or the other

**Management**

- **Scleral buckling and PVR**
  - fundamental requirement for most eyes with established PVR
it is virtually impossible to remove the whole vitreous base.

- **Vitrectomy and PVR**
  - vitrectomy to remove all vitreous gel, cellular and inflammatory material, blood, and fibroblastic membranes.
  - relieve all traction by division and peeling or delamination of fixed membranes and to remove as much as possible of the vitreous base

- **Surgical steps for established PVR**
  - Anesthesia
  - Operative technique
  - Management of the lens in PVR
  - Core vitrectomy and removal of the vitreous base
  - Removal of epiretinal membranes and use of perfluorocarbon heavy fluid
  - Removal of anterior tractional membranes
  - Testing adequacy of relief of traction and relaxing retinotomy: tested by a complete fluid-air exchange
  - Removal of subretinal membranes
  - FAX
  - Creating chorioretinal adhesion and scleral indentation
  - Intraocular tamponade
    - SO: Standard or Heavy
    - GAS

- **Postoperative management**

- **Complications**
  - deliberate relaxing retinotomy for relief of traction was required in 29% of eyes treated in the silicone study
  - **Intraoperative**
    - bleeding may occur during dissection of dense membranes
    - corneal edema, pupillary constriction, or lens clouding
- Failure to flatten the retina with internal drainage and fluid-air exchange
- Choroidal hemorrhagic detachment
- Serous choroidal detachment

- **Early postoperative**
  - Elevated intraocular pressure is the most common, occurring in 10-15% of eyes.
  - overfill of intraocular gas
  - overfill of oil
  - persistent corneal epithelial defect
  - Endophthalmitis

- **Late postoperative**
  - regrowth of surface retinal membranes leading to retinal detachment and tractional retinal tears: 25-50%
  - commonest situation is inferior recurrence of retinal detachment with or without a new or reopened retinal break
  - *perisilicone proliferation*: small meniscus of vitreous fluid remains inferiorly when the patient is upright, protein, inflammatory and metaplastic cells and lack of tamponade in this area can lead to further proliferation
  - Macular pucker and discrete tractional membranes: 5-15%
  - prolonged intraocular SO.
    - Emulsification
    - late secondary glaucoma
    - Keratopathy: 27%
  - Cataract
  - late cystoid macular edema with or without preretinal membranes
  - cx associated with a scleral buckle
    - squint and double vision
    - low-grade infection
- **Medical adjunctive therapy**
  - Systemic prednisolone
  - subTenon’s injection of long-acting Celestone or triamcinolone
  - Antiproliferative agents including 5-fluorouracil and daunomycin

- **Results**
  - A scleral buckle without vitrectomy successfully reattached up to 50% of milder cases
  - In current practice, up to 90% of all cases of PVR can be anatomically reattached
  - Functional success defined as improved visual acuity is more problematic, as any macula detached for more than a few days is unlikely to recover more than 10-20% of central vision

- **Macular pucker** has some cellular features in common but is usually not classified as PVR. It is not associated with retinal breaks and usually not complicated by retinal detachment. Macular pucker has a much better overall prognosis compared with PVR, even though it can compromise central vision.

- The formation of abnormal membranes on the outer retinal surface is clinically known as subretinal fibrosis. Subretinal fibrosis can disrupt the normal intercellular relationship between the photoreceptors and RPE, thus preventing the regeneration of photoreceptor outer segments after reattachment.

---

**Ocular Trauma**

- **1996, Ocular Trauma Classification Group**
  - **International Society of Ocular Trauma Standardized classification**
  - **Eyewall**: Sclera and cornea
  - **Closed globe**: The eyewall does not have a full-thickness wound
    - Contusion (no full-thickness wound)
    - Lamellar laceration (partial-thickness wound of the eye wall)
- **Open globe**: The eyewall does have a full-thickness wound
  - **Rupture**: Full-thickness eyewall wound caused by a blunt object; the impact results in momentary increase of the IOP and an inside-out injury mechanism
  - **Laceration**: Full-thickness wound of the eyewall, usually caused by a sharp object; the wound occurs at the impact site by an outside-in mechanism
  - **Penetrating (single entry wound; no exit wound)**: Single laceration of the eyewall, usually caused by a sharp object
  - **Perforating (separate entry and exit wounds by same agent)**: Two full-thickness lacerations (entrance + exit) of the eyewall, usually caused by a sharp object or missile
  - **Intraocular foreign body (retained foreign object that caused entry wound)**: Retained foreign object(s) causing body injury and entrance laceration(s)

**Closed Globe Injuries**

**Hyphema**

- anterior chamber hemorrhage
- complications include:
  - corneal blood staining
  - ghost cell glaucoma as a result of blocked outflow from clogging of the trabecular meshwork by erythrocytes
  - central retinal artery occlusion from elevated intraocular pressure
- **Ix**
  - not indicated in most patients
  - blood coagulation tests (partial thromboplastin time, prothrombin time, bleeding time, platelet counts, and liver function tests)
  - sickle cell tests
- management
  - prevention of rebleeding
  - Rebleeding has been reported to complicate up to 35% of cases
o Corticosteroids, both topical (prednisolone acetate 1% q.i.d.) and systemic (prednisone 0.5-1.0 mg/kg per day), reduce iritis and ciliary spasm, increase patient comfort, and theoretically stabilize the clot formation, thereby decreasing the rate of rebleed.

o cycloplegics, miotics, aspirin, conjugated estrogens, unilateral or bilateral patching, elevation of the head, and bed rest.

o oral epsilon-aminocaproic acid, both systemic (Amicar, Lederle Laboratories, Pearl River NY, given 50 mg/kg every 4 hours for 5 days) and topical (Caprogel, ISTA Pharmaceuticals Irvine, CA, given every 6 hours for 5 days)

o tranexamic acid (Cyklokapron, Pfizer, New York, NY) in reducing the incidence of secondary bleeding

• empiric criteria for surgical evaluation

  o intractably elevated intraocular pressure (IOP) despite medical therapy (>60 mmHg for 2 days in sickle-negative patients; or >24 mmHg for more than 1 day in sickle patients)

  o total hyphema for more than 5 days with IOP >25 mmHg

  o corneal bloodstaining

  o persistence of hyphema occupying at least one-half of the anterior chamber volume.

• surgical techniques

  o paracentesis

  o anterior chamber washout with a one-needle irrigation or irrigation-aspiration technique

  o washout with a two-needle technique, clot evacuation with a forceps or cryoprobe through a large limbal incision

  o clot evacuation associated with a trabeculectomy filtering operation

**Lens subluxation and dislocation**

• dislocation or subluxation is not a problem in itself. Patients can have 20/20 vision with a totally dislocated lens and aphakic correction

• Urgent intervention is indicated for cases of pupillary block glaucoma, intractable uveitis, or lens-corneal touch leading to corneal decompensation

• Cataract requires extraction by proper technique as per standard guidelines

• Iridodialysis can be repaired by McCannel suture technique
Vitreous hemorrhage

- from damage to blood vessels in the ciliary body, retina, or choroid
- managed accordingly

Commoitio retinae

- seen after a contusive injury to the globe and appears ophthalmoscopically as retinal whitening.
- Edema involving the macula (termed Berlin’s edema) can impart an appearance similar to a cherry-red spot.
- vision most often improves as the swelling resolves over a 3-4-week period

chorioretinitis sclopetaria

Retinal detachment and macular hole

Open-globe injuries

Preoperative evaluation

- visual acuity
- 5/200 or better had a 28 times greater chance of salvaging acuity at this level
- APD is a strong predictor
- the “flat tire” sign: flattening of the posterior contour of the sclera, occult rupture, seen on CT
- CT
- MRI

Repair of laceration
Management of IOFB

- Traumatic endophthalmitis, particularly associated with the *Bacillus cereus*, is more commonly seen with IOFBs.
- Traditionally, IOFB removal within 24 hours of injury.
- Three instruments are commonly available for IOFB extraction: external magnets, intraocular forceps, and intraocular magnets.

Perforating injury

- 4.4% of lacerated globes.

Sympathetic ophthalmia

- 0.3% and 1.9%.
- High doses of prednisone (up to 200 mg/day) over the first 7-10 days may be particularly critical to the patient's prognosis.

Scleral Buckles
Effects

Geometry of the eye
- **Axial length**
  - increases or decreases in axial length, depending on the scleral buckle material, the location of the buckle, and the height of the buckle
  - spherical eye acquires the shape of a prolate spheroid
  - dumbbell shape at very high circumferential buckle heights
  - two effects where 1 >>> 2
    1. circumferential shortening, increases the axial length
    2. invagination of the sclera around a broad encircling element with mattress sutures, contributes to a decrease in the axial length

- **Refractive errors**
  1. Astigmatic errors: high, anterior radial buckle
  2. Spherical equivalent errors: caused by changes in axial length and lens position
  3. High order aberrations

- **Volume changes**
  - predicted as a function of the following variables: (1) the axial length of the eye; (2) the buckle width measured anterior and/or posterior to the equator; (3) the buckle circumference; and (4) the buckle height.
    - #240: 0.5 ml
    - #276: 1.08-1.13 ml

- **Scleral buckles and ocular rigidity**
  - measure of the elasticity of the eye
  - change in intraocular pressure for a given change in intraocular volume
• **Scleral buckles and ocular blood flow**

• **Internal geometry of indentation:**
  1. shape of the buckle
  2. composition of the buckle (silicone sponge versus hard silicone)
  3. suture placement with respect to the dimensions of the buckle
  4. suture tension
  5. distribution of tension from the suture to the buckle
  6. intraocular pressure

• **Factors decreasing indentation:**
  1. placement of the suture bites too close or too far apart
  2. high intraocular pressure
  3. short suture bites in the sclera
  4. loose sutures
  5. use of a half-thickness sponge compared with a full-thickness sponge.

• **Factors that increased scleral indentation:**
  1. low intraocular pressure
  2. tight sutures

• **Fishmouth phenomenon:** circumferential shortening of the eye beneath an encircling buckle, wedge-shaped buckles and radial scleral buckles minimize the risk.

• **Reattachment forces influenced by scleral buckles**
  1. reduction of vitreoretinal traction by displacing the eye wall and retina centrally;
  2. displacement of subretinal fluid away from the location of the retinal break and scleral buckle;
  3. postoperative increase in the height of the scleral buckle;
4. approximation of the retinal break and adjacent vitreous gel;

5. increase in resistance to fluid flow through the retinal break, with consequent increase in the relative reattachment forces;

6. alteration in the concave shape of the eyeball, resulting in a change in the effect of intraocular currents that encourage liquid vitreous to enter the sub-retinal space.

RPE and Retina

- **Forces that lead to retinal tears and detachments**
  - **Vitreous traction:** perpendicular, tangential, or oblique, radial traction on the retina is more likely to produce retinal breaks than is tangential traction.
  - **Fluid movement and retinal breaks:** The inertia of the vitreous fluid may dissect under the flap of a horseshoe-shaped tear, resulting in retinal detachment.
  - **Epiretinal membranes, cellular proliferation, and retinal breaks:** Tangential tension in an epiretinal membrane with its associated radial retinal traction may exceed the adhesive force of the retina to the retinal pigment epithelium RPE.

- **Forces that promote attachment of the retina**
  - **Physiologic adhesion between retina and RPE**
  - **Thermal chorioretinal adhesions**
    - **Diathermy:** strength reached up to 2 weeks
    - **Cryopexy:** minimal change to the sclera compared with diathermy, maximum strength until about 2 weeks
    - **Laser:** pigmented RPE and choroid, leading to a chorioretinal scar, starts within 24 hours of treatment and increases rapidly within 3 days
  - **Scleral buckles and vitreous traction**
    - decrease vitreous traction on the retinal tear in RRD
    - decrease vitreous traction in TRD
    - **Hook’s law:** The force exerted by a stretched spring is greater than a spring with minimal stretch
  - **Scleral buckles and traction on the retinal surface**
two vectors. The first is **tangential to the retina** and is caused by tension in the contractile epiretinal membrane. The second is directed **radially inward**, toward the center of the eye, and is a result of tangential traction on a curved surface.

- reverses the direction of the radial inward force on the retina (F1) to an outward force (F2), thereby promoting retinal reattachment of an epiretinal membrane
  - **Scleral buckles and fluid movement**
    - distance between the RPE and a retinal tear is reduced
    - displace vitreous fluid away from the tear
    - diminish the flux of vitreous fluid through retinal tears

**Techniques**

- **buckle** = deformation of a structure under stress
- **Explants or Implants**
- implants are now of purely historical interest.
- **Preoperative assessment**
  - Macular involvement
  - *Finding the retinal break*: Lincoff’s rules
  - PVD
- **Anesthesia**
- **Positioning the head for surgery**
- **Preparation and draping**
- **Surgical steps**
  - **Conjunctival peritomy**: limbal or 2 mm limbal frill
  - **Slinging rectus muscles**
  - **Examination under anesthesia and break localization**
Parallax errors may be avoided by draining subretinal fluid and then reforming the globe with air: DACE (drain air cryotherapy explant) procedure

**Retinopexy**
- Cryotherapy
  - Cryotherapy to the disc or macula occurs when the indentation from the shaft of the probe is mistaken for its tip → shaft indentation
- Diode laser

**Scleral explant**
- solid silicone tires: non-compressible
- silicone sponges: easily deformable and compressible
  - Watzke sleeves: cross acting “Watzke” forceps

**Scleral sutures**
- durability, biocompatibility and ease of handling
- Monofilament nylon and polyester
- ½ to 2/3 of sclera
- sclera is pseudolamellar: spatulated needle tends to glide

**Subretinal fluid drainage**
- no consensus on the role of subretinal fluid drainage
- **Timing:** DACE: Drain air cryotherapy explant
- **Location of drain sites:** adjacent to horizontal recti, in the bed of the buckle
- **Drainage techniques:**
  - Cut down techniques
  - Single-stage techniques: Charles, Hypodermic needle, suture needle
- Air injection

**Encirclement**
- Early PVR
- Very extensive scleromalacia
- Extensive detachment in which breaks are difficult to detect (for example in some pseudophakic eyes with small anterior breaks and capsular phimosis).
- Multiple breaks in three or more quadrants

- **Final examination of the retina**
  - **Spontaneous pulsation** of the retinal arteries indicates an intraocular pressure *between the systolic and diastolic closing pressure*. Intraocular pressure greater than the systolic closing pressure of the retinal arteries causes a pale disc with thready vessels. Reducing the intraocular pressure, typically by paracentesis, is necessary to prevent permanent visual loss.

- **Closure**
  - **“ship to shore” principle**: sutures are passed from more mobile flaps of conjunctiva towards the incised edge

- **Outcomes**
  - success rate of 84% was achieved following a single operation
  - Functional success with recovery of central vision is somewhat lower than anatomical success

**Complications**
- **Recurrent retinal detachment:**
  - Inadequate buckle
  - Missed retinal break
  - Misplaced buckle
  - Fishmouthing
  - Proliferative vitreoretinopathy

- **Glaucoma**
  - Steroid response
- buckle-related angle closure glaucoma occur without pupil block

- **Epiretinal membranes**
  - commonest cause of visual loss after successful scleral buckling

- **Extrusion/infection**
- **Band migration**
- **Diplopia**
- **Anterior segment ischemia**

### Vitreoretinal Surgery

#### History

- introduction of pars plana vitrectomy in the early 1970s by Machemer → 17-gauge (1.5mm diameter)
- 1974, O’Malley → 0.9mm (20-gauge).
- 1990, de Juan → 25-gauge (0.5mm diameter)
- Fuji et al → 23-gauge microcannular system and an array of 25-gauge instruments referred to as transconjunctival sutureless vitrectomy system (TSV)

#### 23G

**Advantages over 20-gauge vitrectomy**

1. Minimal trauma of the conjunctiva and sclera. No postoperative scleral thinning in the area of the sclerotomy. High postoperative stability of the sclerotomies

2. Less postoperative astigmatism.

3. Less postoperative discomfort.
Advantages over 25-gauge vitrectomy

1. Instruments are less flexible and more effective.

2. Shorter operative time.


4. Better handling of an acute intraoperative hemorrhage due to the more effective use of the fute needle by its larger inner diameter.

5. Longer durability of the instruments.


Mechanics

- Cutting: separation of a tissue into two parts.

- Peeling: Force along the axis of a collagen fiber bundle causes non-elastic collagen fibers to slightly stretch and ultimately to fail or separate. Membrane peeling is inappropriate in diabetic traction retinal detachment cases.

- Shear: when force is applied along two opposing parallel edges moving past each other.

- Fatigue failure: when repetitive motion, elongation, and compression weaken tissue structure and cause failure. Ultrasonic cavitation (fragmentation, phacoemulsification) is an example of this mode of cutting.

- Infusion system management

- Vitreous cutter considerations

  - Ideal tissue cutting: that producing zero displacement of the tissue to be removed and no vitreoretinal traction

  - High cutting rates ($\geq$5000 cuts/minute) increase port-based flow limiting and thereby decrease pulsatile fluid flow and pulsatile vitreoretinal traction

- Minimizing forces required to hold tools increase the surgeon’s proprioceptive sense (Weber-Fechner law) and decrease fatigue and tremor.
• **Surgical steps**
  
  o 20G vitrectomy is no longer gold standard (only used to remove intraocular foreign bodies and for a fragmenter to remove dense lens material)
  
  o no solid evidence that combining a scleral buckle with vitrectomy improves retinal detachment outcomes
  
  o **Sclerotomies**
  
  o **Vitreous removal**
  
  o **Lens management**
  
  o **Epiretinal membrane management:** peeling, segmentation, or delamination
    
    - Peeling: 25G or 23G, end-grasping ILM forceps
    - Delamination and segmentation: 25G or 23G curved scissors
  
  o **subretinal proliferation**
    
    - placoid, band-like, or annular in configuration
    - If the retina cannot be reattached with an undistorted macula due to subretinal proliferation, subretinal surgery is indicated
  
  o **Extrusion techniques**
    
    - foot pedal controlled machine-driven aspiration
    - Soft-tip 23/25G cannulas with low suction levels
    - for removing free blood products, PFO (perfluoro-n-octane), oil droplets, or small pieces of lens material from the retinal surface
    - preferable to using the flute cannula
  
  o **Interfacial surface tension management**
    
    - Air (gas) interface with aqueous (72 dyne/cm²)
    - silicone-aqueous interface (40 dyne/cm²)
    - Force due to interfacial surface tension is far more significant than buoyancy effects provided by air, gas, or silicone
    - purpose → to eliminate trans-hole fluid flow, restoring a transretinal pressure gradient
    - this effect is known as **rhegmatogenous confinement:**
• addresses missed breaks
• breaks from subsequent surface proliferation
• the opportunity for retinopexy avoidance in inflamed eyes (can be performed weeks or months later when retinal edema, subretinal fluid, and inflammation have subsided)

- Silicone and gases may increase reproliferation by sequestering cells and factors at the retinal surface, and decrease access of therapeutic agents to the retina
- no scientific evidence that 5000 cSt oil has lower emulsification rates than 1000 cSt
- best silicone oils are those with the highest electrical resistance, lowest vapor pressure, and 1000 cSt (centi-Stokes) viscosity.

- Fluid-air exchange
  - An air pump infuses air through the infusion cannula and maintains intraocular pressure while intraocular and subretinal fluid is removed with a proportionally controlled soft-tip cannula

- Air-gas exchange
  - isoexpansive concentration (25% SF₆ or 18% C₃F₈)

- Liquid perfluorocarbon
  - repositioning giant retinal breaks and can be used for removal of subretinal fluid as well as stabilization of the retina to offset membrane peeling forces

  - Fogging
    - room temperature infusion fluid cools the IOL and the infused air is saturated with water vapor
    - capsule defect as well as discontinuity in anterior vitreous cortex is necessary for fogging to occur
    - Silicone IOL >> PMMA IOL >> Acrylic IOL

- Air-silicone exchange
  - fluid-air exchange with internal drainage of SRF to reattach the retina should precede silicone infusion

- Perfluorocarbon-silicone oil exchange
• preferred over an intermediate step of fluid-air exchange followed by air-perfluorocarbon exchange in giant retinal break cases
• reduced chance of posterior slippage of the giant break.

  o Retinectomy
    ▪ performed in conjunction with fluid-air exchange and internal drainage of SRF

  o Hemostasis
    ▪ Transient (approximately 5 minute) elevation of intraocular pressure
    ▪ Endophotocoagulation
    ▪ bipolar endodiathermy
    ▪ Diathermy causes a larger area of retinal necrosis than laser

  o Retinopexy
    ▪ should be used as little as possible
    ▪ Continuous (painting) laser endophotocoagulation is preferable to rows of spots (results in more uniform tissue destruction and greater tensile strength)
    ▪ PRP should only be used for neovascular retinopathies, never for PVR.
    ▪ Avoid Cryopexy as far as possible.

  o Panretinal photocoagulation
    ▪ reduces VEGF production
    ▪ causes the RPE to release an antiangiogenesis cytokine
    ▪ increases choroidal oxygen transport to the retina

Complications

• Trochar Insertion: ALWAYS MEASURE
• Suprachoroidal Infusion
• Subretinal Insertion of Endo-illuminator
- Dislocated IOL and Capsular Tension Ring
- Iatrogenic Breaks during the Induction of Posterior Vitreous Detachment
- Iatrogenic Macular Hole during VMT Surgery
- Iatrogenic Breaks during the Delamination of Diabetic Traction Retinal Detachment
- Point Pressure Hemostasis during Diabetic Vitrectomy
- Iatrogenic Retinal Break during ERM Peeling
- Subretinal Brilliant Blue
- Peripheral Retinal Detachment during Macular Hole Surgery
- Subretinal Hemorrhage
- Macular Fold
- Subretinal Perfluorocarbon
- Subretinal Perfluorocarbon Injection during En Bloc Perfluorodissection
- Intraocular Foreign Body Dislodged on the Macula
- Suprachoroidal Hemorrhage
- Hemorrhagic Choroidal Detachment after “One Stitch” Vitrectomy Surgery
- Dislocated Phakic IOL
- Dislocation of the Tip of the Soft Tip Cannula
- Iatrogenic Peripheral Retinal Breaks during IOFB Extraction
- Peri-silicone Proliferation
Primary Vitrectomy

- term “primary vitrectomy” was introduced by Klöti
- Traditionally, scleral buckling (SB) was viewed as the gold standard treatment for uncomplicated RRD.

Advantages

- view of the retinal periphery is enhanced
- identification of retinal breaks is rendered easier
- achievement of complete intraoperative retinal attachment is possible
- the risks of hemorrhage or retinal incarceration inherent to the external drainage procedure applied during SB is eliminated
- technique is less likely to cause a refractive change
- MIVS is less invasive, affords fast recovery, and is sutureless

Patient selection

- wide and bullous RD
- older patients with a liquefied vitreous
- RD with marked traction with different anterior posterior depth of breaks
- presence of breaks in multiple quadrants
- absence of an apparent retinal break in a pseudophakic patient
- preoperative PVR grade C
- giant tear-induced RD
- macular hole RD

Surgical outcomes

- SOSR (single operation success rate): primary success rates for RRD repair by PPV range from 64-94%
o 40% of patients will not achieve reading ability, 10-40% will need more than one surgical procedure, and approximately 5% will suffer permanent anatomical and functional failure

• Prognostic factors
  o risk factors for surgical failure after PPV in the repair of RRD include
    ▪ duration of symptoms
    ▪ older age
    ▪ extent of RD
    ▪ macular detachment
    ▪ involvement of inferior quadrants
    ▪ absence of detectable retinal breaks
    ▪ high myopia
    ▪ hypotony
    ▪ PVR-related risk factors such as pseudophakia/aphakia, uveitis, vitreous hemorrhage, and preoperative PVR.
    ▪ previous lens extraction is a risk factor for development of PVR

• Complications
  o high rates of iatrogenic retinal breakage (0.78-24%)
  o crystalline lens damage (0.03-9%)
  o transient or persistent intraocular pressure increases have been reported in 15-24%
  o nuclear cataracts
  o retinal redetachment, with or without PVR, usually by new or missed breaks, or reopening of former breaks.
  o Several less serious complications include retinal incarceration at retinotomy sites (0.6-2.9%), corneal abrasion (0.6%), scleral rupture (0.2%), and choroidal effusion (0.5%),
  o MIVS: postoperative hypotony and endophthalmitis

Pneumatic Retinopexy
Ohm performed the first intravitreal air injection for retinal detachment in 1911.

In 1938, Rosengren reported the use of intravitreal air with drainage of subretinal fluid.

1973, Norton reported intravitreal sulfur hexafluoride (SF6) injection used with SB or vitrectomy for various surgical problems, such as giant breaks, large posterior breaks, and fishmouthing.

Blodi and Folk treated detachments due to a macular hole using intravitreal gas.

retinal detachments treated with “repeated insufflations of expansive gas” were described by Dominguez et al.

Hilton and Grizzard introduced the term “pneumatic retinopexy” at the 1985 AAO.

Lincoff’s technique/ ballon: 1979

SOSR 80%, increasing to 98% after reoperations

Basic principles

Intraocular gases

- Sulfur hexafluoride (SF₆) and perfluoropropane (C₃F₈)
- three features:
  1. buoyancy: applies upward pressure on the detached retina
  2. surface tension: closes the retinal break and prevents the bubble from passing into the subretinal space
  3. isolation of retinal tears from intraocular currents

Diffusion and Expansion

- Because of their low solubility in water, SF₆ and C₃F₈ tend to diffuse from the eye very slowly
- the nitrogen and oxygen that are in solution in the surrounding tissues of the eye are much more soluble and pass relatively quickly into the gas bubble, following the law of partial pressures
- 0.22 µm Millipore filter is sufficient to render gas sterile

<table>
<thead>
<tr>
<th>Gas</th>
<th>Typical dose</th>
<th>Average duration</th>
<th>Largest size</th>
<th>Average expansion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air</td>
<td>0.8 mL</td>
<td>4 days</td>
<td>Immediate</td>
<td>No expansion</td>
</tr>
</tbody>
</table>
Gas   Typical dose  Average duration  Largest size  Average expansion
---  --------  ---------------  -----------  -----------------
SF₆   0.5 mL    12 days       36 hours    Doubles
C₃F₈  0.3 mL    38 days      3 days      Quadruples

- **Retina-gas interface**
  - 0.3 mL gas bubble: 45° of arc of the retina
  - but it takes approximately a 1.2 mL bubble to cover 80-90°

- **Case selection**
  - **Indications**
    - 
  - **Exclusion**
    - Breaks larger than 1 clock-hour or multiple breaks extending over more than 1 clock-hour of the retina.
    - Breaks in the inferior 4 clock-hours of the retina.
    - Presence of PVR grade C or D.
    - Physical disability or mental incompetence precluding maintenance of the required positioning.
    - Severe or uncontrolled glaucoma.
    - Cloudy media precluding full assessment of the retina.

- PR is especially advantageous in the management of the following six situations:
  - Macular breaks and other posterior retinal breaks.
  - Redetachment or persistent detachment after scleral buckling
  - Isolated tears under the superior rectus
- Filtering blebs
- Impending macular detachment
- Bullous detachment

**Surgical technique**

- one session, with cryopexy applied to the retinal breaks just before gas injection
- two-session procedure, with initial gas injection followed by laser photocoagulation 1 or 2 days later
- **Anesthesia**
- **One-session versus two-session procedure**
- **Cryopexy versus laser**
- **Applying retinopexy**
- **Amount and type of gas to inject**
  - PR usually requires a gas bubble large enough to cover all detached breaks simultaneously for about 5 days.
  - moderately larger than the largest retinal break to prevent subretinal gas
  - approximately 1.0 mL
    - which requires an injection of 0.5 mL of pure SF₆.
    - room air at least 0.8 mL
- **Sterilization of the ocular surface**
- **Preparation of the gas**
- **Performing a paracentesis**
- **Injection of gas**
- **Assessing intraocular pressure**
  - The patency of the central retinal artery:
    - If it is difficult to tell whether the artery is patent, the eye is compressed with gradually increasing force while monitoring with an indirect
ophthalmoscope. If pulsation of the central retinal artery cannot be induced in this manner, it is probably closed

- indentation tonometry (Schiøtz) gives falsely low IOP
- 1 mL gas: the error of Schiøtz tonometry is approximately 8 mmHg for intraocular pressures in the range of 10–20 mmHg and approximately 15 mmHg for intraocular pressures in the range of 30–40 mmHg.

- Do GAT.

  - **Instructing the patient**

- **Special procedures**
  - **Fish eggs**
    - Multiple small intravitreal gas bubbles
    - To prevent
      1. Make sure that the needle tip is placed shallowly within the vitreous at the time of injection.
      2. Make sure that the injection site is uppermost.
      3. Inject moderately briskly, not too briskly, nor too slowly.
      4. Inject with the needle vertical
    - Mx
      - strictly position patient to keep the bubbles away from retinal breaks
      - can be caused to coalesce by flicking the eye with a cotton-tipped applicator or gloved finger
  
  - **Gas entrapment at the injection site**
    - probably trapped in the canal of Petit
    - forming a partial ring, variously described as the “bagel,” “donut,” or “sausage” sign

- **Postoperative management**
If the fluid is not resorbing
- there may be a new or missed break
- traction may be keeping the break open
- the bubble may be too small
- patient may not have maintained proper positioning.

As long as the fluid is not increasing, there are no detached retinal breaks, and the macula is attached, reoperation is not necessary

**Results**
- SOSR: 80% which increased with reoperation to 95%

**Complications**
- Operative
  - Incarceration of vitreous
  - Subconjunctival gas
- Postoperative
  - New or missed breaks: 11-14%
  - PVR: 4%
  - Redetachment
  - Mild macular pucker
  - Persistent subretinal fluid
  - Minimal epiretinal membrane
  - Reopening of original break
  - Vitreous haze, 3-8 days
  - Choroidal detachment
  - Anterior gas entrapment
  - Vitreous hemorrhage
  - Subretinal gas
- shift of subretinal fluid
- macular hole

**Adjuncts to Treatment**

**Intraocular gases**

- **Properties of an ideal intraocular gas**
  - Availability: Readily available, Cheap/not expensive
  - Biocompatibility and safety: Nontoxic, Odorless, Colorless, Inflammable, Not cause lens opacity
  - Variability in terms of longevity and expansile property: Water soluble
  - Stable when mixed with air

- **Gases investigated for intraocular use**
  - Nonexpansile: Air, Xe, N₂, He, O₂, Ar, Kr, CO₂
  - Expansile: SF₆, CF₄, C₂F₆, C₃F₈

- **Functions of gas**
  - Internal tamponade:
    - spherical cap is the shape of gas bubble
  - Unfolding and folding of the retina
    - surface tension and buoyancy force of the bubble
  - Postoperative visualization
    - possible to glean a view of the upper fundus by looking through the gas bubble from lower flat surface
  - Replace globe volume
  - Reduces intraocular currents

- **Dynamics of the gas bubble inside the eye**
Different phases of gas resorption:

1. **Expansion**: most rapid in the initial 6-8 hours, and is similar for all gases.
2. **Equilibration**: maximum size, IOP may rise if the outflow facility cannot cope with the rapid increase. When partial pressure of all gases within the bubble equals that in the fluid compartment, the dissolution phase begins.
3. **Dissolution**: longest phase, tamponade is ineffective and no therapeutic effect can be achieved.

The time taken for complete resorption of the bubble also depends on other factors such as lens status, aqueous turnover, presence of vitreous, presence of periretinal membranes, ocular blood flow, and ocular elasticity. The lifespan of SF$_6$ and C$_3$F$_8$ may be more than twice as long in phakic nonvitrectomized eyes than in aphakic vitrectomized eyes.

Special considerations when under general anesthesia:

- Nitrous oxide (N$_2$O) is, respectively, 34 times and 117 times more water-soluble than nitrogen and SF$_6$.
- Wristband to wear, indicating clearly the type and time of intraocular gas injection.

Response to changes in altitude:

- Airplane cabin pressure is only equal to atmosphere pressure at an altitude of 8000 feet.
- Climb rate occurs at roughly 2000-3000 feet per minute during airplane ascent.
- Air bubble size may change during scuba diving.

**Preparation for injection**

- Silicone tubing is first connected to the cylinder at one end, and to two 0.22 µm Millipore filters (Millex-GS) at the external end. A 50 mL syringe is then connected to the filters. The syringe is then flushed two to three times to remove air trapped within the tubing and filters. Pure gas is then drawn into the syringe to the desired volume.
- For pure gas injection, the syringe could then be connected to either a needle or the infusion for use.
- For air-gas mixtures, the syringe should be disconnected from the cylinder at the junction between the two filters, having one filter still connected on the syringe. Sterile air is then drawn into the syringe to achieve the desired concentration of air-gas mixture.

**Clinical applications and surgical techniques**
- In vitrectomy for retinal detachments
- In pneumatic retinopexy
- In scleral buckling for retinal detachments
- In macular hole surgery
- In displacement of subretinal blood
- In postvitrectomy gas exchange

• **Postoperative care**
  - Head posture after intraocular gas injection
    - If the patient has good compliance to facedown posturing, precipitates could be noted on the central corneal endothelium, which are sometimes referred as “positioning spots”.
  - Fundal exam in the postoperative period
  - Intraocular pressure measurements
  - Laser photocoagulation
  - Vision change after surgery
  - Changes in altitude

• **Complications and management**
  - Cataract formation:
  - Raised intraocular pressure: 26-59%
  - Hypotony
  - Subretinal gas
  - Gas in the anterior chamber and corneal decompensation
  - Intraocular lens capture

**Perfluorocarbon liquid**
• initially designed for use as a blood substitute

• Clark and Gollan first used it as an oxygen transporter

• 1987, Chang pioneered its use in humans especially intraoperative use in retinal surgery

• THIRD HAND of surgeon

• **Types and properties**
  
  o Straight chain: C$_5$ to C$_9$
  
  o cyclic compounds: C$_3$ to C$_{17}$
  
  o Remember, **carbon chain shorter than C$_5$ are gases**
  
  o odorless, colorless, low viscosity, and have higher specific gravity and density than water
  
  o stable under high temperatures
  
  o do not absorb wavelengths of commonly used lasers
  
  o Molecular weight (g/mol): 438-670
  
  o Specific gravity: **1.7 - 2.03**
  
  o Surface tension (dyn/cm at 25°C): 14-20
  
  o Refractive index: **1.27-1.34**
  
  o Vapor pressure (mmHg at 37°C):
  
  o Viscosity (cSt at 25°C): **0.8-3**

• several advantages:
  
  1. **optical clarity** allows manipulations under PFCL possible
  
  2. **high density and specific gravity** allows flattening of the retina and unrolling of folds

  3. avoids the need for a posterior retinotomy to **drain subretinal fluid (SRF)**

  4. different refractive indexes from saline allow a **visible PFCL-fluid interface**, which aids intraocular maneuvers, and ease of removal

  5. **Higher boiling point** than water and **no interference to laser wavelengths** allows endophotocoagulation under PFCL

  6. **low surface tension and high interfacial tension** tends to hold it in a big bubble, and reduce the risk of PFCL migration into subretinal space through the break

  7. low viscosity allows **easy injection and aspiration** even with small gauge vitrectomies
8. **immiscibility with water** resists incursion by saline and blood and allows a clear operating field despite intraoperative bleeding

9. **immiscibility with silicone oil allows PFCL-SO exchange**, which is helpful when treating giant retinal tears by reducing risk of slippage

- **Technique**
  - Injection
    - dual-bore cannula preferred if 20G, not in 23G
    - syringe with a Luer lock is preferred
  - Removal
    - PFCL-fluid, PFCL-air, or PFCL-SO exchange
    - flute needle or a soft-tip needle

- **Indications for use**
  - **Proliferative vitreoretinopathy**
  - **Vitreous base shaving**: bimanual technique with the surgeon in control of the indentation
  - **Giant tears** (previously Stryker table was used as described by Peyman)
  - **Ocular trauma**: Traumatic RD, RIOFB, lens/ IOL removal
  - **Dislocated lens**
  - **Suprachoroidal hemorrhage**
  - **Other indications**
    - Retinal detachment associated with diabetic retinopathy, detachment associated with disc coloboma, detachment from retinopathy of prematurity, vitrectomy for endophthalmitis, displacement of submacular hemorrhage during surgical drainage, and the excision of subretinal membranes

- **Complications and management**
  - **Subretinal PFCL**: 1) PFCL breaking into globules; (2) giant retinal tears; and (3) incomplete relief of tractional membranes on the retina.
I notes RETINA Dhaval Patel MD

- **Intraocular toxicity**
  - Chemical
    - vasoconstriction of the retinal blood vessel due to high O2 capacity
    - loss of pericytes and endothelial cells of the retinal vessels
  - Mechanical
    - extended compression of inferior retina
    - loss of the outer plexiform layer, displacement of photoreceptor nuclei into the outer segments, and atrophy of the retinal pigment epithelium
    - due to the exclusion of water from the surface of the retina, thus, disrupting the potassium siphoning mechanism of the Müller cells
- **PFCL in the anterior chamber**: visual disturbance, corneal endothelial loss, as well as rise in IOP

**Silicon Oil**

- first introduced by Paul Cibis in the 1960s
- injected into nonvitrectomized eyes as an aid to overcome traction

- **Chemical properties**
  - repeating units of siloxane
  - Types
    - **Lighter-than-water silicone oils**
      - conventional SOs
      - polydimethylsiloxane PDMS
      - SG 0.97
    - **Heavier-than-water SO**
      - fluorosilicone oils
      - mixture of polymethylsiloxane and semifluorinated alkanes or alkenes
• SG 1.25-1.3
  o highly purified.

• **Physical properties**
  o **Specific gravity:** 0.97 of PDMS
  o **Buoyancy:**
    ▪ **More Buoyancy:** spherical cap (sphere with a flat bottom) → larger area of contact, GAS
    ▪ **Less Buoyancy:** normal sphere → less contact, SiO
  o **Surface tension and interfacial tension**
    ▪ **Surface tension** refers to the Van de Waal forces between molecules, which always acts to try and reduce the surface for a given volume
    ▪ **Interfacial tension** is a term relating to the surface tension between two immiscible liquids, it is a force that tends to keep a bubble as a whole. It should be above 6 mN/m
  o **Viscosity**
    ▪ Normally refers to shear viscosity.
    ▪ resistance of a fluid towards being deformed when under shear stress
    ▪ 1000 to 5000 cSt
    ▪ extensional viscosity:
      ▪ dispersion refers to the break up of a large bubble of oil into smaller droplets.
      ▪ Emulsification only occurs when this surface energy is reduced by the presence of surfactants.

• **Indications**
  o **Retinal detachments with proliferative vitreoretinopathy**
    ▪ **The Silicone Study:** SO was found to be as effective as C₃F₈, and better than SF₆, in reattaching the retina
  o **Giant retinal tears**
  o **Severe proliferative diabetic retinopathy:** stabilized the neovascularization in 83% of eyes, and achieved retinal attachment in 56%
- **Macular hole**: lower closure rate with SO, gas is preferred now
- **Viral retinitis**: SO tamponade, and ganciclovir implant insertion, 100% reattachment rate was achieved and 80% showed no CMV retinitis progression
- **Complicated pediatric retinal detachments**
- **Retinal detachments associated with choroidal coloboma**
- **Trauma**
- **Endophthalmitis**: Azad et al, better visual outcome

- **Surgical techniques of silicone oil infusion**
  - Practical differences between SO of different viscosities are threefold: (1) difficulty in injection is higher as the viscosity goes up; (2) ease of removal is higher as the viscosity goes down; and (3) risk of emulsification. The tamponade effect appears to be similar among SO with different viscosities
  - Cataract invariably occurs following SO tamponade, even if SO is removed shortly after surgery (i.e., 6 weeks).
  - **Air-silicone oil exchange** In aphakic eyes, an inferior peripheral iridectomy (Ando’s PI) needs to be done
  - **Perfluorocarbon liquid-silicone oil exchange**

- **Complications**
  - **Silicone oil in the anterior chamber**: aphakia, loose zonular support, blockage of the inferior peripheral iridectomy, or a break in the posterior capsule.
  - **Glaucoma**
    - pupil block glaucoma
    - overfill of SO
    - secondary open-angle glaucoma: drainage device is preferable over trabeculectomy (periocular fibrosis)
    - migration of SO into the AC
    - secondary angle closure glaucoma.
  - **Chronic hypotony**: defined as having IOP ≤5 mmHg in the Silicone Study
    - increased aqueous uveal-scleral outflow and reduced production.
- hypotony with IOP <10 mmHg is a relatively contraindication to SO removal.
  
  o **Cataract formation**
    - Causes: SO, vitrectomy or surgical trauma
  
  o **Recurrent retinal detachment:** 360° laser as prophylaxis in high-risk patients could be considered, as an adjunct to enhance the chance of anatomical success after SO removal
  
  o **Emulsification:** dependent on rate of eye movement, less with 5000 cSt
  
  o **Keratopathy:** 27% at the 24-month follow-up
  
  o **Unexplained visual loss following silicone oil tamponade:** sudden change in physiological environment affecting ionic exchange; in particular, potassium pumping by the Müller cells; or phototoxicity may be a potential mechanism

### Heavy Temponade

- Agents used
  
  o perfluorocarbon liquids (PFCL)
  
  o Fluorinated SOs
  
  o **Doublefilling:** combining the use of SO and fluorosilicone oil, SO and perfluorocarbon liquid, or SO with perfluorohexyloctane

- The semifluorinated alkanes and alkenes have a **specific gravity of around 1.35 at 25°C.**

- force exerted by the heaviest PFCL amounts to 2-3 mmHg

- amphiphilic

- newer generations
  
  o Densiron 68
  
  o Oxane HD
  
  o HWS 46-3000.

- **Heavy Silicone Oil Study:** results that were not superior to conventional SO
Prevention of RD

- Following anatomically successful surgery, visual acuity returns to 20/50 or better in only approximately 50% of cases
- Initial surgical attempts to reattach the retina currently fail in approximately 10-20% of cases, and reoperations are unsuccessful in as many as 5% of cases
- Retinal detachment might be avoided by:
  1. Preventing vitreous liquefaction and associated PVD: no treatment yet
  2. Relieving vitreoretinal traction: by vitrectomy or by scleral buckling
  3. Creating a chorioretinal adhesion around vitreoretinal adhesions and retinal breaks: laser and cryo

- Risk factors for rhegmatogenous retinal detachment
  - Hereditary/congenital/developmental/degenerative: Male, Hereditary vitreoretinopathies, Myopia, Lattice, Cystic retinal tuft, Degenerative retinoschisis, Retinal breaks
  - Prior ocular surgery:
  - Prior ocular trauma:
  - Inflammatory: CMV retinitis, ARN
  - Other: Fellow-eye nontraumatic retinal detachment

- Symptomatic eyes
  - Photopsia and/or increased vitreous floaters associated with an acute posterior vitreous detachment
  - 15% of eyes with a symptomatic PVD develop retinal tears of various types
  - Tears with persistent vitreoretinal traction
    - Horseshoe-shaped tears
      - Cause retinal detachment in 33-55% of cases
      - Do cryo or laser
• Round tears
  - Operculated
  - persistent vitreoretinal traction on a nearby retinal vessel
  - treat or not ?? not given clearly

• Tears unassociated with persistent vitreoretinal traction: no need to treat

• Retinal holes and precursors of retinal detachment: pre-existing

• Asymptomatic eyes without high-risk factors
  - Lattice degeneration
    - 30% of retinal detachments
    - 94% of these detachments occur in primary (nonfellow) eyes
    - 8% of the population
    - Subclinical retinal detachments: subretinal fluid extending more than one disc diameter (DD) from the break but not posterior to the equator
  - Cystic retinal tufts
    - 10% of clinical retinal detachments has tear near retinal tufts
    - not worthy of prophylactic therapy
  - Degenerative retinoschisis
    - 6% of consecutive detachment
    - prophylactic therapy is indicated only in the presence of obvious significant progression of subretinal fluid posterior to the equator
  - Asymptomatic Retinal Breaks
    - phakic nonfellow eyes is usually not recommended

• Asymptomatic nonfellow eyes with high-risk factors
  - Myopic nonfellow eyes
    - Lattice degeneration associated with retinal holes did not correlate with degree of myopia
- Cystic retinal tufts and degenerative retinoschisis are not more common in myopic eyes
- Asymptomatic retinal breaks are more common in myopic eyes

  - **Aphakic and pseudophakic nonfellow eyes**
    - HST is treated, no data for asymptomatic retinal holes

  - **Family history of retinal detachment**
    - Stickler syndrome

- **Asymptomatic patients with retinal detachment in the fellow eye**
  - Incidence is 9% to as high as 40%

  - **Phakic fellow eyes**
    - Lattice degeneration
    - **Retinal breaks:** horseshoe-shaped tears that are discovered in asymptomatic fellow eyes is sometimes recommended
    - **Giant retinal tears:** increased vitreous liquefaction, and “white-with-pressure” in other eye is treated

  - **Asymptomatic aphakic and pseudophakic fellow eyes**
    - 14-41%
    - **Precursors of retinal breaks**
    - **Retinal breaks**
    - **Giant retinal tears**

- **Prophylactic therapy in eyes undergoing vitreoretinal surgery**
  - During silicone oil removal in previously operated eyes: 360 EL recommended
  - During primary vitrectomy for nonretinal detachment: subsequent RD in 11.4% of the nontreated cases and in 3.5% of those that were treated
  - During pneumatic retinopexy
Retinotomies and Retinectomies

- **Retinotomy**: cutting the retina, vary from a small hole created for drainage of subretinal fluid or removal of a subretinal membrane to a 360° cut to release massive peripheral traction
- **Retinectomy**: excision of retina, may mean limited excision of the fixed edge of a retinal flap or total excision of peripheral fibrotic retina.

- **Drainage retinotomy**
  - retinal hole created to allow removal of subretinal fluid
  - posterior drainage retinotomy is less frequently used today
  - after as complete a removal as possible of periretinal membranes
  - unimanual, bipolar endodiathermy probe: complete hemostasis and whitening

- **Technique**
  - Surgical technique in conjunction with perfluorocarbon liquid (PFCL)
  - Surgical technique without PFCL

- **Retinotomy to gain access to the subretinal space**
  - Subretinal foreign body
  - Removal of subretinal PFCL
  - Retinal or subretinal mass

- **Retinotomies to mobilize retina: macular translocation**
  - Retinotomies to obtain abnormal retinal tissue: retinal biopsy
  - Retinectomy for treatment of intractable glaucoma
- **Relaxing retinotomy and retinectomy**

- **Indications**
  - Retinal incarceration in traumatic or surgical wound
  - Proliferative vitreoretinopathy
    - Focal contraction (star fold)
    - Diffuse contraction
    - Circumferential contraction
    - Intrinsic retinal contraction
    - Anterior retinal displacement
    - Extensive fibrous periretinal proliferation
    - Contraction and fibrosis of flap of giant retinal tear
  - Proliferative vascular retinopathy
  - Inner wall of congenital retinoschisis

- **Anterior retinal displacement**
  - Important cause of retinal detachment with PVR and is primarily found in patients who have undergone a previous vitrectomy.\(^1\)
  - Vitreous base pull peripheral retina anteriorly to the pars plana, pars ciliaris, or even to the posterior iris

- **Complications**
  - Hemorrhage
  - Inability to unfold and reattach the retina
  - Hypotony, visual field loss
  - Recurrent fibrous proliferation from the retinectomy site
  - Persistent traction leading to retinal detachment when the retinectomy is too small.
Macular Translocation

- 1983, Lindsey first proposed
- Machemer published the first human surgical cases in 1993.
- original MTS360 technique: PPV with transscleral injection of subretinal fluid with 360° retinectomy, removal of subretinal blood and choroidal neovascularization (CNV); partial fill with silicone oil; retinal translocation; complete silicone oil fill, and finally laser retinopexy.
- retinal rotation results in significant cyclotorsion, extraocular muscle surgery to counter-rotate the globe is used routinely to manage the cyclotropia
- limited macular translocation (LMT):
  - De Juan: shorten the sclera following detachment of the superotemporal retina across the macula
  - variable and limited distance of macular displacement, this procedure has decreased in use
- Principles
  - relocate the fovea to a new location of healthier subretinal tissues in order to preserve and maintain foveal function to maximize visual acuity
  - MTS360: average foveal displacement of 3500 µm
  - LMT: maximum translocation distance of 1500 µm
  - translocating the macula upward off:
    - position the blind spot in the superior visual field
    - to position the macula in an optimal superior location for silicone oil tamponade
    - to avoid placing the macula over RPE that has been in an area of chronic exudate or hemorrhage, which is more likely inferior to the macula
    - to allow for the most effective surgery for the cyclotropia since advancing the inferior oblique produces more torsional effect than advancing the superior oblique.
- Indications
  - Bilateral disease
  - Severe loss of central vision in second affected eye for no more than 6 months*
Best-corrected Snellen visual acuity between 20/50 and 20/400 in the surgically treated eye

*Contra-Indications*
- No light perception visual acuity
- Previous thermal laser treatment of fovea
- Other ocular disease

*Surgical technique*

**MTS360**
- Complete pars plana vitrectomy with elevation of the posterior hyaloid
- Close shaving of the vitreous base 360
- Retinal detachment is induced with subretinal fluid injection through peripheral retinotomy
- After total RD → peripheral retinotomy
- PFCL to stabilize
- Relocation
  - Typically approximately 45° off the CNV bed, which equates to the center of the old CNV bed under the inferotemporal arcade
  - Laser

*Limited macular translocation*
- Rectus traction sutures are placed prior to vitrectomy under the LR, SR or IR according to desired location
- 5-6 sutures
  - Creates choriocapillary infolding

*Positioning*
- Face-down positioning or alternating side-to-side positioning

*Extraocular muscle surgery following macular translocation*
- Translocation that occurs during MTS360, often 30-45° in an upward direction, the amount of torsion exceeds the maximum amplitude of cyclofusion (typically around 15°)
- Freedman technique: surgery 8 weeks after the MTS360
- Eckardt technique: Simultaneous extraocular muscle surgery is performed during the initial MTS360 procedure
- Windmill technique:

- **Complications**
  - RD is the most common complications with a prevalence of 7.8-42.8%.
  - Recurrence of CNV: 0-27%
  - CME: 0-40%
  - ERM: 6-28%
  - Macular Hole
  - Hypotony
  - Keratopathy

**Diagnostic and Therapeutic Vitrectomy**

**Indications of diagnostic Vitrectomy**
- Infectious uveitis: Endophthalmitis, Vitritis, Retinitis, Choroiditis, Retinal vasculitis
- Noninfectious uveitis: Autoimmune uveitis, Primary intraocular lymphoma, Carcinoma metastasis, Choroidal melanoma

**Techniques**
- **Preoperative preparation:** Standard
- **Vitreous sampling**
  - 3-port pars plana vitrectomy (PPV)
  - Vitreous cutter connected directly to a 3 or 5 mL syringe: 1.5 mL can be obtained
  - Using continuous air or perfluorocarbon liquid (PFCL) infusion:
Indications for Therapeutic Vitrectomy

1. media opacity causing significant visual loss
2. intractable cystoid macular edema (CME)
3. other vitreoretinal complications, including tractional retinal detachment, rhegmatogenous retinal detachment, macular pucker, hemophthalmos, hypotony, or macular hole

Common indications for biopsy

- Vitreous: Endophthalmitis (bacterial or fungal), Intraocular lymphoma, Retinitis with associated vitritis
- Retinal: Retinitis (atypical or not responsive to empiric therapy)
- Choroidal: Tumor, Choroiditis (atypical or not responsive to empiric therapy)

Transplantation and Artificial Vision

Pharmacology at Surgery

Pharmacologic vitreolysis

- PVD involves both syneresis (liquefaction) and synchysis (separation).
- spontaneous PVD is very often incomplete
- concept initially introduced by Sebag in 1998
- Enzymatic vitreolysis
• **Microplasmin**
  - recombinant protein that contains the catalytic domain of human plasmin
  - nonspecific serine proteases cleaving a variety of glycoproteins such as fibronectin, laminin, fibrin and thrombospondin
  - 125 µg microplasmin was associated with a greater likelihood of induction and progression of PVD than placebo injection

• **Plasmin**
  - Autologous plasmin
  - transient reduction of the b-wave amplitude in the electroretinogram

• **Hyaluronidase**
  - potential to liquefy the vitreous, but does not induce a PVD in animal models

• **Dispase**
  - preferentially cleaves fibronectin and type IV collagen
  - retinal bleedings, epimacular membrane formation, abnormalities in the electroretinogram responses and ultrastructural retinal damage
  - not evaluated further

**Antiproliferative agents**
- colchicine, daunomycin and 5-fluorouracil
- alkylphosphocholines (APCs)

**TPA**
Read from ARMD

**Dyes**
Read from Macular Hole

**VEGF**
Read from ARMD/DME
Artificial Vision

- Foerster, a German neurosurgeon, observed that electrical stimulation of the visual cortex caused his subject to detect a spot of light (phosphene).
- **Giles Brindley**: 80-electrode device onto the visual cortex of a blind patient
- 625 electrodes implanted in a 1 cm² area near the foveal representation in the visual cortex could produce a phosphene image with a visual acuity of approximately 20/30 and reading rates near 170 words/minute with scrolled text and 100 words/minute with fixed text. Further, a degree of learning was noted as walking speeds increased five-fold during 3 weeks of training
- Write about ARGUS-II trial

PFVS

- The fetal vasculature is composed of two parts:
  1. **Tunica vasculosa lentis**: It is situated anteriorly encircling the lens. It has anterior and posterior divisions. Anteri-or division has additional attachments to the pupillary frill of the iris. Posterior division has additional attachments to the ciliary process and continues with the hyaloid artery posteriorly.
2. **Hyaloid artery**: It is situated posteriorly behind the lens. It is also called primary vitreous. The hyaloid vessel extends from posterior surface of lens to the disc. The vasculature fills the vitreous cavity & has many attachments to the retinal surface

- During development blood flow to the eye is through hyaloid artery. At the 240-mm stage (seventh month), blood flow in the hyaloid artery ceases. Hyaloid vascular regression occurs in following manner:
  
- The developing lens separates the fetal vasculature from vascular endothelial growth factor (VEGF) producing cells, inducing apoptosis.
  
  o Initial apoptosis induced by macrophages in a single endothelial cell.
  
  o Secondary apoptosis induced by synchronous process followed by obstruction of lumen of vasculature.

- Persistence of the hyaloid vascular system occurs in 3% of full-term infants and in 95% of premature infants. There is a spectrum of disorders resulting from persistence of the fetal vasculature.
  
  o Mittendorf’s dot is a remnant of the former site of anastomosis of the anterior tunica vasculosa lentis and posterior hyaloid artery. It is usually inferonasal to the posterior pole of the lens and is not associated with any known visual dysfunction

  o Bergmeister’s papilla is the occluded remnant of posterior portion of the hyaloid artery, associated with glial tissue. It appears as a gray, linear structure anterior to the optic disc. It also has no visual dysfunction.

  o Vitreous cysts are generally benign lesions that are found in eyes with abnormal regression of the anterior or posterior hyaloid vascular system. It can occur in otherwise normal eyes or eyes with coexisting ocular disease, such as retinitis pigmentosa, retinochoroidal colobomas and uveitis. Vitreous cysts are generally not symptomatic and thus do not require surgical intervention

- It is unilateral approximately 90% of the time.

- PFVS does not progress during the course of the child’s life, but tractional intraocular changes can occur later, most likely due to eye growth. The stalk also can cause traction on the posterior lens capsule leading to posterior lenticonus. Traction on the ciliary body can lead to hypotony. Traction on the retina, leads to tractional retinal detachment.

- Retinal Dysplasia: Microscopic and Macroscopic
• There are three types of PFVS:
  o **Anterior PFVS**: It has predominant features of persistent anterior tunica vasculosa lentis without much or any posterior hyaloid component.
    ▪ Presentation age 1-2 weeks after birth with leukocoria.
    ▪ Microphthalmos.
    ▪ Posterior lens opacity → cataract.
    ▪ Retrolental fibrovascular membrane.
    ▪ Shallow AC → glaucoma.
    ▪ Elongated ciliary process → hypotony.
    ▪ Stalk extending from posterior part of lens to optic disc may or may-not be present
  o **Posterior PFVS**: It has predominant features of persistent posterior hyaloid artery without much or any anterior tunica vasculosa lentis.
    ▪ Microphthalmos (may or may-not be present).
    ▪ Posterior lens opacity.
    ▪ Vitreous stalk.
    ▪ Retinal fold.
    ▪ Tractional retinal detachment.
    ▪ Hypoplastic optic nerve & macula.
  o **Mixed PFVS**: Occurs when both the tunica vasculosa lentis and hyaloid system is present. It has a spectrum of presentations depending on the degree of involution of the hyaloid and tunica vasculosa lentis.

• **Associated diseases**
  o **Norrie disease gene**
  o **oculo-palatal-cerebral syndrome**, intrauterine herpes simplex virus infection, intrauterine exposure to clomiphene, oral-facial-digital syndrome, anterior and posterior colobomas or even cystic globes and tuberous sclerosis

• **DD**
• Retinoblastoma
• Norrie disease: When bilateral PFV syndrome is present.
• Congenital cataract.
• Walker-Warburg syndrome.
• Trisomy.
• Familial exudative vitreoretinopathy.
• Incontinentia pigmenti.
• Retinopathy of prematurity

• Investigations
  • B scan ultrasound
  • CT-MRI

• Mx
  • Anterior PFVS
  • Posterior PFVS
    • Surgery not required if no traction present
    • Lens sparing vitrectomy is the surgery of choice.

MISC

Q: Anti VEGF
• Michaelson first suggested that a diffusible “Factor X” from the retina stimulated the retinal and iris neovascularization seen in diabetic retinopathy
• In 1989, Napoleon Ferrara and colleagues identified a molecule in the conditioned media from bovine pituitary follicular cells that promoted the proliferation of endothelial cells; they called it vascular endothelial growth factor (VEGF)

• Write other things from ARMD Discussion.

**Macular Infarction**

pharmacological (aminoglycoside toxicity)

vascular stasis (sickle cell disease)

prothrombotic states (thrombotic thrombocytopenic purpura, disseminated intravascular coagulation).

**Leber Congenital Amaurosis**

• Theodor Leber in 1869

• AR → 15 genes

• Leber: Tapetoretinale Degeneration mit Amblyopie

• 1957: Franceschetti and Dieterle → severely reduced electroretinogram

• 3 in 100,000 newborn babies.

• 5% of all inherited retinopathies and approximately 20% of children attending schools for the blind

• Clinical features
  - Severe visual loss at or near birth
  - Wandering nystagmus
  - Amaurotic pupils
- Pigmentary retinopathy